CHINA TELECOM CORP LTD Form 20-F April 28, 2016 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 20-F

" REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

OR

" SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission file number 1-31517

(Exact Name of Registrant as Specified in Its Charter)

China Telecom Corporation Limited

(Translation of Registrant s Name into English)

People s Republic of China

(Jurisdiction of Incorporation or Organization)

31 Jinrong Street, Xicheng District

Beijing, People s Republic of China 100033

(Address of Principal Executive Offices)

Mr. Xu Fei

China Telecom Corporation Limited

31 Jinrong Street, Xicheng District

Beijing, People s Republic of China 100033

Email: xufei@chinatelecom.com.cn

Telephone: (+86-10) 5850 2281

Fax: (+86-10) 6601 0728

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of Each Class American depositary shares

Name of Each Exchange On Which Registered New York Stock Exchange, Inc.

H shares, par value RMB1.00 per share

New York Stock Exchange, Inc.*

* Not for trading, but only in connection with the listing on the New York Stock Exchange, Inc. of American depositary shares, each representing 100 H shares.

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer s classes of capital or common stock as of the close of the period covered by the annual report.

As of December 31, 2015, 67,054,958,321 domestic shares and 13,877,410,000 H shares, par value RMB1.00 per share, were issued and outstanding. H shares are ordinary shares of the Company listed on The Stock Exchange of Hong Kong Limited.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No "

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes "No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes "No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer x Accelerated Filer " Non-Accelerated Filer "

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.

U.S. GAAP "

International Financial Reporting Standards as issued by the International Accounting Standards Board x

Other "

If Other has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 " Item 18 "

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes "No x

CHINA TELECOM CORPORATION LIMITED

TABLE OF CONTENTS

<u>PART</u>	<u>[]</u>		<u>Page</u> - 2 -
	Item 1.	Identity of Directors, Senior Management and Advisers	- 2 -
	Item 2.	Offer Statistics and Expected Timetable	- 2 -
	Item 3.	Key Information	- 2 -
	Item 4.	Information on the Company	- 16 -
	Item 4A.	Unresolved Staff Comments	- 36 -
	Item 5.	Operating and Financial Review and Prospects	- 36 -
	Item 6.	Directors, Senior Management and Employees	- 49 -
	Item 7.	Major Shareholders and Related Party Transactions	- 57 -
	Item 8.	Financial Information	- 64 -
	Item 9.	The Offer and Listing	- 65 -
	Item 10.	Additional Information	- 65 -
	Item 11.	Quantitative and Qualitative Disclosures about Market Risk	- 75 -
	Item 12.	Description of Securities Other than Equity Securities	- 79 -
PAR7	<u>Γ ΙΙ</u>		- 79 -
	Item 13.	Defaults, Dividend Arrearages and Delinquencies	- 79 -
	Item 14.	Material Modifications to the Rights of Security Holders and Use of Proceeds	- 79 -
	Item 15.	Controls and Procedures	- 80 -
	Item 16A.	Audit Committee Financial Expert	- 81 -
	Item 16B.	Code of Ethics	- 81 -
	Item 16C.	Principal Accountant Fees and Services	- 82 -
	Item 16D.	Exemptions from the Listing Standards for Audit Committees	- 82 -
	Item 16E.	Purchases of Equity Securities by the Issuer and Affiliated Purchasers	- 82 -
	Item 16F.	Change in Registrant s Certifying Accountant	- 82 -
	Item 16G.	Corporate Governance	- 82 -
	Item 16H.	Mine Safety Disclosure	- 82 -
	Item 17.	Financial Statements	- 83 -
	Item 18.	<u>Financial Statements</u>	- 83 -
	Item 19.	<u>Exhibits</u>	- 83 -

FORWARD-LOOKING STATEMENTS

This annual report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are, by their nature, subject to significant risks and uncertainties, and include, without limitation, statements relating to:

our network expansion and capital expenditure plans;
our operations and business prospects;
the expected benefit of any acquisitions or other strategic transactions;
our financial condition and results of operations;
the expected impact of new services on our business, financial condition and results of operations;
the future prospects of and our ability to integrate acquired businesses and assets;
the industry regulatory environment as well as the industry outlook generally; and

future developments in the telecommunications industry in the People s Republic of China, or the PRC.

The words anticipate, believe, could, estimate, expect, intend, may, plan, seek, will, would and they relate to us, are intended to identify a number of these forward-looking statements.

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. We are under no obligation to update these forward-looking statements and do not intend to do so. Actual results may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risk factors set forth in Item 3. Key Information D. Risk Factors and the following:

any changes in the regulations or policies of the Ministry of Industry and Information Technology (prior to March 2008, the Ministry of Information Industry, or the MII), or the MIIT, and other relevant government

authorities relating to, among other matters:		
the granting and approval of licenses;		
tariff policies;		
interconnection and settlement arrangements;		
capital investment priorities;		
the provision of telephone and other telecommunications services to rural areas in the PRC;		
the convergence of television broadcast, telecommunications and Internet access networks, or three-network convergence; and		
spectrum and numbering resources allocation;		
the effects of competition on the demand for and price of our services;		
any potential further restructuring or consolidation of the PRC telecommunications industry;		
changes in the PRC telecommunications industry as a result of the issuance of the fourth generation mobile telecommunications, or 4G, licenses by the MIIT;		
the development of new technologies and applications or services affecting the PRC telecommunications industry and our current and future business;		
changes in political, economic, legal and social conditions in the PRC, including changes in the PRC government s specific policies with respect to foreign investment in and entry by foreign companies into the PRC telecommunications industry, economic growth, inflation, foreign exchange and the availability of credit;		
results and effects of any investigation by the relevant PRC regulatory authorities;		
implementation of a value-added tax to replace the business tax in the PRC; and		

the uncertainties involved in the operations and the future performance of the Tower Company.

CERTAIN DEFINITIONS AND CONVENTIONS

As used in this annual report, references to us, we, the Company, our Company and China Telecom are to China Telecom Corporation Limited and its consolidated subsidiaries except where we make clear that the term means China Telecom Corporation Limited or a particular subsidiary or business group only. References to matters relating to our H shares or American depositary shares, or ADSs, or matters of corporate governance are to the H shares, ADSs and corporate governance of China Telecom Corporation Limited. In respect of any time prior to our incorporation, references to us, we and China Telecom are to the telecommunications business in which our predecessors were engaged and which were subsequently assumed by us. All references to China Telecom Group are to China Telecommunications Corporation, our controlling shareholder. Unless the context otherwise requires, these references include all of its subsidiaries, including us and our subsidiaries. Unless otherwise indicated, references to and statements regarding China and the PRC in this annual report do not apply to Hong Kong Special Administrative Region, Macau Special Administrative Region or Taiwan.

PART I

Item 1. Identity of Directors, Senior Management and Advisers. Not applicable.

Item 2. Offer Statistics and Expected Timetable. Not applicable.

Item 3. Key Information.

A. Selected Financial Data

The following table presents our selected financial data. The selected consolidated statements of financial position data as of December 31, 2014 and 2015, and the selected consolidated statements of comprehensive income (except for earnings per ADS) and consolidated cash flow data for the years ended December 31, 2013, 2014 and 2015, are derived from our audited consolidated financial statements included elsewhere in this annual report, and should be read in conjunction with those consolidated financial statements. The selected consolidated statements of financial position data as of December 31, 2011, 2012 and 2013 and the selected consolidated statements of comprehensive income (except for earnings per ADS) and consolidated cash flow data for the years ended December 31, 2011 and 2012 are derived from our consolidated financial statements which are not included in this annual report. Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board.

The selected financial data reflect the acquisitions and divestment in 2012 and 2013, the establishment of new subsidiaries in 2014 and the tower assets disposal in 2015 described under Item 4. Information on the Company A. History and Development of the Company Our Acquisition from China Telecom Group of the CDMA Network Assets and Associated Liabilities , Changes in Our Corporate Organization in 2013 , Changes in Our Corporate Organization in 2014 and Establishment of the Tower Company and the Disposal and Use of the Telecommunications Towers .

On December 31, 2012, we purchased from China Telecom Group certain assets and associated liabilities relating to the CDMA network located in 30 provinces, municipalities and autonomous regions in the PRC for a total consideration of approximately RMB87,210.35 million, of which RMB25,500 million was paid in January 2013 and the balance will be payable at any time on or before the fifth anniversary of December 31, 2012, or the Mobile Network Acquisition. The Mobile Network Acquisition was recognized as an assets acquisition and the assets and associated liabilities acquired by the Company are stated at their respective purchase prices, including related tax expenses, on December 31, 2012.

As of or for the year ended December 31, 2011 RMB 2012 RMB 2013 RMB 2014 RMB 2015 RMB 2015 US\$ (in millions, except share numbers and per share and per ADS data)

Consolidated Statements of							
Comprehensive Income Data:							
Operating revenues	245,149	283,176	321,584	324,394	331,202	51,129	
Operating expenses	(221,028)	(261,968)	(294,116)	(295,886)	(304,760)	(47,047)	
Operating income	24,121	21,208	27,468	28,508	26,442	4,082	
Earnings before income tax	22,006	19,817	23,088	23,257	26,693	4,121	
Income tax	(5,416)	(4,753)	(5,422)	(5,498)	(6,551)	(1,011)	
Profit attributable to equity holders of							
the Company	16,494	14,949	17,545	17,680	20,054	3,096	
Basic earnings per share ⁽¹⁾	0.20	0.18	0.22	0.22	0.25	0.04	
Basic earnings per ADS ⁽¹⁾	20.38	18.47	21.68	21.85	24.78	3.83	
Cash dividends declared per share	0.07	0.07	0.08	0.08	0.08	0.01	

As of or for the year ended December 31, 2011 RMB 2012 RMB 2013 RMB 2014 RMB 2015 RMB 2015 US\$ (in millions, except share numbers and per share and per ADS data)

a 14.7 · 1.8 · · · · · · · · · · · · · · · · · · ·		· •		-	-	<i>'</i>
Consolidated Statements of Financial						
Position Data:						
Cash and cash equivalents	27,475	30,099	16,070	20,436	31,869	4,920
Accounts receivable, net	18,486	18,782	20,022	21,562	21,105	3,258
Total current assets	59,713	65,375	52,783	59,543	78,108	12,058
Property, plant and equipment, net	268,925	373,781	374,341	372,876	373,981	57,733
Total assets	419,331	545,291	543,239	561,274	629,561	97,187
Short-term debt	9,187	6,523	27,687	43,976	51,636	7,971
Current portion of long-term debt	11,766	10,212	20,072	82	84	13
Accounts payable	44,460	68,948	81,132	88,458	118,055	18,225
Total current liabilities	127,397	193,610	200,098	206,325	255,929	39,509
Long-term debt and payable	31,150	83,070	62,617	62,494	64,830	10,008
Deferred revenues (including current						
portion)	4,805	3,445	2,431	1,858	2,482	383
Total liabilities	162,376	279,191	264,575	271,166	324,810	50,142
Equity attributable to equity holders of the						
Company	256,167	265,139	277,741	289,183	303,784	46,896
Consolidated Cash Flow Data:						
Net cash generated from operating						
activities	73,025	70,722	88,351	96,405	108,750	16,788
Net cash used in investing activities ⁽²⁾	(43,646)	(48,295)	(107,948)	(81,708)	(102,250)	(15,785)
Capital expenditures ⁽²⁾	(48,506)	(50,071)	(70,921)	(80,273)	(101,898)	(15,730)
Net cash (used in) / generated from						
financing activities	(27,723)	(19,802)	5,637	(10,327)	4,809	742

(1)

The basic earnings per share have been calculated based on the respective net profit attributable to equity holders of the Company in 2011, 2012, 2013, 2014 and 2015 and the weighted average number of shares in issue during each of the relevant years of 80,932,368,321 shares. Basic earnings per ADS have been computed as if all of our issued and outstanding shares, including domestic shares and H shares, are represented by ADSs during each of the years presented. Each ADS represents 100 H shares.

(2) Capital expenditures are part of and not an addition to net cash used in investing activities. Pursuant to the shareholders—approval at the annual general meeting held on May 27, 2015, a final dividend of RMB6,160 million (RMB0.076120 per share equivalent to HK\$0.095 per share, pre-tax) for the year ended December 31, 2014 was declared, all of which has been fully paid. Pursuant to a resolution passed at the Directors meeting on March 23, 2016, a final dividend of approximately RMB6,461 million (RMB0.079829 equivalent to HK\$0.095 per share, pre-tax) for the year ended December 31, 2015 was proposed for shareholders—approval at the forthcoming annual general meeting.

Exchange Rate Information

Our business is primarily conducted in China and substantially all of our revenues are denominated in Renminbi. We present our historical consolidated financial statements in Renminbi. In addition, solely for the convenience of the reader, this annual report contains translations of certain Renminbi and Hong Kong dollar amounts into U.S. dollars at specific rates. For any date and period, the exchange rate refers to the exchange rate as set forth in the H.10 statistical release of the Federal Reserve Board. Unless otherwise indicated, conversions of Renminbi or Hong Kong dollars into U.S. dollars in this annual report are based on the exchange rate on December 31, 2015 (RMB6.4778 to US\$1.00 and HK\$7.7507 to US\$1.00). We make no representation that any Renminbi or Hong Kong dollar amounts could have been, or could be, converted into U.S. dollars or vice versa, as the case may be, at any particular rate, the rates stated below, or at all. For a detailed explanation of the risk of currency rate fluctuations, please see D. Risk Factors Risks Relating to the People s Republic of China Fluctuation of the Renminbi could materially affect our financial condition, results of operations and cash flows. under this Item. The PRC government imposes controls over its foreign currency reserves in part through direct regulation of the conversion of Renminbi into foreign exchange. Examples of such government regulations and restrictions are set forth in Risk Factors Risks Relating to the People s Republic of China Government control of currency conversion may adversely affect our financial condition.

On April 22, 2016, the daily exchange rates reported by the Federal Reserve Board was RMB6.5004 to US\$1.00 and HK\$7.7564 to US\$1.00. The following table sets forth additional information concerning exchange rates between Renminbi and U.S. dollars and between Hong Kong dollars and U.S. dollars for the periods indicated. These rates are provided solely for your convenience and are not necessarily the exchange rates that we use in this annual report or will use in the preparation of our future periodic reports or any information to be provided to you.

	RMB per US\$1.00			HK\$ per US\$1.00	
	High	Low		High	Low
October 2015	6.3591	6.3180	October 2015	7.7503	7.7495
November 2015	6.3945	6.3180	November 2015	7.7526	7.7498
December 2015	6.4896	6.3883	December 2015	7.7527	7.7496
January 2016	6.5932	6.5219	January 2016	7.8270	7.7505
February 2016	6.5795	6.5154	February 2016	7.7969	7.7700
March 2016	6.5500	6.4480	March 2016	7.7745	7.7528
April 2016 (through April 22, 2016)			April 2016 (through April 22,		
•	6.5004	6.4571	2016)	7.7569	7.7537

The following table sets forth the average exchange rates between Renminbi and U.S. dollars and between Hong Kong dollars and U.S. dollars for each of 2011, 2012, 2013, 2014 and 2015 calculated by averaging the exchange rates on the last day of each month during each of the relevant years.

Average Exchange Rate

	RMB per US\$ 1.00	HK\$ per US\$1.00
2011	6.4475	7.7793
2012	6.2990	7.7556
2013	6.1412	7.7565
2014	6.1704	7.7554

2015 6.2869 7.7519

B. Capitalization and Indebtedness

Not applicable.

C. Reasons for the Offer and Use of Proceeds

Not applicable.

- 4 -

D. Risk Factors Risks Relating to Our Business

We face increasing competition, which may materially and adversely affect our business, financial condition and results of operations.

The telecommunications industry in the PRC is rapidly evolving.

After the industry restructuring in 2008, China Unicom (Hong Kong) Limited (formerly known as China Unicom Limited), or China Unicom, and our Company have full-service capabilities and compete with each other in both wireline and wireless telecommunications services. China Mobile Limited, or China Mobile, continues to be the leading provider of mobile telecommunications services in the PRC and competes with us in mobile telecommunications services and other telecommunications services.

In particular, in December 2013, each of China Mobile Communications Corporation, or China Mobile Group, China Telecom Group and China United Network Communications Group Company Limited (formerly known as China United Telecommunications Corporation prior to its merger with China Network Communications Group Corporation), or Unicom Group, received a license from the MIIT to operate 4G business nationwide. The licenses permit each of China Mobile Group, China Telecom Group and Unicom Group to provide 4G services based on LTE/Time Division Duplex standard, or TD-LTE technologies. In addition, in February 2015, each of China Telecom Group and Unicom Group was granted by the MIIT the permit to provide 4G service based on Frequency-Division Long-Term Evolution standard, or LTE FDD technologies nationwide. We have been authorized by China Telecom Group to operate 4G business nationwide based on both TD-LTE technologies and LTE FDD technologies. We cannot assure you that: (i) our 4G services will deliver the quality and levels of services currently anticipated; (ii) we will be able to provide all planned 4G services or we will be able to provide such services on schedule; (iii) there will be sufficient demand for 4G services for us to deliver these services profitably; (iv) our competitors 4G, or newer technology based, services will not be more popular among potential subscribers; or (v) we will not encounter unexpected technological difficulties in providing 4G services. The failure of any of these possible developments to occur could impede our growth, which could have a material adverse effect on our business, financial condition and results of operations. We expect that the market competition will be further intensified as a result of our competitors expanding their 4G services, which could materially and adversely affect our business and prospect.

In December 2013, China Mobile Group received permission from the MIIT to authorize China Mobile to operate fixed-line telecommunications businesses. Prior to December 2013, China Unicom, China Tietong Telecommunications Corporation, or China Railcom, which is a wholly-owned subsidiary of China Mobile Group, CITIC NETWORKS Co., Ltd., and our Company were the only operators licensed by the MIIT to provide fixed-line telecommunications services in China. At the end of December 2015, China Mobile completed its acquisition from China Mobile Group of the fixed-line telecommunications businesses operated by China Railcom. China Mobile s entry into the fixed-line broadband market has intensified and may continue to intensify competition in this sector, which could have a material adverse effect on our business, financial condition and results of operations.

We also face increasing competition from other competitors outside the telecommunications industry. Television cable companies providing fixed-line broadband services, Internet services providers and mobile software and application developers (such as Over-the-Top messaging services providers who offer contents and services on the Internet without their proprietary telecommunications network infrastructure), are competing with us in voice or data services. During the past few years, some of our traditional revenue contributors have experienced a slowdown in the growth rate or negative growth, primarily due to the alternative means of communication becoming increasingly popular among the consumers. For example, the aggregate revenues contributed by our wireline and mobile voice

services grew at a rate of 4.7% in 2013 but decreased at a rate of 8.9% in 2014 and further decreased at a rate of 11.0% in 2015. We cannot assure you that such trend will not continue with respect to some of our traditional services, or our other services will not experience slowdown amid the intense market competition, which could have a material adverse effect on our business, financial condition and results of operations.

In addition, the PRC government has taken various initiatives to encourage competition in the telecommunications industry, such as the three-network convergence policy and the policy encouraging non-State owned companies to enter the industry. For more details of the three-network convergence policy, please see Item 4. Information on the Company B. Business Overview Three-Network Convergence Policy. In May 2010, the PRC State Council issued Certain Opinion on Encouraging and Guiding the Sound Development of Private Investment, encouraging private investment in industry sectors that are mainly state-controlled, such as basic telecommunications services. In June 2012, the MIIT issued Opinions on Encouraging and Guiding Private Investment in the Telecommunications Industry, encouraging private-sector investment in the telecommunications industry. On May 17, 2013, the MIIT issued the Trial Plan of Mobile Telecommunications Resale Business, pursuant to which the MIIT would grant qualified companies mobile telecommunications resale business approvals on a pilot basis which would allow them to purchase mobile telecommunications services in bulk from mobile networks operators and resell such services to customers. On January 6, 2016, the MIIT issued the Guidance on the Wholesale Price Adjustments of Mobile Telecommunications Resale Business , pursuant to which the MIIT required that the wholesale price for resale of mobile telecommunications services should be lower than the per unit price (or package price) for similar businesses of the mobile networks operators. All of these measures are expected to encourage non-State owned companies to provide telecommunications services that could compete with our services. On December 25, 2014, the MIIT issued the Notice on Opening the Broadband Access Market to Private Capital, encouraging private capital to invest in the construction and operation of the broadband access network and cooperate with basic telecommunications operators in various ways to provide broadband access services and broadband resale services to customers and determining 17 cities including Beijing to be the first group of cities that would open their broadband access markets to private capital on a pilot basis. On September 23, 2015, the MIIT issued the Notice on Further Broadening the Scope of Trial Opening of the Broadband Access Business, to include another 44 cities into the trial scope that opens up the broadband access market to private capital. As of December 31, 2015, the MIIT granted broadband access pilot enterprises licenses to over 50 private companies. As of April 19, 2016, 67 cities have opened up their broadband access markets to private capital. As of December 31, 2015, we had entered into resale contracts with 25 out of the 42 mobile virtual network operators which had obtained the licenses from the MIIT, and 11 of these companies had started to offer 4G services. As a result, the competitive landscape in the PRC telecommunications industry may further diversify, causing more intensified competition.

Increasing competition from other existing telecommunications services providers, including China Mobile and China Unicom, as well as competition from new competitors, could materially and adversely affect our business and prospect by, among other factors, forcing us to lower our tariffs, reducing or reversing the growth of our customer base and reducing usage of our services. Any of these developments could materially and adversely affect our revenues and profitability. We cannot assure you that the increasingly competitive environment and any change in the competitive landscape of the telecommunications industry in the PRC would not have a material adverse effect on our business, financial condition or results of operations.

The growth of our mobile business is subject to uncertainties involved in the future operations of the Tower Company.

On July 11, 2014, the Company, China United Network Communications Corporation Limited (CUCL) and China Mobile Communication Company Limited (CMCL) entered into a Promoters Agreement for China Communications Facilities Services Corporation Limited to jointly establish China Communications Facilities Services Corporation Limited (later renamed as China Tower Corporation Limited, the Tower Company). The Tower Company will be responsible for constructing and operating telecommunications towers and ancillary facilities, while the basic telecommunications services providers, including us, will rent these telecommunications assets from the Tower Company. According to the policies of the MIIT, starting from January 1, 2015, in principle, the three telecommunications operators, including us, will no longer construct their own telecommunications towers. On

October 14, 2015, the Company, CUCL, CMCL, the Tower Company and certain other parties entered into an Agreement on Purchase of Stock Tower-related Assets by Issuance of Shares and Payment of Cash, or the Transfer Agreement, pursuant to which each of the Company, CUCL and CMCL agreed to sell certain telecommunications towers and related assets to the Tower Company in exchange for new shares issued by the Tower Company, among others. On January 29, 2016, the Company and the Tower Company entered into a Share Subscription Agreement to acknowledge the number and price of the shares issued by the Tower Company to the Company. Currently, the Company and Tower Company have reached preliminary understanding and are in the process of negotiating arrangements in respect of our usage of certain telecommunications towers and related assets owned by the Tower Company. See Item 4. Information on the Company A. History and Development of the Company Establishment of the Tower Company and the Disposal and Use of the Telecommunications Towers .

The Tower Company will be of significant importance to the development of our mobile business and our results of operations. In particular, we are expected to use the telecommunications towers owned by the Tower Company for our mobile business. Because we do not control the Tower Company, we cannot assure you that it will act in the best interests of us. Given its short operational history, the operations of the Tower Company are subject to various uncertainties, including uncertainties as to the construction progress of the telecommunications towers and the quality of services provided by the Tower Company. In addition, we are in the process of negotiating with the Tower Company regarding the arrangements for our usage of its telecommunications towers and related assets, and we font-family:times;">Not subject to any extensions of the admissions thresholds under the 25 Percent Rule. LTCHs in this category are subject to a payment adjustment for discharged Medicare patients exceeding 25% of the LTCH's total Medicare population. Percentage admissions threshold was raised from 25% to 50%. This relief is now effective for five years starting with cost reporting periods beginning on or after October 1, 2007. In the special case of rural LTCHs, LTCHs co-located with an urban single hospital, or LTCHs co-located with an MSA-dominant hospital the referral percentage was raised to 75%. Grandfathered HIHs (two owned hospitals) Percentage admissions threshold is suspended for five years starting with cost reporting periods beginning on or after October 1, 2012. Percentage admission threshold is suspended for five years starting with cost reporting periods beginning on or after October 1, 2012. Percentage admission threshold is suspended for five years starting with cost reporting periods beginning on or after October 1, 2012.

15

Table of Contents

Type of LTCH

Grandfathered satellites (no owned hospitals)

Non Co-located Admissions

Not subject to any extensions of the admissions thresholds under the 25 Percent Rule. LTCHs in this category are subject to a payment adjustment for discharged Medicare patients exceeding 25% of the LTCH's total Medicare population.

Co-located Admissions

Percentage admissions threshold was raised from 25% to 50%. This relief is now effective for five years starting with cost reporting periods beginning on or after July 1, 2007, plus one additional year starting with cost reporting periods beginning on or after October 1, 2012. In the special case of rural LTCHs, LTCHs co-located with an urban single hospital, or LTCHs co-located with an MSA-dominant hospital the referral percentage was raised to 75%.

25 Percent Rule not applicable.

Freestanding facilities (32 owned hospitals)

Facilities co-located with a provider-based, off-campus, non-inpatient location of an inpatient prospective payment system hospital (no owned hospitals)

HIHs and satellite facilities opened on or after October 1, 2004 (seven owned hospitals)

Percentage admissions threshold is suspended for five years starting with cost reporting periods beginning on or after July 1, 2007, plus one additional year starting with cost reporting periods beginning on or after October 1, 2012. Percentage admissions threshold is suspended for five years starting with cost reporting periods beginning on or after July 1, 2007, plus one additional year starting with cost reporting periods beginning on or after October 1, 2012. LTCHs in this category are subject to a payment adjustment for discharged Medicare patients exceeding 25% of the LTCH's total Medicare population.

Percentage admission threshold is suspended for five years starting with cost reporting periods beginning on or after July 1, 2007, plus one additional year starting with cost reporting periods beginning on or after October 1, 2012.

LTCHs in this category are subject to a payment adjustment for discharged Medicare patients exceeding 25% of the LTCH's total Medicare population. In the special case where an LTCH is co-located with an MSA-dominant hospital, the referral percentage is no more than 50%, nor less than 25%.

After the expiration of the regulatory relief, as described above, our LTCHs (whether freestanding, HIH or satellite) will be subject to a downward payment adjustment for any Medicare patients who were admitted from a co-located or a non-co-located hospital and that exceed the applicable percentage threshold of all Medicare patients discharged from the LTCH during the cost reporting period. These regulatory changes will have an adverse financial impact on the net operating revenues and profitability of many of these hospitals for cost reporting periods on or after October 1, 2013.

16

Table of Contents

In the preamble to the proposed update to the Medicare policies and payment rates for fiscal year 2013, CMS indicated that "within the near future" it may recommend revisions to the payment policies addressing patient-level and facility-level criteria. CMS also indicated that these recommendations may render unnecessary the existing payment reductions for Medicare patients admitted from a general acute care hospital in excess of the applicable admission thresholds. We cannot predict whether CMS will adopt additional patient-level and facility-level criteria in the future or, if adopted, how such criteria would affect the application of the 25 Percent Rule to our LTCHs.

Moratorium on New LTCHs, LTCH Satellite Facilities and LTCH beds

The SCHIP Extension Act imposed a moratorium on the establishment and classification of new LTCHs, LTCH satellite facilities and LTCH beds in existing LTCHs or satellite facilities. The PPACA extended this moratorium by two years. The moratorium expired on December 28, 2012. Unless Congress or CMS take further action, new LTCHs, LTCH satellite facilities and LTCH beds may be established and enrolled in the Medicare program.

One-Time Budget Neutrality Adjustment

Congress required that the LTC-DRG payment rates maintain budget neutrality during the first years of the prospective payment system with total expenditures that would have been made under the previous reasonable cost-based payment system. The LTCH-PPS regulations give CMS the ability to make a one-time adjustment to the standard federal rate to correct any "significant difference between actual payments and estimated payments for the first year" of LTCH-PPS. The SCHIP Extension Act precluded CMS from implementing the one-time prospective adjustment to the LTCH standard federal rate for a period of three years. The PPACA extended the stay on CMS's ability to adopt a one-time budget neutrality adjustment to LTCH-PPS through December 28, 2012. In the update to the Medicare policies and payment rates for fiscal year 2013, CMS adopted a one-time budget neutrality adjustment that results in a permanent negative adjustment of 3.75% to the LTCH base rate. CMS is implementing the adjustment over a three-year period by applying a factor of 0.98734 to the standard federal rate in fiscal years 2013, 2014 and 2015, except that the adjustment would not apply to payments for discharges occurring on or after October 1, 2012 through December 28, 2012.

Proposed Legislation

On August 2, 2011, the "Long-Term Care Hospital Improvement Act of 2011," was introduced in the United States Senate and referred to the Senate Finance Committee. The proposed legislation would have implemented new patient-level and facility-level criteria for LTCHs, including a standardized preadmission screening process, specific criteria for admission and continued stay in an LTCH, and a list of core services that an LTCH must offer. In addition, the legislation would have required LTCHs to meet additional classification criteria to continue to be paid under LTCH-PPS. After a phase-in period, a threshold percentage of an LTCH's Medicare fee-for-service discharges would have been required to meet specified criteria. The proposed legislation would have repealed, and prohibited CMS from applying, the 25 Percent Rule that applies to Medicare patients discharged from LTCHs who were admitted from a co-located hospital or a non-co-located hospital and caused the LTCH to exceed the applicable percentage thresholds for discharged Medicare patients.

Though no action was taken by Congress with respect to the proposed legislation, hospital industry groups continue to press for similar legislation. In the meantime, CMS has delayed the full implementation of the 25 Percent Rule for one year. We cannot predict whether legislation similar to the legislation previously proposed will be enacted in the future or, if enacted, to what degree such legislation will resemble the provisions described here.

Annual Payment Rate Update

<u>Fiscal Year 2011</u>. On August 16, 2010, CMS published the policies and payment rates for LTCH-PPS for fiscal year 2011 (affecting discharges and cost reporting periods beginning on or after October 1, 2010

17

Table of Contents

through September 30, 2011). The standard federal rate for fiscal year 2011 was \$39,600, which was a decrease from the fiscal year 2010 standard federal rate of \$39,897 in effect from October 1, 2009 to March 31, 2010 and the fiscal year 2010 standard federal rate of \$39,795 that went into effect on April 1, 2010. The update to the standard federal rate for fiscal year 2011 included a market basket increase of 2.5%, less a reduction of 2.5% to account for what CMS attributed as an increase in case-mix in prior periods that resulted from changes in documentation and coding practices, less an additional market basket reduction of 0.5% as mandated by the PPACA. The final rule established a fixed-loss amount for high cost outlier cases for fiscal year 2011 of \$18,785, which was an increase from the fiscal year 2010 fixed-loss amount of \$18,425 in effect from October 1, 2009 to March 31, 2010 and the \$18,615 fixed-loss amount that went into effect on April 1, 2010.

<u>Fiscal Year 2012</u>. On August 18, 2011, CMS published the policies and payment rates for LTCH-PPS for fiscal year 2012 (affecting discharges and cost reporting periods beginning on or after October 1, 2011 through September 30, 2012). The standard federal rate for fiscal year 2012 was \$40,222, which was an increase from the fiscal year 2011 standard federal rate of \$39,600. The update to the standard federal rate for fiscal year 2012 included a market basket increase of 2.9%, less a productivity adjustment of 1.0%, and less an additional market basket reduction of 0.1% as mandated by the PPACA. The final rule established a fixed-loss amount for high cost outlier cases for fiscal year 2012 of \$17,931, which was a decrease from the fixed-loss amount in the 2011 fiscal year of \$18,785.

Fiscal Year 2013. On August 1, 2012, CMS published the final rule updating the policies and payment rates for LTCH-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013). Two different standard federal rates apply during fiscal year 2013. The standard federal rate for discharges on or after October 1, 2012 and before December 29, 2012 is \$40,916 and the standard federal rate for discharges on or after December 29, 2012 for the remainder of fiscal year 2013 is \$40,398, both of which are an increase from the fiscal year 2012 standard federal rate of \$40,222. The update to the standard federal rate for fiscal year 2013 through December 28, 2012 includes a market basket increase of 2.6%, less a productivity adjustment of 0.7%, and less an additional market basket reduction of 0.1% as mandated by the PPACA. The standard federal rate for the period of December 29, 2012 through the remainder of fiscal 2013 is further reduced by a portion of the one-time budget neutrality adjustment of 1.266%, as discussed above. The final rule establishes a fixed-loss amount for high cost outlier cases for fiscal year 2013 of \$15,408, which is a decrease from the fixed-loss amount in the 2012 fiscal year of \$17,931.

Medicare Market Basket Adjustments

The PPACA instituted a market basket payment adjustment to LTCHs. In fiscal year 2014 the market basket update will be reduced by 0.3%. In fiscal years 2015 and 2016 the market basket update will be reduced by 0.2%. Finally, in fiscal years 2017 through 2019, the market basket update will be reduced by 0.75%. The PPACA specifically allows these market basket reductions to result in less than a 0% payment update and payment rates that are less than the prior year.

Medicare Reimbursement of Inpatient Rehabilitation Facility Services

IRFs are paid under a prospective payment system specifically applicable to this provider type, which is referred to as "IRF-PPS." Under the IRF-PPS, each patient discharged from an IRF is assigned to a case mix group, or "IRF-CMG," containing patients with similar clinical conditions that are expected to require similar amounts of resources. An IRF is generally paid a pre-determined fixed amount applicable to the assigned IRF-CMG (subject to applicable case adjustments related to length of stay and facility level adjustments for location and low income patients). The payment amount for each IRF-CMG is intended to reflect the average cost of treating a Medicare patient's condition in an IRF relative to patients with conditions described by other IRF-CMGs. The IRF-PPS also includes special payment policies that adjust the payments for some patients based on the patient's length of stay, the facility's costs, whether the patient was discharged and readmitted and other factors.

18

Table of Contents

Facility Certification Criteria

Our rehabilitation hospitals must meet certain facility criteria to be classified as an IRF by the Medicare program, including: (1) a provider agreement to participate as a hospital in Medicare; (2) a preadmission screening procedure; (3) ensuring that patients receive close medical supervision and furnish, through the use of qualified personnel, rehabilitation nursing, physical therapy, and occupational therapy, plus, as needed, speech therapy, social or psychological services, and orthotic and prosthetic services; (4) a full-time, qualified director of rehabilitation; (5) a plan of treatment for each inpatient that is established, reviewed, and revised as needed by a physician in consultation with other professional personnel who provide services to the patient; (6) a coordinated multidisciplinary team approach in the rehabilitation of each inpatient, as documented by periodic clinical entries made in the patient's medical record to note the patient's status in relationship to goal attainment, and that team conferences are held at least every two weeks to determine the appropriateness of treatment. Failure to comply with any of the classification criteria may result in the denial of claims for payment or cause a hospital to lose its status as an IRF and be paid under the prospective payment system that applies to general acute care hospitals.

Patient Classification Criteria

Under the IRF certification criteria that has been in effect since 1983, in order to qualify as an IRF, a hospital was required to satisfy certain operational criteria as well as demonstrate that, during its most recent 12-month cost reporting period, it served an inpatient population of whom at least 75% required intensive rehabilitation services for one or more of 10 conditions specified in the regulation. We refer to such 75% requirement as the "75 Percent Rule."

New IRF certification criteria became effective for cost reporting periods beginning on or after July 1, 2004 as a result of the major changes that CMS adopted on May 7, 2004 to the 75 Percent Rule that: (1) temporarily lowered the 75% compliance threshold (starting at 50% and phasing to 75% over four years), (2) modified and expanded from 10 to 13 the medical conditions used to determine whether a hospital qualifies as an IRF, (3) identified the conditions under which comorbidities can be used to verify compliance with the 75 Percent Rule, and (4) changed the timeframe used to determine compliance with the 75 Percent Rule from "the most recent 12-month cost reporting period" to "the most recent, consecutive, and appropriate 12-month period," with the result that a determination of non-compliance with the applicable compliance threshold will affect the facility's certification as an IRF for its cost reporting period that begins immediately after the 12-month review period.

Under the Deficit Reduction Act of 2005, enacted on February 8, 2006, Congress extended the phase-in period for the 75 Percent Rule by maintaining the compliance threshold at 60% (rather than increasing it to the scheduled 65%) during the 12-month period beginning on July 1, 2006. The compliance threshold was then to increase to 65% for cost reporting periods beginning on or after July 1, 2007 and again to 75% for cost reporting periods beginning on or after July 1, 2008. However, the SCHIP Extension Act included a permanent freeze in the 75 Percent Rule patient classification criteria compliance threshold at 60% (with comorbidities counting toward this threshold) and a payment freeze from April 1, 2008 through September 30, 2009.

Annual Payment Rate Update

Fiscal Year 2011. On July 22, 2010, CMS published an update to the payment rates for IRF-PPS for fiscal year 2011 (affecting discharges and cost reporting periods beginning on or after October 1, 2010 through September 30, 2011). The standard payment conversion factor for discharges during fiscal year 2011 was \$13,860, which was an increase from the standard payment conversion factor for fiscal year 2010 of \$13,627. The update to the standard payment conversion factor for fiscal year 2011 included a market basket increase of 2.5%, less a market basket reduction of 0.25% as mandated by the PPACA. CMS increased the outlier threshold amount for fiscal year 2011 to \$11,410 from \$10,721 established in the revised final rule for fiscal year 2010.

19

Table of Contents

Fiscal Year 2012. On August 5, 2011, CMS published the policies and payment rates for IRF-PPS for fiscal year 2012 (affecting discharges and cost reporting periods beginning on or after October 1, 2011 through September 30, 2012). The standard payment conversion factor for discharges during fiscal year 2012 was \$14,076, which was an increase from the fiscal year 2011 standard payment conversion factor of \$13,860. The update to the standard payment conversion factor for fiscal year 2012 included a market basket increase of 2.9%, less a productivity adjustment of 1.0%, and less an additional market basket reduction of 0.1% as mandated by the PPACA CMS decreased the outlier threshold amount for fiscal year 2012 to \$10,660 from \$11,410 established in the final rule for fiscal year 2011. In a notice published September 26, 2011, CMS corrected its calculation of the outlier threshold amount for fiscal year 2012 to \$10,713.

Fiscal Year 2013. On July 30, 2012, CMS published the policies and payment rates for IRF-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013). The standard payment conversion factor for discharges during fiscal year 2013 is \$14,343, which is an increase from the fiscal year 2012 standard payment conversion factor of \$14,076. The update to the standard payment conversion factor for fiscal year 2013 includes a market basket increase of 2.7%, less a productivity adjustment of 0.7%, less an additional market basket reduction of 0.1% as mandated by the PPACA. CMS decreased the outlier threshold amount for fiscal year 2013 to \$10,466 from \$10,713 established in the final rule for fiscal year 2012.

Medicare Market Basket Adjustments

The PPACA instituted a market basket payment adjustment for IRFs. For fiscal year 2014, the reduction is 0.3%. For fiscal years 2015 and 2016, the reduction is 0.2%. For fiscal years 2017 through 2019, the reduction is 0.75%.

Medicare Reimbursement of Outpatient Rehabilitation Services

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. The Medicare physician fee schedule rates are automatically updated annually based on a formula, called the sustainable growth rate, or "SGR," formula, contained in legislation. The SGR formula has resulted in automatic reductions in rates every year since 2002; however, for each year through 2013 CMS or Congress has taken action to prevent the SGR formula reductions. The American Taxpayer Relief Act of 2012 froze the Medicare physician fee schedule rates at 2012 levels through December 31, 2013, averting a scheduled 26.5% cut as a result of the SGR formula that would have taken effect on January 1, 2013. A reduction in the Medicare physician fee schedule payment rates will occur on January 1, 2014, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect. For the year ended December 31, 2012, we received approximately 10% of our outpatient rehabilitation net operating revenues from Medicare.

In addition, MedPAC recommended that Congress direct CMS to collect data on provider service volume and work time to establish more accurate relative value unit payment rates and to identify and reduce overpriced fee schedule services. Similarly, the PPACA requires CMS to identify and review potentially misvalued codes and make appropriate adjustments to the relative values of those services identified as being misvalued. In the final update to the Medicare physician fee schedule for calendar year 2012 CMS identified several CPT codes used by physical therapists as codes they will review.

Therapy Caps

Beginning on January 1, 1999, the Balanced Budget Act of 1997 subjected certain outpatient therapy providers reimbursed under the Medicare physician fee schedule to annual limits for therapy expenses. Effective January 1, 2013, the annual limit on outpatient therapy services is \$1,900 for combined physical and speech language pathology services and \$1,900 for occupational therapy services. The per beneficiary caps were \$1,880 for calendar year 2012. The annual limits for therapy expenses historically did not apply

20

Table of Contents

to services furnished and billed by outpatient hospital departments. Although, the American Taxpayer Relief Act of 2012 extended the annual limits on therapy expenses and manual medical review thresholds to services furnished in hospital outpatient department settings from October 1, 2012 through December 31, 2013. The application of annual limits to hospital outpatient department settings will sunset at the end of 2013 unless Congress extends it into 2014. We operated 979 outpatient rehabilitation clinics at December 31, 2012, of which 145 are provider-based outpatient rehabilitation clinics operated as departments of the inpatient rehabilitation hospitals we operated.

In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual limit for therapy expenses. Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) is able to request an exception from the therapy caps if the provision of therapy services was deemed to be medically necessary. Therapy cap exceptions have been available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity. The American Taxpayer Relief Act of 2012 extends the exceptions process for outpatient therapy caps through December 31, 2013. Unless Congress extends the exceptions process, the therapy caps will apply to all outpatient therapy services beginning January 1, 2014, except those services furnished and billed by outpatient hospital departments.

The Middle Class Tax Relief and Job Creation Act of 2012 made several changes to the exceptions process to the annual limit for therapy expenses. For any claim above the annual limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record. Effective October 1, 2012, all claims exceeding \$3,700 are subject to a manual medical review process. The \$3,700 threshold is applied separately to the combined physical therapy/speech therapy cap and the occupational therapy cap. The American Taxpayer Relief Act of 2012 extends through December 31, 2013 the requirement that Medicare perform manual medical review of therapy services when an exception is requested for cases in which the beneficiary has reached a specified dollar aggregate threshold. Effective October 1, 2012, all therapy claims, whether above or below the annual limit, must include the national provider identifier (NPI) of the physician responsible for certifying and periodically reviewing the plan of care.

Several government agencies are expected to release reports on aspects of the Medicare payment system for therapy services. In the final 2011 Medicare physician fee schedule rule, CMS indicated the agency is evaluating alternative payment methodologies that would provide appropriate payment for medically necessary and effective therapy services furnished to Medicare beneficiaries based on patient needs rather than the current therapy caps. The Middle Class Tax Relief and Job Creation Act of 2012 directed MedPAC to submit a report to Congress by June 15, 2013 making recommendations on how to reform the payment system to better reflect acuity, condition, and the therapy needs of the patient. The MedPAC report is to include an examination of private sector initiatives related to therapy benefits. In addition, the Government Accountability Office, or "GAO," was directed to issue a report no later than May 1, 2013 regarding implementation of the manual medical review process instituted by the Middle Class Tax Relief and Job Creation Act of 2012. The report must detail the number of beneficiaries subject to the process, the number of reviews conducted, and the outcome of the reviews. Finally, The Middle Class Tax Relief and Job Creation Act of 2012 directed CMS to implement a claims-based data collection effort. Specifically, beginning on January 1, 2013, CMS is required to collect additional data on therapy claims related to patient function during the course of therapy in order to better understand patient conditions and outcomes. While reporting of data will begin on January 1, 2013, the first 6 months of the year will be a testing period for providers. Beginning on July 1, 2013, CMS will reject claims that do not include the required data codes and modifiers. The stated purpose of the claims based data collection effort is to assist in reforming the Medicare payment system for outpatient therapy services.

Multiple Procedure Payment Reduction

CMS adopted a multiple procedure payment reduction for therapy services in the final update to the Medicare physician fee schedule for calendar year 2011. This multiple procedure payment reduction policy

21

Table of Contents

became effective January 1, 2011 and applies to all outpatient therapy services paid under Medicare Part B. Furthermore, the multiple procedure payment reduction policy applies across all therapy disciplines—occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the therapy procedure or unit of service with the highest Relative Value Unit, and then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the second and subsequent therapy service furnished during the same day for the same patient were reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increases the payment reduction to 50%, in either setting, effective April 1, 2013. Our outpatient rehabilitation therapy services are primarily offered in institutional settings and, as such, are subject to the applicable 25% payment reduction in the practice expense component for the second and subsequent therapy services furnished by us to the same patient on the same day until April 1, 2013 when the payment reduction will increase to 50%. In 2013, this reduction will be partially offset due to the phase in of the final year of the transition to the new practice expense relative value units that resulted from CMS's use of new survey data.

Other Requirements for Payment

Historically, outpatient rehabilitation services have been subject to scrutiny by the Medicare program for, among other things, medical necessity for services, appropriate documentation for services, supervision of therapy aides and students and billing for single rather than group therapy when services are furnished to more than one patient. CMS has issued guidance to clarify that services performed by a student are not reimbursed even if provided under "line of sight" supervision of the therapist. Likewise, CMS has reiterated that Medicare does not pay for services provided by aides regardless of the level of supervision. CMS also has issued instructions that outpatient physical and occupational therapy services provided simultaneously to two or more individuals by a practitioner should be billed as group therapy services.

Budget Control Act of 2011

The Budget Control Act of 2011, enacted on August 2, 2011, increased the federal debt ceiling in connection with deficit reductions over the next ten years. The Budget Control Act of 2011 requires automatic reductions in federal spending by approximately \$1.2 trillion split evenly between domestic and defense spending. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. The American Taxpayer Relief Act of 2012 temporarily delays the automatic, across-the-board "sequestration" cuts in federal spending imposed by the Budget Control Act of 2011, which are expected to reduce Medicare payments by more than \$11 billion in fiscal year 2013 and \$123 billion over the period of fiscal years 2013 to 2021. Unless further legislation is enacted, we believe this will generally result in a 2% reduction to Medicare payments for services furnished on or after April 1, 2013, which reduction will have an adverse financial impact on our net operating revenues and profitability.

Specialty Hospital Medicaid Reimbursement

The Medicaid program is designed to provide medical assistance to individuals unable to afford care. The program is governed by the Social Security Act of 1965, funded jointly by each individual state and the federal government, and administered by state agencies. Medicaid payments are made under a number of different systems, which include cost based reimbursement, prospective payment systems or programs that negotiate payment levels with individual hospitals. In addition, Medicaid programs are subject to statutory and regulatory changes, administrative rulings, interpretations of policy by the state agencies and certain government funding limitations, all of which may increase or decrease the level of program payments to our hospitals. Net operating revenues generated directly from the Medicaid program represented approximately 5% of our specialty hospital net operating revenues for the year ended December 31, 2012.

22

Table of Contents

Workers' Compensation

Workers' compensation is a state mandated, comprehensive insurance program that requires employers to fund or insure medical expenses, lost wages and other costs resulting from work related injuries and illnesses. Workers' compensation benefits and arrangements vary on a state-by-state basis and are often highly complex. In some states, payment for services covered by workers' compensation programs are subject to cost containment features, such as requirements that all workers' compensation injuries be treated through a managed care program, or the imposition of payment caps. In addition, these workers' compensation programs may impose requirements that affect the operations of our outpatient rehabilitation services. Net operating revenues generated directly from workers' compensation programs represented approximately 18% of our net operating revenue from outpatient rehabilitation services and 1% of our net operating revenue from our specialty hospitals for the year ended December 31, 2012.

Other Medicare Regulations

Medicare Quality Reporting

The PPACA requires that CMS establish new quality data reporting programs for LTCHs and IRFs. By October 1, 2014, CMS is required to select and implement quality measures for these providers. These programs are mandatory. If a provider fails to report on the selected quality measures, its reimbursement will be reduced by 2% of the annual market basket update. The reduction can result in payment rates less than the prior year. However, the reduction will not carry over into the subsequent fiscal years. CMS is required to establish the quality measures applicable to fiscal year 2014 no later than October 1, 2012.

Medicare Productivity Adjustment

The PPACA implemented a separate annual productivity adjustment for the first time for hospital inpatient services beginning in fiscal year 2012 for LTCHs and IRFs. This provision applied a negative productivity adjustment to the market basket that is used to update the standard federal rate on an annual basis. The market basket does not currently account for increases in provider productivity that could reduce the actual cost of providing services (e.g., through new technology or fewer inputs). The productivity adjustment will equal the 10-year moving average of changes in the annual economy-wide private non-farm business multi-factor productivity. This is a statistic reported by the Bureau of Labor Statistics and updated in the spring of each year. While this adjustment will change each year, it is currently estimated that this adjustment to the market basket will be approximately minus 1.0% on average.

Hospital Wage Index

As part of the methodology for determining prospective payments to LTCHs and IRFs, CMS adjusts the standard payment amounts for area differences in hospital wage levels by a factor reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. This adjustment factor is the hospital wage index. CMS currently defines hospital geographic areas (labor market areas) based on the definitions of Core-Based Statistical Areas established by the Office of Management and Budget. The PPACA calls for CMS to develop and present to Congress a comprehensive reform plan using Bureau of Labor Statistics data, or other data or methodologies, to calculate relative wages for each geographic area involved. In the preamble to the proposed rule for LTCH-PPS for fiscal year 2012, CMS solicited public comments on ways to redefine the geographic reclassification requirements to more accurately define labor markets. To date CMS has not presented a comprehensive reform plan to Congress.

23

Table of Contents

Independent Payment Advisory Board

The PPACA established an independent board called the "Independent Payment Advisory Board" that will develop and submit proposals to the President and Congress beginning in 2014. The Independent Payment Advisory Board's proposals must be designed to reduce Medicare spending by targeted amounts compared to the trajectory of Medicare spending under current law. The Independent Payment Advisory Board's first proposal with savings recommendations could be submitted by January 14, 2014, for implementation in 2015, if the Medicare per capita target growth rate is exceeded, as described in the PPACA. However, the Independent Payment Advisory Board is precluded from submitting proposals that reduce Medicare payments prior to December 31, 2019 for providers scheduled to receive a reduction in their payment updates as a result of the Medicare productivity adjustment (discussed above).

Physician-Owned Hospital Limitations

CMS regulations include a number of hospital ownership and physician referral provisions, including certain obligations requiring physician-owned hospitals to disclose ownership or investment interests held by the referring physician or his or her immediate family members. In particular, physician-owned hospitals must furnish to patients, on request, a list of physicians or immediate family members who own or invest in the hospital. Moreover, a physician-owned hospital must require all physician owners or investors who are also active members of the hospital's medical staff to disclose in writing their ownership or investment interests in the hospital to all patients they refer to the hospital. CMS can terminate the Medicare provider agreement of a physician-owned hospital if it fails to comply with these disclosure provisions or with the requirement that a hospital disclose in writing to all patients whether there is a physician on-site at the hospital 24 hours per day, seven days per week.

Under the transparency and program integrity provisions of the PPACA, the exception to the federal self-referral law, or "Stark law," that permits physicians to refer patients to hospitals in which they have an ownership or investment interest has been dramatically curtailed. Only hospitals, including LTCHs, with physician ownership and a provider agreement in place on December 31, 2010 are exempt from the general ban on self-referral. Existing physician-owned hospitals are prohibited from increasing the percentage of physician ownership or investment interests held in the hospital after March 23, 2010. In addition, physician-owned hospitals are prohibited from increasing the number of licensed beds after March 23, 2010, unless meeting specific exceptions related to the hospital's location and patient population. In order to retain their exemption from the general ban on self-referrals, our physician-owned hospitals are required to adopt specific measures relating to conflicts of interest, bona fide investments and patient safety. As of December 31, 2012, we operated ten hospitals that are owned in-part by physicians.

Provider and Employee Screening

The PPACA imposed new screening requirements on all Medicare providers, including LTCHs, IRFs and outpatient rehabilitation providers. The screening must include a licensure check and may include other procedures such as a criminal background check, fingerprinting, unscheduled and unannounced site visits, database checks, and other screening techniques CMS deems appropriate to prevent fraud, waste and abuse. Effective March 23, 2011, Medicare providers and suppliers submitting new enrollment applications or revalidating their existing enrollment status are required to pay a \$500 application fee that is adjusted annually by the percentage change in the consumer price index. The PPACA also imposed new disclosure requirements and authorizes surety bonds for the enrollment of new providers and suppliers.

In addition, the PPACA requires LTCHs to conduct national and state criminal background checks, including fingerprint checks of their employees and contractors who have (or may have) one-on-one contact with patients. Our LTCHs are prohibited from hiring or retaining workers with a history of patient or resident abuse.

24

Table of Contents

Medicare Compliance Requirements and Penalties

The PPACA included new compliance requirements and increases existing penalties for non-compliance with federal law and the Medicare conditions of participation. In addition, Medicare claims will be paid only if submitted within 12 months. Penalties for submitting false claims and for submitting false statements material to a false claim will be increased. The Secretary will be granted the authority to suspend payments to a provider pending an investigation of credible allegations of fraud. Further, the Recovery Audit Contractor program has been extended to Medicare Parts C and D and Medicaid.

Other Healthcare Regulations

Medicare Recovery Audit Contractors. The Tax Relief and Health Care Act of 2006 instructed CMS to contract with third-party organizations, known as Recovery Audit Contractors, or "RACs," to identify Medicare underpayments and overpayments, and to authorize RACs to recoup any overpayments. The compensation paid to each RAC is based on a percentage of overpayment recoveries identified by the RAC. CMS has selected and entered into contracts with four RACs, each of which has begun their audit activities in specific jurisdictions. RAC audits of our Medicare reimbursement may lead to assertions that we have been overpaid, require us to incur additional costs to respond to requests for records and pursue the reversal of payment denials, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict the impact of future RAC reviews on our results of operations or cash flows.

Fraud and Abuse Enforcement. Various federal and state laws prohibit the submission of false or fraudulent claims, including claims to obtain payment under Medicare, Medicaid and other government healthcare programs. Penalties for violation of these laws include civil and criminal fines, imprisonment and exclusion from participation in federal and state healthcare programs. In recent years, federal and state government agencies have increased the level of enforcement resources and activities targeted at the healthcare industry. In addition, the federal False Claims Act and similar state statutes allow individuals to bring lawsuits on behalf of the government, in what are known as qui tam or "whistleblower" actions, alleging false or fraudulent Medicare or Medicaid claims or other violations of the statute. The use of these private enforcement actions against healthcare providers has increased dramatically in recent years, in part because the individual filing the initial complaint is entitled to share in a portion of any settlement or judgment. Revisions to the False Claims Act enacted in 2009 expanded significantly the scope of liability, provided for new investigative tools, and made it easier for whistleblowers to bring and maintain False Claims Act suits on behalf of the government. See "Legal Proceedings."

From time to time, various federal and state agencies, such as the Office of Inspector General of the Department of Health and Human Services, or "OIG," issue a variety of pronouncements, including fraud alerts, the OIG's Annual Work Plan and other reports, identifying practices that may be subject to heightened scrutiny. These pronouncements can identify issues relating to LTCHs, IRFs or outpatient rehabilitation services or providers. For example, the OIG's 2010 and 2011 Work Plans identified as an area of concern whether the patient assessment instruments prepared by IRFs were submitted in accordance with Medicare regulations. Among other things, the 2011 Work Plan indicated that CMS would review the appropriateness of provider-based designations for outpatient clinics, outlier payments made to hospitals for beneficiaries who incur unusually high costs, and the effectiveness of a claims processing edit designed to capture hospital readmissions that are subject to a single payment for both inpatient stays. The 2012 Work Plan identified the appropriateness of admissions to IRFs as an area subject to review. The OIG indicated that it would examine the level of therapy being provided in IRFs and how much concurrent and group therapy IRFs are providing. Under the 2012 work plan, the OIG also will review the quality of care and safety of Medicare beneficiaries transferred from general acute care hospitals to IRFs and LTCHs. We monitor government publications applicable to us to supplement and enhance our compliance efforts.

25

Table of Contents

We endeavor to conduct our operations in compliance with applicable laws, including healthcare fraud and abuse laws. If we identify any practices as being potentially contrary to applicable law, we will take appropriate action to address the matter, including, where appropriate, disclosure to the proper authorities, which may result in a voluntary refund of monies to Medicare, Medicaid or other governmental healthcare programs.

Remuneration and Fraud Measures. The federal anti-kickback statute prohibits some business practices and relationships under Medicare, Medicaid and other federal healthcare programs. These practices include the payment, receipt, offer or solicitation of remuneration in connection with, to induce, or to arrange for, the referral of patients covered by a federal or state healthcare program. Violations of the anti-kickback law may be punished by a criminal fine of up to \$50,000 or imprisonment for each violation, or both, civil monetary penalties of \$50,000 and damages of up to three times the total amount of remuneration, and exclusion from participation in federal or state healthcare programs.

The Stark Law prohibits referrals for designated health services by physicians under the Medicare and Medicaid programs to other healthcare providers in which the physicians have an ownership or compensation arrangement unless an exception applies. Sanctions for violating the Stark Law include civil monetary penalties of up to \$15,000 per prohibited service provided, assessments equal to three times the dollar value of each such service provided and exclusion from the Medicare and Medicaid programs and other federal and state healthcare programs. The statute also provides a penalty of up to \$100,000 for a circumvention scheme. In addition, many states have adopted or may adopt similar anti-kickback or anti-self-referral statutes. Some of these statutes prohibit the payment or receipt of remuneration for the referral of patients, regardless of the source of the payment for the care. While we do not believe our arrangements are in violation of these prohibitions, we cannot assure you that governmental officials charged with the responsibility for enforcing the provisions of these prohibitions will not assert that one or more of our arrangements are in violation of the provisions of such laws and regulations.

Provider-Based Status. The designation "provider-based" refers to circumstances in which a subordinate facility (e.g., a separately certified Medicare provider, a department of a provider or a satellite facility) is treated as part of a provider for Medicare payment purposes. In these cases, the services of the subordinate facility are included on the "main" provider's cost report and overhead costs of the main provider can be allocated to the subordinate facility, to the extent that they are shared. We operate 18 specialty hospitals that are treated as provider-based satellites of certain of our other facilities, 145 of the outpatient rehabilitation clinics we operated were provider-based and are operated as departments of the IRFs we operated, and we provide rehabilitation management and staffing services to hospital rehabilitation departments that may be treated as provider-based. These facilities are required to satisfy certain operational standards in order to retain their provider-based status.

Health Information Practices. The Health Insurance Portability and Accountability Act of 1996, or "HIPAA," mandates the adoption of standards for the exchange of electronic health information in an effort to encourage overall administrative simplification and enhance the effectiveness and efficiency of the healthcare industry, while maintaining the privacy and security of health information. Among the standards that the Department of Health and Human Services has adopted or will adopt pursuant to HIPAA are standards for electronic transactions and code sets, unique identifiers for providers (referred to as National Provider Identifier), employers, health plans and individuals, security and electronic signatures, privacy and enforcement. If we fail to comply with the HIPAA requirements, we could be subject to criminal penalties and civil sanctions. The privacy, security and enforcement provisions of HIPAA were enhanced by the Health Information Technology for Economic and Clinical Health Act, or "HITECH," which was included in the ARRA. Among other things, HITECH establishes security breach notification requirements, allows enforcement of HIPAA by state attorneys general, and increases penalties for HIPAA violations.

The Department of Health and Human Services has adopted standards in three areas in which we are required to comply that affect our operations.

26

Table of Contents

Standards relating to the privacy of individually identifiable health information govern our use and disclosure of protected health information and require us to impose those rules, by contract, on any business associate to whom such information is disclosed.

Standards relating to electronic transactions and code sets require the use of uniform standards for common healthcare transactions, including healthcare claims information, plan eligibility, referral certification and authorization, claims status, plan enrollment and disenrollment, payment and remittance advice, plan premium payments and coordination of benefits.

Standards for the security of electronic health information require us to implement various administrative, physical and technical safeguards to ensure the integrity and confidentiality of electronic protected health information.

We maintain a HIPAA committee that is charged with evaluating and monitoring our compliance with HIPAA. The HIPAA committee monitors regulations promulgated under HIPAA as they have been adopted to date and as additional standards and modifications are adopted. Although health information standards have had a significant effect on the manner in which we handle health data and communicate with payors, the cost of our compliance has not had a material adverse effect on our business, financial condition or results of operations. We cannot estimate the cost of compliance with standards that have not been issued or finalized by the Department of Health and Human Services.

In addition to HIPAA, there are numerous federal and state laws and regulations addressing patient and consumer privacy concerns, including unauthorized access or theft of personal information. State statutes and regulations vary from state to state. Lawsuits, including class actions and action by state attorneys general, directed at companies that have experienced a privacy or security breach also can occur. Although our policies and procedures are aimed at complying with privacy and security requirements and minimizing the risks of any breach of privacy or security, there can be no assurance that a breach of privacy or security will not occur. If there is a breach, we may be subject to various penalties and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals.

Compliance Program

Our Compliance Program

In late 1998, we voluntarily adopted our code of conduct. The code is reviewed and amended as necessary and is the basis for our company-wide compliance program. Our written code of conduct provides guidelines for principles and regulatory rules that are applicable to our patient care and business activities. These guidelines are implemented by a compliance officer, a compliance and internal audit committee, and employee education and training. We also have established a reporting system, auditing and monitoring programs, and a disciplinary system as a means for enforcing the code's policies.

Compliance and Internal Audit Committee

Our compliance and internal audit committee is made up of members of our senior management and in-house counsel. The compliance and internal audit committee meets on a quarterly basis and reviews the activities, reports and operation of our compliance program. In addition, the HIPAA committee provides reports to the compliance and internal audit committee. The vice president of compliance and audit services meets with the compliance and internal audit committee on a quarterly basis to provide an overview of the activities and operation of our compliance program.

Operating Our Compliance Program

We focus on integrating compliance responsibilities with operational functions. We recognize that our compliance with applicable laws and regulations depends upon individual employee actions as well as company operations. As a result, we have adopted an operations team approach to compliance. Our corporate executives, with the assistance of corporate experts, designed the programs of the compliance

27

Table of Contents

and internal audit committee. We utilize facility leaders for employee-level implementation of our code of conduct. This approach is intended to reinforce our company-wide commitment to operate in accordance with the laws and regulations that govern our business.

Compliance Issue Reporting

In order to facilitate our employees' ability to report known, suspected or potential violations of our code of conduct, we have developed a system of reporting. This reporting, anonymous or attributable, may be accomplished through our toll-free compliance hotline, compliance e-mail address or our compliance post office box. The compliance officer and the compliance and internal audit committee are responsible for reviewing and investigating each compliance incident in accordance with the compliance and audit services department's investigation policy.

Compliance Monitoring and Auditing / Comprehensive Training and Education

Monitoring reports and the results of compliance for each of our business segments are reported to the compliance and internal audit committee on a quarterly basis. We train and educate our employees regarding the code of conduct, as well as the legal and regulatory requirements relevant to each employee's work environment. New and current employees are required to acknowledge and certify that the employee has read, understood and has agreed to abide by the code of conduct. Additionally, all employees are required to re-certify compliance with the code on an annual basis.

Policies and Procedures Reflecting Compliance Focus Areas

We review our policies and procedures for our compliance program from time to time in order to improve operations and to ensure compliance with requirements of standards, laws and regulations and to reflect the ongoing compliance focus areas which have been identified by the compliance and internal audit committee.

Internal Audit

In addition to and in support of the efforts of our compliance and audit department, during 2001 we established an internal audit function. The vice president of compliance and audit services manages the combined compliance and audit department and meets with the audit and compliance committee of the board of directors on a quarterly basis to discuss audit results and provide an overview of the activities and operation of our compliance program.

Available Information

We are subject to the information and periodic reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance therewith, file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information is available for inspection and copying at the SEC's Public Reference Room at 100 F Street, NE., Washington, DC 20549, or may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains a website at www.sec.gov that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC.

Our website address is www.selectmedicalholdings.com and can be used to access free of charge, through the investor relations section, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after we electronically file such material with or furnish it to the SEC. The information on our website is not incorporated as a part of this annual report.

28

Table of Contents

Executive Officers of the Registrant

The following table sets forth the names, ages and titles, as well as a brief account of the business experience, of each person who was an executive officer of the Company as of January 1, 2013:

Name	Age	Position			
Rocco A. Ortenzio					
	80	Executive Chairman			
Robert A. Ortenzio					
	55	Chief Executive Officer			
Patricia A. Rice					
	66	President			
David S. Chernow					
	56	President and Chief Administrative Officer			
Martin F. Jackson					
	58	Executive Vice President and Chief Financial Officer			
John A. Saich					
	44	Executive Vice President and Chief Human Resources Officer			
James J. Talalai					
	51	Executive Vice President and Chief Operating Officer			
Michael E. Tarvin					
	52	Executive Vice President, General Counsel and Secretary			
Scott A. Romberger					
	52	Senior Vice President, Controller and Chief Accounting Officer			
Robert G. Breighner, Jr.		Vice President, Compliance and Audit Services and Corporate Compliance			
	44	Officer			

Rocco A. Ortenzio co-founded the Company and he served as our Chairman and Chief Executive Officer from February 1997 until September 2001. Mr. Ortenzio has served as our Executive Chairman since September 2001. In 1986, he co-founded Continental Medical Systems, Inc., and served as its Chairman and Chief Executive Officer until July 1995. In 1979, Mr. Ortenzio founded Rehab Hospital Services Corporation, and served as its Chairman and Chief Executive Officer until June 1986. In 1969, Mr. Ortenzio founded Rehab Corporation and served as its Chairman and Chief Executive Officer until 1974. Mr. Ortenzio is the father of Robert A. Ortenzio, our Chief Executive Officer.

Robert A. Ortenzio co-founded the Company and has served as a director since February 1997. Mr. Ortenzio has served as our Chief Executive Officer since January 1, 2005 and as our President and Chief Executive Officer from September 2001 to January 1, 2005. Mr. Ortenzio also served as our President and Chief Operating Officer from February 1997 to September 2001. He was an Executive Vice President and a director of Horizon/CMS Healthcare Corporation from July 1995 until July 1996. In 1986, Mr. Ortenzio co-founded Continental Medical Systems, Inc., and served in a number of different capacities, including as a Senior Vice President from February 1986 until April 1988, as Chief Operating Officer from April 1988 until July 1995, as President from May 1989 until August 1996 and as Chief Executive Officer from July 1995 until August 1996. Before co-founding Continental Medical Systems, Inc., he was a Vice President of Rehab Hospital Services Corporation. Until August 17, 2010, Mr. Ortenzio served on the board of directors of Odyssey Healthcare, Inc., a hospice healthcare company. Mr. Ortenzio also served on the board of directors of US Oncology, Inc. until December 30, 2010. Mr. Ortenzio is the son of Rocco A. Ortenzio, our Executive Chairman.

Patricia A. Rice has served as our President since January 1, 2005. She served as President and Chief Operating Officer from January 2005 to December 2011. Prior to this, she served as our Executive Vice President and Chief Operating Officer since January 2002 and as our Executive Vice President of Operations from November 1999 to January 2002. She served as Senior Vice President of Hospital Operations from December 1997 to November 1999. She was Executive Vice President of the Hospital Operations Division for Continental Medical Systems, Inc. from August 1996 until December 1997. Prior

29

Table of Contents

to that time, she served in various management positions at Continental Medical Systems, Inc. from 1987 to 1996.

David S. Chernow has served as our President and Chief Administrative Officer since March 2012. Prior to such time, Mr. Chernow served as our President and Chief Development and Strategy Officer from September 13, 2010. Mr. Chernow served as a director of the Company from January 2002 until February 2005 and from August 2005 until September 2010. From May 2007 to February 2010, Mr. Chernow served as the President and Chief Executive Officer of Oncure Medical Corp., one of the largest providers of free-standing radiation oncology care in the United States. From July 2001 to June 2007, Mr. Chernow served as the President and Chief Executive Officer of JA Worldwide, a nonprofit organization dedicated to the education of young people about business (formerly, Junior Achievement, Inc.). From 1999 to 2001, he was the President of the Physician Services Group at US Oncology, Inc. Mr. Chernow co-founded American Oncology Resources in 1992 and served as its Chief Development Officer until the time of the merger with Physician Reliance Network, Inc., which created US Oncology, Inc. in 1999.

Martin F. Jackson has served as our Executive Vice President and Chief Financial Officer since February 2007. He served as our Senior Vice President and Chief Financial Officer from May 1999 to February 2007. Mr. Jackson previously served as a Managing Director in the Health Care Investment Banking Group for CIBC Oppenheimer from January 1997 to May 1999. Prior to that time, he served as Senior Vice President, Health Care Finance with McDonald & Company Securities, Inc. from January 1994 to January 1997. Prior to 1994, Mr. Jackson held senior financial positions with Van Kampen Merritt, Touche Ross, Honeywell and L'Nard Associates. Mr. Jackson also serves as a director of several private companies.

John A. Saich has served as our Executive Vice President and Chief Human Resources Officer since December 15, 2010. He served as our Senior Vice President, Human Resources from February 2007 to December 2010. He served as our Vice President, Human Resources from November 1999 to January 2007. He joined the Company as Director, Human Resources and HRIS in February 1998. Previously, Mr. Saich served as Director of Benefits and Human Resources for Integrated Health Services in 1997 and as Director of Human Resources for Continental Medical Systems, Inc. from August 1993 to January 1997.

James J. Talalai has served as our Executive Vice President and Chief Operating Officer since January 2012. Prior to this, he served as our Executive Vice President and Chief Information Officer from February 2007 to December 2011. He served as our Senior Vice President and Chief Information Officer from August 2001 to February 2007. He joined the Company in May 1997 and served in various leadership capacities within Information Services. Before joining us, Mr. Talalai was Director of Information Technology for Horizon/ CMS Healthcare Corporation from 1995 to 1997. He also served as Data Center Manager at Continental Medical Systems, Inc. in the mid-1990s.

Michael E. Tarvin has served as our Executive Vice President, General Counsel and Secretary since February 2007. He served as our Senior Vice President, General Counsel and Secretary from November 1999 to February 2007. He served as our Vice President, General Counsel and Secretary from February 1997 to November 1999. He was Vice President Senior Counsel of Continental Medical Systems from February 1993 until February 1997. Prior to that time, he was Associate Counsel of Continental Medical Systems from March 1992. Mr. Tarvin was an associate at the Philadelphia law firm of Drinker Biddle & Reath, LLP from September 1985 until March 1992.

Scott A. Romberger has served as our Senior Vice President and Controller since February 2007. He served as our Vice President and Controller from February 1997 to February 2007. In addition, he has served as our Chief Accounting Officer since December 2000. Prior to February 1997, he was Vice President — Controller of Continental Medical Systems from January 1991 until January 1997. Prior to that time, he served as Acting Corporate Controller and Assistant Controller of Continental Medical Systems from June 1990 and December 1988, respectively. Mr. Romberger is a certified public accountant and was employed by a national accounting firm from April 1985 until December 1988.

30

Table of Contents

Robert G. Breighner, Jr. has served as our Vice President, Compliance and Audit Services since August 2003. He served as our Director of Internal Audit from November 2001 to August 2003. Previously, Mr. Breighner was Director of Internal Audit for Susquehanna Pfaltzgraff Co. from June 1997 until November 2001. Mr. Breighner held other positions with Susquehanna Pfaltzgraff Co. from May 1991 until June 1997.

Item 1A. Risk Factors.

In addition to the factors discussed elsewhere in this Form 10-K, the following are important factors which could cause actual results or events to differ materially from those contained in any forward-looking statements made by or on behalf of us.

If there are changes in the rates or methods of government reimbursements for our services, our net operating revenues and profitability could decline.

Approximately 47% of our net operating revenues for the year ended December 31, 2010, 48% of our net operating revenues for the year ended December 31, 2012 came from the highly regulated federal Medicare program. Unless further legislation is enacted, we expect the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, will generally result in a 2% reduction to Medicare payments for services furnished on or after April 1, 2013, including services furnished by our facilities to Medicare beneficiaries, which reduction will have an adverse financial impact on our net operating revenues and profitability.

In recent years, through legislative and regulatory actions, the federal government has made substantial changes to various payment systems under the Medicare program. President Obama signed into law comprehensive reforms to the healthcare system, including changes to the methods for, and amounts of, Medicare reimbursement. Additional reforms or other changes to these payment systems, including modifications to the conditions on qualification for payment, bundling payments to cover both acute and post-acute care or the imposition of enrollment limitations on new providers, may be proposed or could be adopted, either by the U.S. Congress or by CMS. If revised regulations are adopted, the availability, methods and rates of Medicare reimbursements for services of the type furnished at our facilities could change. Some of these changes and proposed changes could adversely affect our business strategy, operations and financial results. In addition, there can be no assurance that any increases in Medicare reimbursement rates established by CMS will fully reflect increases in our operating costs.

We conduct business in a heavily regulated industry, and changes in regulations, new interpretations of existing regulations or violations of regulations may result in increased costs or sanctions that reduce our net operating revenues and profitability.

The healthcare industry is subject to extensive federal, state and local laws and regulations relating to (1) facility and professional licensure, including certificates of need, (2) conduct of operations, including financial relationships among healthcare providers, Medicare fraud and abuse and physician self-referral, (3) addition of facilities and services and enrollment of newly developed facilities in the Medicare program, (4) payment for services and (5) safeguarding protected health information.

Both federal and state regulatory agencies inspect, survey and audit our facilities to review our compliance with these laws and regulations. While our facilities intend to comply with existing licensing, Medicare certification requirements and accreditation standards, there can be no assurance that these regulatory authorities will determine that all applicable requirements are fully met at any given time. A determination by any of these regulatory authorities that a facility is not in compliance with these requirements could lead to the imposition of requirements that the facility takes corrective action, assessment of fines and penalties, or loss of licensure, Medicare certification or accreditation. These consequences could have an adverse effect on our company.

31

Table of Contents

In addition, there have been heightened coordinated civil and criminal enforcement efforts by both federal and state government agencies relating to the healthcare industry. The ongoing investigations relate to, among other things, various referral practices, cost reporting, billing practices, physician ownership and joint ventures involving hospitals. In the future, different interpretations or enforcement of these laws and regulations could subject us to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services and capital expenditure programs. These changes may increase our operating expenses and reduce our operating revenues. If we fail to comply with these extensive laws and government regulations, we could become ineligible to receive government program reimbursement, suffer civil or criminal penalties or be required to make significant changes to our operations. In addition, we could be forced to expend considerable resources responding to any related investigation or other enforcement action.

Full implementation of Medicare admission thresholds applicable to LTCHs operated as HIHs or as "satellites" will have an adverse effect on our future net operating revenues and profitability.

Effective for hospital cost reporting periods beginning on or after October 1, 2004, LTCHs that are operated as HIHs or as HIH "satellites," are subject to a payment reduction for those Medicare patients admitted from their host hospitals that are in excess of a specified percentage threshold. These HIHs and their HIH satellites are separate hospitals located in space leased from, or located on the same campus of, another hospital, which we refer to as "host hospitals." For HIHs opened after October 1, 2004, the Medicare admissions threshold has been established at 25% except for HIHs located in rural areas or co-located with an MSA dominant hospital or single urban hospital (as defined by the current regulations) in which cases the percentage is no more than 50%, nor less than 25%. Certain grandfathered HIHs were initially excluded from the Medicare admission threshold regulations. Grandfathered HIHs refer to certain HIHs that were in existence on or before September 30, 1995, and grandfathered satellite facilities refer to satellites of grandfathered HIHs that were in existence on or before September 30, 1999.

The SCHIP Extension Act, as amended by the ARRA and the PPACA, limited the application of the Medicare admission threshold on HIHs in existence on October 1, 2004. For these HIHs, the admission threshold was no lower than 50% for a five year period to commence on an LTCH's first cost reporting period to begin on or after October 1, 2007. Under the SCHIP Extension Act, for HIHs located in rural areas the percentage threshold was no more than 75% for the same five year period. For HIHs that are co-located with MSA dominant hospitals or single urban hospitals, the percentage threshold was no more than 75% during the same five year period. The SCHIP Extension Act, as amended, limited the full application of the Medicare percentage threshold and, in some cases, postponed application of the percentage threshold until cost reporting periods beginning on or after July 1, 2012 or October 1, 2012. Through regulations published on August 1, 2012, CMS adopted a one-year extension of relief granted by the SCHIP Extension Act from the full application of Medicare admission thresholds. As a result, full implementation of the Medicare admission thresholds will not go into effect until cost reporting periods beginning on or after October 1, 2013, except for certain LTCHs with cost reporting periods that begin between July 1, 2012 and September 30, 2012.

As of December 31, 2012, we owned 77 LTCH HIHs; five of these HIHs were subject to a maximum 25% Medicare admission threshold, two HIHs are co-located with an MSA dominant hospital and was subject to a Medicare admission threshold of no more than 50%, nor less than 25%, 18 of these HIHs were co-located with a MSA dominant hospital or single urban hospital and were subject to a Medicare admission threshold of no more than 75%, 47 of these HIHs were subject to a maximum 50% Medicare admissions threshold, three of these HIHs were located in a rural area and were subject to a maximum 75% Medicare admission threshold, and two of these HIHs were grandfathered HIHs and not subject to a Medicare admission threshold.

Because these rules are complex and are based on the volume of Medicare admissions from our host hospitals as a percent of our overall Medicare admissions, we cannot predict with any certainty the impact on our future net operating revenues of compliance with these regulations. Additionally, in the absence of

32

Table of Contents

an additional extension of relief by CMS, like that granted in its regulations published on August 1, 2012, or the passage of new legislation similar to the legislation proposed in 2011 and discussed above, we expect many of our HIHs will experience an adverse financial impact when full implementation of the Medicare admission thresholds goes into effect for LTCHs with cost reporting periods beginning on or after October 1, 2013, or sooner for certain LTCHs with cost reporting periods that begin between July 1, 2012 and September 30, 2012. As a result, we expect these rules will adversely affect our future net operating revenues and profitability.

Full implementation of Medicare admission thresholds applicable to LTCHs operated as free-standing or grandfathered HIHs or grandfathered "satellites" will have an adverse effect on our future net operating revenues and profitability.

For cost reporting periods beginning on or after July 1, 2007, CMS expanded the current Medicare HIH admissions threshold to apply to Medicare patients admitted from any individual hospital. Previously, the admissions threshold was applicable only to Medicare HIH admissions from hospitals co-located with an LTCH or satellite of an LTCH. Under the expanded rule, free-standing LTCHs and grandfathered LTCH HIHs are subject to the Medicare admission thresholds, as well as HIHs that admit Medicare patients from non-co-located hospitals. To the extent that any LTCH's or LTCH satellite facility's discharges that are admitted from an individual hospital (regardless of whether the referring hospital is co-located with the LTCH or LTCH satellite) exceed the applicable percentage threshold during a particular cost reporting period, the payment rate for those discharges is subject to a downward payment adjustment. Cases admitted in excess of the applicable threshold are reimbursed at a rate comparable to that under IPPS. IPPS rates are generally lower than LTCH-PPS rates. Cases that reach outlier status in the discharging hospital do not count toward the limit and are paid under LTCH-PPS.

The SCHIP Extension Act, as amended, postponed the application of the percentage threshold to free-standing LTCHs and grandfathered HIHs for a five-year period commencing on an LTCH's first cost reporting period on or after July 1, 2007. However, the SCHIP Extension Act did not postpone the application of the percentage threshold to Medicare patients discharged from an LTCH HIH or HIH satellite that were admitted from a non-co-located hospital. In addition, the SCHIP Extension Act, as interpreted by CMS, did not provide relief from the application of the threshold for patients admitted from a co-located hospital to certain non-grandfathered HIHs. The ARRA limits application of the admission threshold to no more than 50% of Medicare admissions to grandfathered satellites from a co-located hospital for a five year period commencing on the first cost reporting period beginning on or after July 1, 2007. Through regulations published on August 1, 2012, CMS adopted a one-year extension of relief granted by the SCHIP Extension Act from the full application of Medicare admission thresholds. As a result, full implementation of the Medicare admission thresholds will not go into effect until cost reporting periods beginning on or after October 1, 2013, except for certain LTCHs with cost reporting periods that begin between July 1, 2012 and September 30, 2012. Those freestanding facilities, grandfathered HIHs and grandfathered satellites with cost reporting periods beginning on or after July 1, 2012 and before October 1, 2012 are subject to a modified admission threshold for discharges occurring in a three month period between July 1, 2012 and September 30, 2012.

Of the 109 LTCHs we owned as of December 31, 2012, 32 were operated as free-standing hospitals and two qualified as grandfathered LTCH HIHs. Because these rules are complex and are based on the volume of Medicare admissions from other referring hospitals as a percent of our overall Medicare admissions, we cannot predict with any certainty the impact on our future net operating revenues of compliance with these regulations. However, if the Medicare admission thresholds are implemented as currently written, there will be an adverse financial impact to the net operating revenues and profitability of many of these hospitals for cost reporting periods on or after October 1, 2013.

33

Table of Contents

Expiration of the moratorium imposed on the payment adjustment for very short-stay cases in our LTCHs will reduce our future net operating revenues and profitability.

On May 1, 2007, CMS published a new provision that changed the payment methodology for Medicare patients with a length of stay that is less than the IPPS comparable threshold. Beginning with discharges on or after July 1, 2007, for these very short-stay cases, the rule lowered the LTCH payment to a rate based on the general acute care hospital IPPS per diem. SSO cases with covered lengths of stay that exceed the IPPS comparable threshold would continue to be paid under the existing SSO payment policy. The SCHIP Extension Act and PPACA prevented CMS from applying this change to SSO policy for a period of five years through December 28, 2012. The implementation of the payment methodology for very short-stay outliers discharged after December 29, 2012 will reduce our future net operating revenues and profitability.

If our LTCHs fail to maintain their certifications as LTCHs or if our facilities operated as HIHs fail to qualify as hospitals separate from their host hospitals, our net operating revenues and profitability may decline.

As of December 31, 2012, we operated 110 LTCHs, all of which are currently certified by Medicare as LTCHs. LTCHs must meet certain conditions of participation to enroll in, and seek payment from, the Medicare program as an LTCH, including, among other things, maintaining an average length of stay for Medicare patients in excess of 25 days. An LTCH that fails to maintain this average length of stay for Medicare patients (including both Medicare covered and non-covered days) greater than 25 days during a single cost reporting period is generally allowed an opportunity to show that it meets the length of stay criteria during the subsequent cost reporting period. If the LTCH can show that it meets the length of stay criteria during this cure period, it will continue to be paid under the LTCH-PPS. If the LTCH again fails to meet the average length of stay criteria during the cure period, it will be paid under the general acute care inpatient prospective payment system at rates generally lower than the rates under the LTCH-PPS.

Similarly, our HIHs must meet conditions of participation in the Medicare program, which include additional criteria establishing separateness from the hospital with which the HIH shares space. If our LTCHs or HIHs fail to meet or maintain the standards for certification as LTCHs, they will receive payment under the general acute care hospitals IPPS which is generally lower than payment under the system applicable to LTCHs. Payments at rates applicable to general acute care hospitals would result in our LTCHs receiving significantly less Medicare reimbursement than they currently receive for their patient services.

Implementation of additional patient or facility criteria for LTCHs that limit the population of patients eligible for our hospitals' services or change the basis on which we are paid could adversely affect our net operating revenue and profitability.

CMS and industry stakeholders have, for a number of years, explored the development of facility and patient certification criteria for LTCHs, potentially as an alternative to the current specific payment adjustment features of LTCH-PPS. In its June 2004 report to Congress, MedPAC recommended the adoption by CMS of new facility staffing and services criteria and patient clinical characteristics and treatment requirements for LTCHs in order to ensure that only appropriate patients are admitted to these facilities. MedPAC is an independent federal body that advises Congress on issues affecting the Medicare program. After MedPAC's recommendation, CMS awarded a contract to Research Triangle Institute International to examine such recommendation. However, while acknowledging that Research Triangle Institute International's findings are expected to have a substantial impact on future Medicare policy for LTCHs, CMS stated in its payment update published in May 2006, that many of the specific payment adjustment features of LTCH-PPS then in place may still be necessary and appropriate even with the development of patient- and facility-level criteria for LTCHs. In early 2008, CMS indicated that Research Triangle Institute International continues to work with the clinical community to make recommendations to CMS regarding payment and treatment of critically ill patients in LTCHs. The SCHIP Extension Act

34

Table of Contents

requires the Secretary of the Department of Health and Human Services to conduct a study and submit a report to Congress on the establishment of national LTCH facility and patient criteria and to consider the recommendations contained in MedPAC's June 2004 report to Congress.

Legislation was introduced in the United States Senate on August 2, 2011. The proposed legislation would have implemented new patient-level and facility-level criteria for LTCHs, including a standardized preadmission screening process, specific criteria for admission and continued stay in an LTCH, and a list of core services that an LTCH must offer. In addition, the legislation would have required LTCHs to meet additional classification criteria to continue to be paid under LTCH-PPS. After a phase-in period, a threshold percentage of an LTCH's Medicare fee-for-service discharges would have been required to meet specified criteria. The proposed legislation would have repealed, and prohibited CMS from applying, the 25 Percent Rule that applies to Medicare patients discharged from LTCHs who were admitted from a co-located hospital or a non-co-located hospital and caused the LTCH to exceed the applicable percentage thresholds for discharged Medicare patients. Though no action was taken by Congress with respect to the proposed legislation, hospital industry groups continue to press for similar legislation. Implementation of these or other criteria that may limit the population of patients eligible for our LTCHs' services or change the basis on which we are paid could adversely affect our net operating revenues and profitability. See "Business Government Regulations Overview of U.S. and State Government Reimbursements Long Term Acute Care Hospital Medicare Reimbursement."

Decreases in Medicare reimbursement rates received by our outpatient rehabilitation clinics, implementation of annual caps, and payment reductions applied to the second and subsequent therapy services will reduce our future net operating revenues and profitability.

Our outpatient rehabilitation clinics receive payments from the Medicare program under a fee schedule. The Medicare physician fee schedule rates are automatically updated annually based on the SGR formula, contained in legislation. The American Taxpayer Relief Act of 2012 froze the Medicare physician fee schedule rates at 2012 levels through December 31, 2013, averting a scheduled 26.5% cut as a result of the SGR formula that would have taken effect on January 1, 2013. If no further legislation is passed by Congress and signed by the President, the SGR formula will likely reduce our Medicare outpatient rehabilitation payment rates beginning January 1, 2014.

Congress has established annual caps that limit the amount that can be paid (including deductible and coinsurance amounts) for outpatient therapy services rendered to any Medicare beneficiary. As directed by Congress in the Deficit Reduction Act of 2005, CMS implemented an exception process for therapy expenses incurred in 2006. Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) was able to request an exception from the therapy caps if the provision of therapy services was deemed to be medically necessary. Therapy cap exceptions were available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity. The exception process has been extended by Congress several times. Most recently, the American Taxpayer Relief Act of 2012 extended the exceptions process through December 31, 2013. The exception process will expire on January 1, 2014 unless further extended by Congress. There can be no assurance that Congress will extend it further. To date, the implementation of the therapy caps has not had a material adverse effect on our business. However, if the exception process is not renewed, our future net operating revenues and profitability may decline.

CMS adopted a multiple procedure payment reduction for therapy services in the final update to the Medicare physician fee schedule for calendar year 2011. The policy became effective January 1, 2011 and applies to all outpatient therapy services paid under Medicare Part B occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the therapy procedure or unit of service with the highest Relative Value Unit, and then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012 the second and

35

Table of Contents

subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increases the payment reduction to 50% effective April 1, 2013. Our outpatient rehabilitation therapy services are primarily offered in institutional settings and, as such, are subject to the applicable 25% payment reduction in the practice expense component for the second and subsequent therapy services furnished by us to the same patient on the same day until April 1, 2013 when the payment reduction will increase to 50%. For the years ended December 31, 2010, 2011 and 2012, we received approximately 10% of our outpatient rehabilitation net operating revenues from Medicare. See "Business" Government Regulations."

Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information.

HIPAA required the United States Department of Health and Human Services to adopt standards to protect the privacy and security of individually identifiable health-related information. The department released final regulations containing privacy standards in December 2000 and published revisions to the final regulations in August 2002. The privacy regulations extensively regulate the use and disclosure of individually identifiable health-related information. The regulations also provide patients with significant rights related to understanding and controlling how their health information is used or disclosed. The security regulations require healthcare providers to implement administrative, physical and technical practices to protect the security of individually identifiable health information that is maintained or transmitted electronically. HITECH, which was signed into law in February of 2009, enhanced the privacy, security and enforcement provisions of HIPAA by, among other things establishing security breach notification requirements, allowing enforcement of HIPAA by state attorneys general, and increasing penalties for HIPAA violations. Violations of HIPAA or HITECH could result in civil or criminal penalties.

In addition to HIPAA, there are numerous federal and state laws and regulations addressing patient and consumer privacy concerns, including unauthorized access or theft of personal information. State statutes and regulations vary from state to state. Lawsuits, including class actions and action by state attorneys general, directed at companies that have experienced a privacy or security breach also can occur.

We have developed a comprehensive set of policies and procedures in our efforts to comply with HIPAA and other privacy laws. Our compliance officer, privacy officer and information security officer are responsible for implementing and monitoring compliance with our privacy and security policies and procedures at our facilities. We believe that the cost of our compliance with HIPAA and other federal and state privacy laws will not have a material adverse effect on our business, financial condition, results of operations or cash flows. However, there can be no assurance that a breach of privacy or security will not occur. If there is a breach, we may be subject to various penalties and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals.

As a result of increased post-payment reviews of claims we submit to Medicare for our services, we may incur additional costs and may be required to repay amounts already paid to us.

We are subject to regular post-payment inquiries, investigations and audits of the claims we submit to Medicare for payment for our services. These post-payment reviews are increasing as a result of new government cost-containment initiatives, including enhanced medical necessity reviews for Medicare patients admitted to LTCHs, and audits of Medicare claims under the Recovery Audit Contractor program. These additional post-payment reviews may require us to incur additional costs to respond to requests for records and to pursue the reversal of payment denials, and ultimately may require us to refund amounts paid to us by Medicare that are determined to have been overpaid.

36

Table of Contents

We may be adversely affected by negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes.

Negative press coverage can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes. Adverse publicity and increased governmental scrutiny can have a negative impact on our reputation with referral sources and patients and on the morale and performance of our employees, both of which could adversely affect our businesses and results of operations.

Future acquisitions or joint ventures may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.

As part of our growth strategy, we may pursue acquisitions or joint ventures of specialty hospitals, outpatient rehabilitation clinics and other related healthcare facilities and services. These acquisitions or joint ventures may involve significant cash expenditures, debt incurrence, additional operating losses and expenses that could have a material adverse effect on our financial condition and results of operations.

We may not be able to successfully integrate acquired businesses into ours, and therefore we may not be able to realize the intended benefits from an acquisition. If we fail to successfully integrate acquisitions, our financial condition and results of operations may be materially adversely effected. Acquisitions could result in difficulties integrating acquired operations, technologies and personnel into our business. Such difficulties may divert significant financial, operational and managerial resources from our existing operations and make it more difficult to achieve our operating and strategic objectives. We may fail to retain employees or patients acquired through acquisitions, which may negatively impact the integration efforts. Acquisitions could also have a negative impact on our results of operations if it is subsequently determined that goodwill or other acquired intangible assets are impaired, thus resulting in an impairment charge in a future period.

In addition, acquisitions involve risks that the acquired businesses will not perform in accordance with expectations; that we may become liable for unforeseen financial or business liabilities of the acquired businesses, including liabilities for failure to comply with healthcare regulations; that the expected synergies associated with acquisitions will not be achieved; and that business judgments concerning the value, strengths and weaknesses of businesses acquired will prove incorrect, which could have an material adverse effect on our financial condition and results of operations.

Future cost containment initiatives undertaken by private third-party payors may limit our future net operating revenues and profitability.

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs affect the profitability of our specialty hospitals and outpatient rehabilitation clinics. These payors attempt to control healthcare costs by contracting with hospitals and other healthcare providers to obtain services on a discounted basis. We believe that this trend may continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments reduce the amounts they pay for services, our profit margins may decline, or we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

If we fail to maintain established relationships with the physicians in the areas we serve, our net operating revenues may decrease.

Our success is partially dependent upon the admissions and referral practices of the physicians in the communities our hospitals and our outpatient rehabilitation clinics serve, and our ability to maintain good relations with these physicians. Physicians referring patients to our hospitals and clinics are generally not our employees and, in many of the local areas that we serve, most physicians have admitting privileges at other hospitals and are free to refer their patients to other providers. If we are unable to successfully cultivate and maintain strong relationships with these physicians, our hospitals' admissions and clinics' businesses may decrease, and our net operating revenues may decline.

37

Table of Contents

Changes in federal or state law limiting or prohibiting certain physician referrals may preclude physicians from investing in our hospitals or referring to hospitals in which they already own an interest.

The Stark Law prohibits a physician who has a financial relationship with an entity from referring his or her Medicare or Medicard patients to that entity for certain designated health services, including inpatient and outpatient hospital services. Under the transparency and program integrity provisions of the PPACA, the exception to the Stark Law that previously permitted physicians to refer patients to hospitals in which they have an ownership or investment interest has been dramatically curtailed. Only hospitals, including LTCHs, with physician ownership and a provider agreement in place on December 31, 2010 are exempt from the general ban on self-referral. Existing physician-owned hospitals are prohibited from increasing the percentage of physician ownership or investment interests held in the hospital after March 23, 2010. In addition, physician-owned hospitals are prohibited from increasing the number of licensed beds after March 23, 2010, unless meeting specific exceptions related to the hospital's location and patient population. In order to retain their exemption from the general ban on self-referrals, our physician-owned hospitals are required to adopt specific measures relating to conflicts of interest, bona fide investments and patient safety. Furthermore, initiatives are underway in some states to restrict physician referrals to physician-owned hospitals. Currently, ten of our hospitals have physicians as minority owners. The aggregate net operating revenue of these ten hospitals was \$200.3 million for the year ended December 31, 2012, or approximately 6.8% of our consolidated net operating revenues for the year ended December 31, 2012. The range of physician minority ownership of these ten hospitals was 2.1% to 49.0% as of the year ended December 31, 2012. There can be no assurance that new legislation or regulation prohibiting or limiting physician referrals to physician-owned hospitals will not be successfully enacted in the future. If such federal or state laws are adopted, among other outcomes, physicians who have invested in our hospitals could be precluded from referring to, investing in or continuing to be physician owners of a hospital. In addition, expansion of our physician-owned hospitals may be limited, and the revenues, profitability and overall financial performance of our hospitals may be negatively affected.

We could experience significant increases to our operating costs due to shortages of healthcare professionals or union activity.

Our specialty hospitals are highly dependent on nurses, and our outpatient rehabilitation division is highly dependent on therapists, for patient care. The market for qualified healthcare professionals is highly competitive. We have sometimes experienced difficulties in attracting and retaining qualified healthcare personnel. We cannot assure you we will be able to attract and retain qualified healthcare professionals in the future. Additionally, the cost of attracting and retaining qualified healthcare personnel may be higher than we anticipate, and as a result, our profitability could decline.

In addition, U.S. healthcare providers are continuing to see an increase in the amount of union activity. Though we cannot predict the degree to which we will be affected by future union activity, there are continuing legislative proposals that could result in increased union activity. We could experience an increase in labor and other costs from such union activity.

Competition may limit our ability to acquire hospitals and clinics and adversely affect our growth.

We have historically faced limited competition in acquiring specialty hospitals and outpatient rehabilitation clinics, but we may face heightened competition in the future. Our competitors may acquire or seek to acquire many of the hospitals and clinics that would be suitable acquisition candidates for us. This increased competition could hamper our ability to acquire companies, or such increased competition may cause us to pay a higher price than we would otherwise pay in a less competitive environment. Increased competition from both strategic and financial buyers could limit our ability to grow by acquisitions or make our cost of acquisitions higher and therefore decrease our profitability.

38

Table of Contents

If we fail to compete effectively with other hospitals, clinics and healthcare providers in the local areas we serve, our net operating revenues and profitability may decline.

The healthcare business is highly competitive, and we compete with other hospitals, rehabilitation clinics and other healthcare providers for patients. If we are unable to compete effectively in the specialty hospital and outpatient rehabilitation businesses, our net operating revenues and profitability may decline. Many of our specialty hospitals operate in geographic areas where we compete with at least one other hospital that provides similar services. Our outpatient rehabilitation clinics face competition from a variety of local and national outpatient rehabilitation providers. Other outpatient rehabilitation clinics in local areas we serve may have greater name recognition and longer operating histories than our clinics. The managers of these clinics may also have stronger relationships with physicians in their communities, which could give them a competitive advantage for patient referrals.

Our business operations could be significantly disrupted if we lose key members of our management team.

Our future success depends to a significant degree upon the continued contributions of our senior officers and other key employees, and our ability to retain and motivate these individuals. We currently have employment agreements in place with four executive officers and change in control agreements and/or non-competition agreements with several other officers. Many of these individuals also have significant equity ownership in our company. We do not maintain any key life insurance policies for any of our employees. The loss of the services of several of these individuals at one time could disrupt significant aspects of our business, could prevent us from successfully executing our business strategy and could have a material adverse affect on our results of operations.

Significant legal actions could subject us to substantial uninsured liabilities.

Physicians, hospitals and other healthcare providers have become subject to an increasing number of legal actions alleging malpractice, product liability or related legal theories. Many of these actions involve large claims and significant defense costs. We are also subject to lawsuits under federal and state whistleblower statutes designed to combat fraud and abuse in the healthcare industry. These whistleblower lawsuits are not covered by insurance and can involve significant monetary damages and award bounties to private plaintiffs who successfully bring the suits. See "Legal Proceedings" and Note 16 in our audited consolidated financial statements.

We currently maintain professional malpractice liability insurance and general liability insurance coverages under a combination of policies with a total annual aggregate limit of \$30.0 million. Our insurance for the professional liability coverage is written on a "claims-made" basis and our commercial general liability coverage is maintained on an "occurrence" basis. These coverages apply after a self-insured retention of \$2.0 million per medical incident for professional liability claims and \$2.0 million per occurrence for general liability claims. We review our insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. In addition, our insurance coverage does not generally cover punitive damages and may not cover all claims against us. See "Business Government Regulations Other Healthcare Regulations."

Concentration of ownership among our existing executives, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.

Welsh Carson and Thoma Cressey beneficially own approximately 37.2% and 8.2%, respectively, of Holdings' outstanding common stock as of February 1, 2013. Our executives, directors and principal stockholders, including Welsh Carson and Thoma Cressey, beneficially own, in the aggregate, approximately 63.3% of Holdings' outstanding common stock as of February 1, 2013. As a result, these stockholders have significant control over our management and policies and are able to exercise influence over all matters requiring stockholder approval, including the election of directors, amendment of our certificate of incorporation and approval of significant corporate transactions. The directors elected by

39

Table of Contents

these stockholders are able to make decisions affecting our capital structure, including decisions to issue additional capital stock, implement stock repurchase programs and incur indebtedness. This influence may have the effect of deterring hostile takeovers, delaying or preventing changes in control or changes in management, or limiting the ability of our other stockholders to approve transactions that they may deem to be in their best interest.

Our substantial indebtedness may limit the amount of cash flow available to invest in the ongoing needs of our business.

We have a substantial amount of indebtedness. As of December 31, 2012, we had approximately \$1,470.2 million of total indebtedness. For the years ended December 31, 2010, December 31, 2011 and December 31, 2012, we paid cash interest of \$105.9 million, \$107.5 million and \$80.7 million, respectively, on our indebtedness.

Our indebtedness could have important consequences to you. For example, it:

requires us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, reducing the availability of our cash flow to fund working capital, capital expenditures, development activity, acquisitions and other general corporate purposes;

increases our vulnerability to adverse general economic or industry conditions;

limits our flexibility in planning for, or reacting to, changes in our business or the industries in which we operate;

makes us more vulnerable to increases in interest rates, as borrowings under our senior secured credit facilities;

limits our ability to obtain additional financing in the future for working capital or other purposes; and

places us at a competitive disadvantage compared to our competitors that have less indebtedness.

See "Management's Discussion and Analysis of Financial Condition and Results of Operations Liquidity and Capital Resources."

Our senior secured credit facilities require Select to comply with certain financial covenants, the default of which may result in the acceleration of certain of our indebtedness.

The senior secured credit facilities require Select to maintain a leverage ratio (based upon the ratio of indebtedness to consolidated EBITDA as defined in the agreement), which is tested quarterly and becomes more restrictive over time. The senior secured credit facilities also prohibit Select from making capital expenditures in excess of \$125.0 million in any fiscal year (subject to a 50% carry-over provision). Failure to comply with these covenants would result in an event of default under the senior secured credit facilities and, absent a waiver or an amendment from the lenders, preclude Select from making further borrowings under the revolving credit facility and permit the lenders to accelerate all outstanding borrowings under the senior secured credit facilities.

As of December 31, 2012, Select was required to maintain its leverage ratio (its ratio of total indebtedness to consolidated EBITDA for the prior four consecutive fiscal quarters) at less than 4.75 to 1.00. For the four quarters ended December 31, 2012, Select's leverage ratio was 3.18 to 1.00.

While Select has never defaulted on compliance with any of these financial covenants, its ability to comply with these ratios in the future may be affected by events beyond its control. Inability to comply with the required financial covenants could result in a default under our senior secured credit facilities. In the event of any default under our senior secured credit facilities, the lenders under our senior secured credit facilities could elect to terminate borrowing commitments and declare all borrowings outstanding, together with accrued and unpaid interest and other fees, to be immediately due and payable.

Table of Contents

Despite our substantial level of indebtedness, we and our subsidiaries may be able to incur additional indebtedness. This could further exacerbate the risks described above.

We and our subsidiaries may be able to incur additional indebtedness in the future. Although our senior secured credit facilities contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of qualifications and exceptions, and the indebtedness incurred in compliance with these restrictions could be substantial. Also, these restrictions do not prevent us or our subsidiaries from incurring obligations that do not constitute indebtedness. As of December 31, 2012, we had \$135.9 million of revolving loan availability under our senior secured credit facilities (after giving effect to \$34.1 million of outstanding letters of credit). In addition, to the extent new debt is added to our and our subsidiaries' current debt levels, the substantial leverage risks described above would increase.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

We currently lease most of our facilities, including clinics, offices, specialty hospitals and our corporate headquarters. We own 25 of our specialty hospitals.

We lease all but two of our outpatient rehabilitation clinics and related offices, which, as of December 31, 2012 included 866 leased outpatient rehabilitation clinics throughout the United States. We also lease the majority of our LTCH facilities except for the facilities described above. As of December 31, 2012, in our specialty hospitals we had 75 HIH leases and 16 free-standing building leases.

We lease our corporate headquarters from companies owned by a related party affiliated with us through common ownership or management. Our corporate headquarters is approximately 132,000 square feet and is located in Mechanicsburg, Pennsylvania. We lease several other administrative spaces related to administrative and operational support functions. As of December 31, 2012, this was comprised of 11 locations throughout the United States with approximately 50,000 square feet in total.

41

Table of Contents

The following is a list by state of the number of our consolidated hospitals and related beds we operated as of December 31, 2012.

Specialty Hospitals							
	Long Term	Inpatient	Outpatient	Total			
	Acute Care	Rehabilitation	Clinics	Facilities			
Alabama	1			1			
Alaska			5	5			
Arizona	3		13	16			
Arkansas	4		1	5			
California			7	7			
Colorado	3		17	20			
Connecticut			38	38			
District of Columbia			2	2			
Delaware	1		1	2			
Florida	9	1	101	111			
Georgia	5		25	30			
Illinois			40	40			
Indiana	5		21	26			
Iowa	1			1			
Kansas	3		14	17			
Kentucky	2		42	44			
Louisiana	1		3	4			
Maine			12	12			
Maryland			23	23			
Massachusetts			9	9			
Michigan	11		13	24			
Minnesota	1		25	26			
Mississippi	5			5			
Missouri	3	2	59	64			
Nebraska	1			1			
Nevada			6	6			
New Hampshire			4	4			
New Jersey	1	3	141	145			
New Mexico			2	2			
North Carolina	3		34	37			
Ohio	15		59	74			
Oklahoma	2		20	22			
Pennsylvania	9	1	112	122			
South Carolina	2		14	16			
South Dakota	1			1			
Tennessee	5		10	15			
Texas	9	5	84	98			
Virginia			22	22			
West Virginia	1			1			
Wisconsin	3			3			
	J			-			
Total Company	110	12	979	1,101			
Total Company	110	12	42	1,101			
			74				

Table of Contents

Item 3. Legal Proceedings.

To cover claims arising out of the operations of the Company's specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company's other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions as well as the cost and possible lack of available insurance could subject the Company to substantial uninsured liabilities.

The Company is subject to legal proceedings and claims that arise in the ordinary course of business, which include malpractice claims covered under insurance policies, subject to self-insured retention of \$2.0 million per medical incident for professional liability claims and \$2.0 million per occurrence for general liability claims. In the Company's opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

On January 8, 2013, a federal magistrate judge unsealed an Amended Complaint in United States of America and the State of Indiana, ex rel. Doe I, Doe II and Doe III v. Select Medical Corporation, Select Specialty Hospital-Evansville, Evansville Physician Investment Corporation, Dr. Richard Sloan and Dr. Jeffrey Selby. The Amended Complaint, which was served on the Company on February 15, 2013, is a civil action filed under seal on September 28, 2012 in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States and Indiana under the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act. The Amended Complaint identifies the plaintiff-relators as Doe I, Doe II and Doe III, and describes them as the CEO and two case managers at the Company's long term acute care hospital in Evansville, Indiana ("SSH-Evansville"). The named defendants include the Company, SSH-Evansville Physician Investment Company, the Company's joint venture partner in SSH-Evansville ("EPIC"), and two physicians who have practiced at SSH-Evansville. On February 6, 2013, the District Court issued an order dismissing EPIC without prejudice after the plaintiff-relators filed, on January 31, 2013, a Notice of Voluntary Dismissal of EPIC, to which the United States and Indiana consented. The Notice of Voluntary Dismissal states, among other things, that the United States filed a notice with the Court on December 28, 2012 that it had not completed its investigation and thus would not intervene in the action at that time. The U.S. Attorney's Office for the Southern District of Indiana has informed the Company's counsel that, despite the lifting of the seal, the United States is continuing its investigation in order to determine whether or not to intervene in the matter at some point.

The Amended Complaint alleges that the defendants manipulated the length of stay of patients at SSH-Evansville in order to maximize reimbursement under the Medicare prospective payment system applicable to long-term acute care hospitals. It also alleges that the defendants manipulated the discharge of patients to other facilities and the timing of readmissions from those facilities in order to enable SSH-Evansville to receive two separate Medicare payments and causing the other facility to submit claims for unnecessary services. The Amended Complaint discusses the federal Stark Law and Anti-Kickback Statute and implies that the behavior of physicians referring to or providing services at SSH-Evansville was based on their financial interests. The Amended Complaint further alleges that Dr. Selby, a pulmonologist formerly on the medical staff of SSH-Evansville, performed unnecessary bronchoscopies at the hospital

43

Table of Contents

with the knowledge of the Company, and that Dr. Sloan, the Chief Medical Officer and an attending physician at SSH-Evansville, falsely coded the diagnoses of Medicare patients in order to increase SSH-Evansville's reimbursement. Moreover, the Amended Complaint alleges that the practices at SSH-Evansville involved corporate policies of the Company used to maximize profit at all Select long-term acute care hospitals. The Amended Complaint alleges that, through these acts, the defendants have violated the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act and are liable for unspecified treble damages and penalties.

As previously disclosed, beginning in April 2012, the Company and SSH-Evansville have received various subpoenas and demands for documents relating to SSH-Evansville, including a request for information and subpoenas from the Office of Inspector General of the U.S. Department of Health and Human Services and subpoenas from the Office of Attorney General for the State of Indiana, and the Evansville (Indiana) Police Department has executed a search warrant at SSH-Evansville. The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

Item 4. Mine Safety Disclosures.

None.

44

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Select Medical Holdings Corporation common stock has been quoted on the New York Stock Exchange under the symbol "SEM" since our initial public offering on September 25, 2009. Prior to that date there was no public market for our common stock. The following table sets forth, for the periods indicated, the high and low sales prices of our common stock, reported by the New York Stock Exchange.

		ces		
Fiscal Year Ended December 31, 2011	H	igh	I	_ow
First Quarter	\$	8.07	\$	6.68
Second Quarter	\$	9.66	\$	7.87
Third Quarter	\$	9.27	\$	5.48
Fourth Quarter	\$	9.16	\$	6.13

		Market Prices				
Fiscal Year Ended December 31, 2012	ŀ	Iigh	I	Low		
First Quarter	\$	8.88	\$	7.45		
Second Quarter	\$	10.25	\$	6.94		
Third Quarter	\$	14.89	\$	9.94		
Fourth Quarter	\$	12.03	\$	9.20		
Holders						

At the close of business on February 1, 2013, Holdings had 140,594,256 shares of common stock issued and outstanding. As of that date, there were 125 registered holders of record. This does not reflect beneficial stockholders who hold their stock in nominee or "street" name through brokerage firms.

Dividend Policy

On October 30, 2012, Holdings declared a special cash dividend of \$1.50 per share, totaling approximately \$210.9 million. This special cash dividend was paid on December 12, 2012 to all stockholders of record at the close of business on December 5, 2012.

Other than the dividend described above, Holdings has not paid or declared any dividends on its common stock. We do not anticipate paying any further dividends on Holdings' common stock in the foreseeable future. We intend to retain future earnings to finance the ongoing operations and growth of our business. Any future determination relating to our dividend policy will be made at the discretion of our board of directors and will depend on conditions at that time, including our financial condition, results of operations, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.

Securities Authorized For Issuance Under Equity Compensation Plans

For information regarding securities authorized for issuance under equity compensation plans, see Part III "Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters."

45

Table of Contents

Stock Performance Graph

The graph below compares the cumulative total stockholder return on \$100 invested at the close of the market on September 25, 2009, the first trading day of the Company's common stock on the New York Stock Exchange, with dividends being reinvested on the date paid through and including the market close on December 31, 2012 with the cumulative total return of the same time period on the same amount invested in the Standard & Poor's 500 Index ("S&P 500") and the Morgan Stanley Healthcare Provider Index ("RXH"), an equal-dollar weighted index of 15 companies involved in the business of hospital management and medical/nursing services. The chart below the graph sets forth the actual numbers depicted on the graph.

	09	9/25/09	12	2/31/09	13	2/31/10	12	2/30/11	12	2/31/12
Select Medical Holding Corporation (SEM)	\$	100.00	\$	105.25	\$	72.45	\$	84.04	\$	107.00
Morgan Stanley Healthcare Provider Index (RXH)	\$	100.00	\$	103.27	\$	125.54	\$	120.47	\$	132.23
S&P 500	\$	100.00	\$	106.77	\$	120.42	\$	120.42	\$	136.56

Item 6. Selected Financial Data.

You should read the following selected historical consolidated financial data in conjunction with our consolidated financial statements and the accompanying notes. You should also read "Management's Discussion and Analysis of Financial Condition and Results of Operations," which is contained elsewhere herein. The historical financial data as of December 31, 2008, 2009, 2010, 2011 and 2012 and for the years ended December 31, 2008, 2009, 2010, 2011 and 2012 have been derived from consolidated financial statements audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm. The selected historical consolidated financial data as of December 31, 2011 and 2012, and for the years

46

Table of Contents

ended December 31, 2010, 2011 and 2012 have been derived from our consolidated financial information included elsewhere herein. The selected historical consolidated financial data as of December 31, 2008, 2009 and 2010 and for the years ended December 31, 2008 and 2009 have been derived from our audited consolidated financial information not included elsewhere herein.

	Select Medical Holdings Corporation									
				Year	En	ded Decembe	er 3	1,		
	$2008^{(1)(2)}$ 2009 2010 2011					2012				
				(In thousa	nds	, except per s	har	re data)		
Statement of Operations Data:										
Net operating revenues	\$ 2	2,153,362	\$	2,239,871	\$	2,390,290	\$	2,804,507	\$	2,948,969
Operating expenses ⁽³⁾⁽⁴⁾		1,885,168		1,933,052		2,085,447		2,422,271		2,548,799
Depreciation and amortization		71,786		70,981		68,706		71,517		63,311
Income from operations		196,408		235,838		236,137		310,719		336,859
Gain (loss) on early retirement of debt ⁽⁵⁾		912		13,575				(31,018)		(6,064)
Equity in earnings (losses) of unconsolidated subsidiaries						(440)		2,923		7,705
Other income (expense)				(632)		632				
Interest expense, net ⁽⁶⁾		(145,423)		(132,377)		(112,337)		(98,894)		(94,950)
Income before income taxes		51,897		116,404		123,992		183,730		243,550
Income tax expense		26,063		37,516		41,628		70,968		89,657
Net income		25,834		78,888		82,364		112,762		153,893
Less: Net income attributable to non-controlling interests ⁽⁷⁾		3,393		3,606		4,720		4,916		5,663
Net income attributable to Select Medical Holdings Corporation		22,441		75,282		77,644		107,846		148,230
Less: Preferred dividends		24,972		19,537		,		,		
Net income (loss) available to common stockholders and										
participating securities		(2,531)		55,745		77,644		107,846		148,230
Other comprehensive income (loss):		())		,-		, -		,		
Unrealized gain (loss) on interest rate swap, net of tax		(7,649)		4,298		8,914				
Comprehensive income (loss) attributable to Select Medical										
Holdings Corporation	\$	(10,180)	\$	60,043	\$	86,558	\$	107,846	\$	148,230
S. C. I		(1, 11,	Ċ	,	·	/	Ċ	,.	•	,
Income (loss) per common share:										
Basic	\$	(0.04)	\$	0.61	\$	0.49	\$	0.71	\$	1.05
Diluted	\$	(0.04)		0.61	\$	0.48	\$	0.71	\$	1.05
Weighted average common shares outstanding:		()								
Basic		59,566		85,587		159,184		150,501		138,767
Diluted		59,566		86,045		159,442		150,725		139,042
Balance Sheet Data (at end of period):										
Cash and cash equivalents	\$	64,260	\$	83,680	\$	4,365	\$	12,043	\$	40,144
Working capital (deficit)		118,370		156,685		(70,232)		99,472		65,200
Total assets		2,579,469		2,588,146		2,722,086		2,772,147		2,761,361
Total debt		1,779,925		1,405,571		1,430,769		1,396,798		1,470,243
Total Select Medical Holdings Corporation stockholders' equity		(174,204)		735,930		780,947		819,679		717,048
	4	17								

Table of Contents

	Select Medical Corporation Year Ended December 31, 2008 ⁽¹⁾ 2009 2010 2011 2012								2012	
		000		2007	Œι	thousands)		2011		2012
Statement of Operations Data:					(11	thousands)				
Net operating revenues	\$ 2,	153,362	\$	2,239,871	\$	2,390,290	\$	2,804,507	\$	2,948,969
Operating expenses ⁽³⁾⁽⁴⁾	1,	885,168		1,933,052		2,085,447		2,422,271		2,548,799
Depreciation and amortization		71,786		70,981		68,706		71,517		63,311
Income from operations		196,408		235,838		236,137		310,719		336,859
Gain (loss) on early retirement of debt ⁽⁵⁾		912		12,446		,		(20,385)		(6,064)
Equity in earnings (losses) of unconsolidated subsidiaries						(440)		2,923		7,705
Other income (expense)		(2,802)		3,204		632				
Interest expense, net ⁽⁶⁾	((110,418)		(99,451)		(84,472)		(80,910)		(83,759)
Income before income taxes		84,100		152,037		151,857		212,347		254,741
Income tax expense		37,334		49,987		51,380		80,984		93,574
Net income		46,766		102,050		100,477		131,363		161,167
Less: Net income attributable to non-controlling interests ⁽⁷⁾		3,393		3,606		4,720		4,916		5,663
Net income attributable to Select Medical Corporation		43,373		98,444		95,757		126,447		155,504
Other comprehensive income (loss):		,		,		,		ĺ		
Unrealized gain (loss) on interest rate swap, net of tax		(6,493)		2,522		8,914				
Comprehensive income attributable to Select Medical										
Corporation	\$	36,880	\$	100,966	\$	104,671	\$	126,447	\$	155,504
•										
Balance Sheet Data (at end of period):										
Cash and cash equivalents	\$	64,260	\$	83,680	\$	4,365	\$	12,043	\$	40,144
Working capital (deficit)		100,127		153,231		(73,481)		97,348		63,217
Total assets	2,	,562,425		2,585,092		2,719,572		2,770,738		2,760,313
Total debt	1,	,469,322		1,100,987		1,124,292		1,229,498		1,302,943

(1)
Adjusted for the adoption of an amendment issued by the FASB in December 2007 to ASC Topic 810, "Consolidation." See Note 1,
Organization and Significant Accounting Policies Non-controlling Interests, in our audited consolidated financial statements.

630,315

1,034,006

1,081,661

983,446

881,317

- (2) Adjusted for the clarification by the FASB that stated share based payment awards that have not vested meet the definition of a participating security provided the right to receive the dividend is non-forfeitable and non-contingent. See Note 13 in our audited consolidated financial statements for additional information.
- Operating expenses include cost of services, general and administrative expenses, and bad debt expenses.

Total Select Medical Corporation stockholders' equity

- (4) Includes stock compensation expense related to restricted stock, stock options and long term incentive compensation for the years ended December 31, 2008, 2009, 2010, 2011 and 2012.
- In the year ended December 31, 2008, we paid approximately \$1.0 million to repurchase and retire a portion of Select's 75/8% senior subordinated notes. These notes had a carrying value of \$2.0 million. The gain on early retirement of debt recognized was net of the

write-off of unamortized deferred financing costs related to the debt. During the year ended December 31, 2009, we paid approximately \$30.1 million to repurchase and retire a

48

Table of Contents

portion of Select's 75/8% senior subordinated notes. These notes had a carrying value of \$46.5 million. The gain on early retirement of debt recognized was net of the write-off of unamortized deferred financing costs related to the debt. These gains were offset by the write-off of deferred financing costs of \$2.9 million that occurred due to our early prepayment on the term loan portion of our senior secured credit facility. In addition, Holdings paid \$6.5 million to repurchase and retire a portion of Holdings' senior floating rate notes. These Notes had a carrying value of \$7.7 million. The gain on early retirement of debt recognized was net of the write-off of unamortized deferred financing costs related to the debt. On June 1, 2011, Select refinanced its senior secured credit facility which consisted of an \$850.0 million term loan facility and a \$300.0 million revolving loan facility. A portion of the proceeds from this transaction were used to repurchase and retire \$266.5 million of Select's 75/8% senior subordinated notes and \$150.0 million to repurchase and retire Holdings 10% senior subordinated notes. A loss on early retirement of debt of \$31.0 million and \$20.4 million for Holdings and Select, respectively, was recognized for the year ended December 31, 2011, which included the write-off of unamortized deferred financing costs, tender premiums and original issue discount. On August 13, 2012, Select entered into an additional credit extension amendment to its senior secured credit facility. Pursuant to the terms and conditions of the additional credit extension amendment, the lenders extended an aggregate principal amount of \$275.0 million in additional term loans to Select at the same interest rate and with the same term as applies to the existing term loan amounts borrowed by Select under its senior secured credit facility. On September 12, 2012, Select used the proceeds of the additional term loans (other than amounts used for fees and expenses) and cash on hand to redeem an aggregate of \$275.0 million principal amount of Select's outstanding 75/8% senior subordinated notes due 2015 at a redemption price of 101.271% of the principal amount. Select recognized a loss on early retirement of debt of \$6.1 million for the year ended December 31, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

- (6) Interest expense, net equals interest expense minus interest income.
- (7)

 Reflects interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by us.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

You should read this discussion together with the "Selected Financial Data" and consolidated financial statements and accompanying notes included elsewhere herein.

Overview

We believe that we are one of the largest operators of both specialty hospitals and outpatient rehabilitation clinics in the United States based on number of facilities. As of December 31, 2012, we operated 110 long term acute care hospitals and 12 acute medical rehabilitation hospitals in 28 states, and 979 outpatient rehabilitation clinics in 32 states and the District of Columbia. We also provide medical rehabilitation services on a contracted basis to nursing homes, hospitals, assisted living and senior care centers, schools and work sites. We began operations in 1997 under the leadership of our current management team. As of December 31, 2012 we had operations in 44 states and the District of Columbia.

We manage our Company through two business segments, our specialty hospital segment and our outpatient rehabilitation segment. We had net operating revenues of \$2,949.0 million for the year ended December 31, 2012. Of this total, we earned approximately 75% of our net operating revenues from our specialty hospitals and approximately 25% from our outpatient rehabilitation business. Our specialty hospital segment consists of hospitals designed to serve the needs of long term stay acute patients and hospitals designed to serve patients that require intensive medical rehabilitation care. Patients are typically admitted to our specialty hospitals from general acute care hospitals. These patients have specialized needs, and serious and often complex medical conditions such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders and cancer. Our outpatient rehabilitation segment consists of clinics and contract services that provide physical, occupational and speech rehabilitation services. Our outpatient rehabilitation patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living.

49

Table of Contents

Significant 2012 Events

Refinancing

On August 13, 2012, Select entered into an additional credit extension amendment to its senior secured credit facility. Pursuant to the terms and conditions of the additional credit extension amendment, the lenders extended an aggregate principal amount of \$275.0 million in additional term loans to Select at the same interest rate and with the same term as applies to the existing term loan amounts borrowed by Select under its senior secured credit facility. On September 12, 2012, Select used the proceeds of the additional term loans (other than amounts used for fees and expenses) and cash on hand to redeem an aggregate of \$275.0 million principal amount of Select's outstanding 75/8% senior subordinated notes due 2015 at a redemption price of 101.271% of the principal amount. Select recognized a loss on early retirement of debt of \$6.1 million for the year ended December 31, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

Stock Repurchase Program

The Company's board of directors has authorized a common stock repurchase program of up to \$250.0 million through March 31, 2013, unless extended by the board of directors. On February 20, 2013, the Company's board of directors increased the authorization to up to \$350.0 million and extended the program through March 31, 2014. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as the Company deems appropriate. The timing of purchases of stock will be based upon market conditions and other factors. The Company is funding this program with cash on hand or borrowings under its revolving credit facility. The Company repurchased 5,725,782 shares at a cost of \$46.8 million, which includes transaction costs, during the year ended December 31, 2012. Since the inception of the program through December 31, 2012, the Company has repurchased 22,490,389 shares at a cost of \$163.6 million, or \$7.28 per share, which includes transaction costs.

Special Cash Dividend

On October 30, 2012, our board of directors declared a special cash dividend of \$1.50 per share, or \$210.9 million, paid on December 12, 2012 to all common stockholders of record (including holders of shares of restricted stock) on December 5, 2012. Cash for the dividend came from cash on hand and borrowings under Select's senior secured revolving credit facility.

Summary Financial Results

Year Ended December 31, 2012

For the year ended December 31, 2012, our net operating revenues increased 5.2% to \$2,949.0 million compared to \$2,804.5 million for the year ended December 31, 2011. For the year ended December 31, 2012, our specialty hospital revenues increased \$102.0 million or 4.9% from the prior year and our outpatient rehabilitation revenues increased \$42.5 million or 6.0% from the prior year. We had income from operations for the year ended December 31, 2012 of \$336.9 million compared to \$310.7 million for the year ended December 31, 2011. We had net income attributable to Holdings for the year ended December 31, 2012 of \$148.2 million compared to \$107.8 million for the year ended December 31, 2011. Our Adjusted EBITDA for the year ended December 31, 2012 was \$405.8 million compared to \$386.0 million for the year ended December 31, 2011. See the section entitled "*Results of Operations*" for a reconciliation of net income to Adjusted EBITDA. The increases in our income from operations and Adjusted EBITDA for the year ended December 31, 2012 are principally due to increases in the operating performance of our specialty hospital segment. We were able to increase our specialty hospital income from operations \$22.8 million or 7.3% and our specialty hospital Adjusted EBITDA \$19.0 million or 5.2% for the year ended December 31, 2012 as compared to the year ended December 31, 2011.

50

Table of Contents

Net income attributable to Holdings increased \$40.4 million to \$148.2 million for the year ended December 31, 2012 compared to \$107.8 million for the year ended December 31, 2011. The increase resulted primarily from an increase in our income from operations described above, increases in our equity in earnings of unconsolidated subsidiaries principally related to our joint venture with the Baylor Health Care System, or the "Baylor JV," and a reduction of interest expense. We also incurred a smaller loss on early retirement of debt related to the refinancing transactions completed in 2012 compared to the refinancing transactions completed in 2011.

Cash flow from operations provided \$298.7 million of cash for the year ended December 31, 2012 for Holdings and \$309.4 million of cash for the year ended December 31, 2012 for Select. The difference between Holdings and Select in cash flow from operations primarily relates to interest payments on Holdings' senior floating rate notes.

Year Ended December 31, 2011

For the year ended December 31, 2011, our net operating revenues increased 17.3% to \$2,804.5 million compared to \$2,390.3 million for the year ended December 31, 2010. This increase in net operating revenues resulted principally from a 23.1% increase in our specialty hospital net operating revenue. The increase in our specialty hospital revenue is primarily due to the Regency hospitals we acquired on September 1, 2010. We had income from operations for the year ended December 31, 2011 of \$310.7 million compared to \$236.1 million for the year ended December 31, 2010. We had net income attributable to Holdings for the year ended December 31, 2011 of \$107.8 million compared to \$77.6 million for the year ended December 31, 2010. Our Adjusted EBITDA for the year ended December 31, 2011 was \$386.0 million compared to \$307.1 million for the year ended December 31, 2010. See the section entitled "Results of Operations" for a reconciliation of net income to Adjusted EBITDA.

The increase in income from operations, net income and Adjusted EBITDA for the year ended December 31, 2011 from the prior year resulted from the addition of the Regency hospitals acquired on September 1, 2010 and improved operating performance at our other specialty hospitals. Holdings' interest expense for the year ended December 31, 2011 was \$99.2 million compared to \$112.3 million for the year ended December 31, 2010. Select's interest expense for the year ended December 31, 2011 was \$81.2 million compared to \$84.5 million for the year ended December 31, 2010. The decrease in interest expense for both Holdings and Select is attributable to a reduction in our average interest rate that resulted from the expiration of interest rate swaps during 2010 that carried higher fixed interest rates, and lower interest rates on portions of the debt we refinanced on June 1, 2011.

Cash flow from operations provided \$217.1 million of cash for the year ended December 31, 2011 for Holdings and \$240.1 million of cash for the year ended December 31, 2011 for Select. The difference between Holdings and Select in cash flow from operations primarily relates to interest payments on Holdings' 10% senior subordinated notes and senior floating rate notes.

Regulatory Changes

The Medicare program reimburses us for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. Net operating revenues generated directly from the Medicare program represented approximately 47%, 48% and 47% of our consolidated net operating revenues for the years ended December 31, 2010, 2011 and 2012, respectively.

The Medicare program reimburses our long term acute care hospitals, inpatient rehabilitation facilities and outpatient rehabilitation providers, using different payment methodologies. Those payment methodologies are complex and are described elsewhere in this report under "Business Government Regulations." The following is a summary of some of the more significant healthcare regulatory changes that have affected our financial performance in the periods covered by this report or are likely to affect our financial performance and financial condition in the future.

51

Table of Contents

Medicare Reimbursement of LTCH Services

In the last few years, there have been significant regulatory changes affecting long term acute care hospitals that have affected our net operating revenues and, in some cases, caused us to change our operating models and strategies. We have been subject to regulatory changes that occur through the rulemaking procedures of the Centers for Medicare & Medicaid Services, or "CMS." Historically, rule updates occurred twice each year. All Medicare payments to our long term acute care hospitals are made in accordance with a prospective payment system specifically applicable to long term acute care hospitals, referred to as "LTCH-PPS." Proposed rules specifically related to LTCHs are generally published in May, finalized in August and effective on October 1st of each year, coinciding with the start of the federal fiscal year.

The following is a summary of significant changes to the Medicare prospective payment system for long term acute care hospitals which have affected our results of operations, as well as the policies and payment rates for fiscal year 2013 that affect our patient discharges and cost reporting periods beginning on or after October 1, 2012.

Fiscal Year 2011. On August 16, 2010, CMS published the policies and payment rates for LTCH-PPS for fiscal year 2011 (affecting discharges and cost reporting periods beginning on or after October 1, 2010 through September 30, 2011). The standard federal rate for fiscal year 2011 was \$39,600, which was a decrease from the fiscal year 2010 standard federal rate of \$39,897 in effect from October 1, 2009 to March 31, 2010 and the fiscal year 2010 standard federal rate of \$39,795 that went into effect on April 1, 2010. This update to the standard federal rate for fiscal year 2011 was based on a market basket increase of 2.5% less a reduction of 2.5% to account for what CMS attributed as an increase in case-mix in prior periods that resulted from changes in documentation and coding practices less an additional market basket reduction of 0.5% as mandated by the PPACA. The final rule established a fixed-loss amount for high cost outlier cases for fiscal year 2011 of \$18,785, which was an increase from the fiscal year 2010 fixed-loss amount of \$18,425 in effect from October 1, 2009 to March 31, 2010 and the \$18,615 that went into effect on April 1, 2010.

Fiscal Year 2012. On August 18, 2011, CMS published the policies and payment rates for LTCH-PPS for fiscal year 2012 (affecting discharges and cost reporting periods beginning on or after October 1, 2011 through September 30, 2012). The standard federal rate for fiscal year 2012 was \$40,222, which was an increase from the fiscal year 2011 standard federal rate of \$39,600. The update to the standard federal rate for fiscal year 2012 included a market basket increase of 2.9%, less a productivity adjustment of 1.0%, and less an additional market basket reduction of 0.1% as mandated by the PPACA. The final rule established a fixed-loss amount for high cost outlier cases for fiscal year 2012 of \$17,931, which was a decrease from the fixed loss amount in the 2011 fiscal year of \$18,785.

Fiscal Year 2013. On August 1, 2012, CMS published the final rule updating the policies and payment rates for LTCH-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013). Two different standard federal rates apply during fiscal year 2013. The standard federal rate for discharges on or after October 1, 2012 and before December 29, 2012 was set at \$40,916 and the standard federal rate for discharges on or after December 29, 2012 for the remainder of fiscal year 2013 is \$40,398 both of which are an increase from the fiscal year 2012 standard federal rate of \$40,222. The update to the standard federal rate for fiscal year 2013 through December 28, 2012 includes a market basket increase of 2.6%, less a productivity adjustment of 0.7%, and less an additional reduction of 0.1% mandated by the PPACA. The standard federal rate for the period of December 29, 2012 through the remainder of fiscal 2013 is further reduced by a portion of the one-time budget neutrality adjustment of 1.266%, as discussed below. The final rule established a fixed-loss amount for high cost outlier cases for fiscal year 2013 of \$15,408, which is a decrease from the fixed loss amount in the 2012 fiscal year of \$17,931.

52

Table of Contents

In the preamble to the proposed update to the Medicare policies and payment rates for fiscal year 2013, CMS indicated that "within the near future" it may recommend revisions to the payment policies addressing patient-level and facility-level criteria. CMS also indicated that these recommendations may render unnecessary the existing payment reductions for Medicare patients admitted from a general acute care hospital in excess of the applicable admission thresholds. We cannot predict whether CMS will adopt additional patient-level and facility-level criteria in the future or, if adopted, how such criteria would affect the application of the 25 Percent Rule to our LTCHs.

Medicare Market Basket Adjustments

The PPACA instituted a market basket payment adjustment to LTCHs. In fiscal year 2014, the market basket update will be reduced by 0.3%. Fiscal years 2015 and 2016 the market basket update will be reduced by 0.2%. Finally, in fiscal years 2017-2019, the market basket update will be reduced by 0.75%. The PPACA specifically allows these market basket reductions to result in less than a 0% payment update and payment rates that are less than the prior year.

25 Percent Rule

The 25 Percent Rule is a downward payment adjustment that applies to Medicare patients discharged from LTCHs who were admitted from a co-located hospital or a non-co-located hospital and caused the LTCH to exceed the applicable percentage thresholds for discharged Medicare patients. The SCHIP Extension Act, as amended by the ARRA and the PPACA, has limited the application of the 25 Percent Rule, as described elsewhere in this report under "Business Government Regulations." CMS adopted through regulations an additional one-year extension of relief from the full application of Medicare admission thresholds. As a result, full implementation of the Medicare admission thresholds will not go into effect until cost reporting periods beginning on or after October 1, 2013, except for certain LTCHs with cost reporting periods that begin between July 1, 2012 and September 30, 2012. Specifically, those freestanding facilities, grandfathered HIHs and grandfathered satellites with cost reporting periods beginning on or after July 1, 2012 and before October 1, 2012 are subject to a modified 25 Percent Rule for discharges occurring in a three month period between July 1, 2012 and September 30, 2012. After the expiration of the extension, our LTCHs will be subject to a downward payment adjustment for any Medicare patients who were admitted from a co-located or a non-co-located hospital and that exceed the applicable percentage threshold of all Medicare patients discharged from the LTCH during the cost reporting period.

One-Time Budget Neutrality Adjustment

The regulations governing LTCH-PPS authorizes CMS to make a one-time adjustment to the standard federal rate to correct any "significant difference between actual payments and estimated payments for the first year" of LTCH-PPS. In the update to the Medicare policies and payment rates for fiscal year 2013, CMS adopted a one-time budget neutrality adjustment that results in a permanent negative adjustment of 3.75% to the LTCH base rate. CMS is implementing the adjustment over a three-year period by applying a factor of 0.98734 to the standard federal rate in fiscal years 2013, 2014 and 2015, except that the adjustment would not apply to payments for discharges occurring on or after October 1, 2012 through December 28, 2012.

Short Stay Outlier Policy

The SCHIP Extension Act prevented CMS from applying the so-called very short stay outlier policy for discharges occurring after July 1, 2007. This policy would result in a payment equivalent to the general acute care hospital rate for cases with a length of stay that is less than the average length of stay plus one standard deviation of a case with the same diagnosis related group under IPPS, regardless of the clinical considerations for admission to the LTCH or the average length of stay an LTCH must satisfy for Medicare certification. The SCHIP Extension Act as amended by PPACA precluded CMS from implementing the

53

Table of Contents

very short stay outlier policy before December 29, 2012. The very short-stay outlier policy is again applicable to discharges occurring on or after December 29, 2012 and will continue to be applied unless Congress or CMS takes further action.

Moratorium on New LTCHs and New LTCH Beds

The SCHIP Extension Act imposed a moratorium on the establishment and classification of new LTCHs, LTCH satellite facilities and LTCH beds in existing LTCHs or satellite facilities subject to certain exceptions. PPACA extended this moratorium by two years. The moratorium expired on December 28, 2012. Unless Congress or CMS take further action, new LTCHs, LTCH satellite facilities and LTCH beds may be established and enrolled in the Medicare program.

Medicare Reimbursement of Inpatient Rehabilitation Facility Services

The following is a summary of significant changes to the Medicare prospective payment system for inpatient rehabilitation facilities which have affected our results of operations during the periods presented in this report, as well as the policies and payment rates for fiscal year 2013 that affect our patient discharges and cost reporting periods beginning on or after October 1, 2012.

Fiscal Year 2011. On July 22, 2010, CMS published an update to the payment rates for IRF-PPS for fiscal year 2011 (affecting discharges and cost reporting periods beginning on or after October 1, 2010 through September 30, 2011). The standard payment conversion factor for discharges during fiscal year 2011 was \$13,860, which was an increase from the standard payment conversion factor from fiscal year 2010 of \$13,627. The update to the standard payment conversion factor for fiscal year 2011 included the market basket reduction of 0.25% required by PPACA. CMS also increased the outlier threshold amount for fiscal year 2011 to \$11,410 from \$10,721.

Fiscal Year 2012. On August 5, 2011, CMS published the policies and payment rates for IRF-PPS for fiscal year 2012 (affecting discharges and cost reporting periods beginning on or after October 1, 2011 and through September 30, 2012). The standard payment conversion factor for discharges during fiscal year 2012 was \$14,076 which was an increase from the fiscal year 2011 standard payment conversion factor of \$13,860. The update to the standard payment conversion factor for fiscal year 2012 included a market basket increase of 2.9%, less a productivity adjustment of 1.0%, and less an additional market basket reduction of 0.1% as mandated by the PPACA. CMS decreased the outlier threshold amount for fiscal year 2012 to \$10,660 from \$11,410 established in the final rule for fiscal year 2011. In a notice published September 26, 2011, CMS corrected its calculation of the outlier threshold amount for fiscal year 2012 to \$10,713.

Fiscal Year 2013. On July 30, 2012, CMS published the policies and payment rates for IRF-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013). The standard payment conversion factor for discharges for fiscal year 2013 is \$14,343, which is an increase from the fiscal year 2012 standard payment conversion factor of \$14,076. The update to the standard payment conversion factor for fiscal year 2013 includes a market basket increase of 2.7%, less a productivity adjustment of 0.7%, less an additional market basket reduction of 0.1% as mandated by the PPACA. CMS decreased the outlier threshold amount for fiscal year 2013 to \$10,466 from \$10,713 established in the final rule for fiscal year 2012.

Medicare Market Basket Adjustments

The PPACA instituted a market basket payment adjustment for IRFs. For fiscal year 2014, the reduction is 0.3%. For fiscal years 2015 and 2016, the reduction is 0.2%. For fiscal years 2017 - 2019, the reduction is 0.75%.

54

Table of Contents

Medicare Reimbursement of Outpatient Rehabilitation Services

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. The Medicare physician fee schedule rates are automatically updated annually based on a formula, called the sustainable growth rate ("SGR") formula, contained in legislation. The SGR formula has resulted in automatic reductions in rates in every year since 2002; however, for each year through 2013 CMS or Congress has taken action to prevent the SGR formula reductions. The American Taxpayer Relief Act of 2012 froze Medicare physician fee schedule rates at 2012 levels through December 31, 2013, averting a scheduled 26.5% cut as a result of the SGR formula that would have taken effect on January 1, 2013. A reduction in the Medicare physician fee schedule payment rates will occur on January 1, 2014, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect. For the year ended December 31, 2012, we received approximately 10% of our outpatient rehabilitation net operating revenues from Medicare.

Therapy Caps

Beginning on January 1, 1999, the Balanced Budget Act of 1997 subjected certain outpatient therapy providers reimbursed under the Medicare physician fee schedule to annual limits for therapy expenses. Effective January 1, 2013, the annual limit on outpatient therapy services is \$1,900 for combined physical and speech language pathology services and \$1,900 for occupational therapy services. The per beneficiary caps were \$1,880 for calendar year 2012. The annual limits for therapy expenses do not apply to services furnished and billed by outpatient hospital departments. In addition, the American Taxpayer Relief Act of 2012 extends the annual limits on therapy expenses and manual medical review thresholds to services furnished in hospital outpatient department settings through December 31, 2013. The application of annual limits to hospital outpatient department settings will sunset at the end of 2013 unless Congress extends it into 2014. We operated 979 outpatient rehabilitation clinics at December 31, 2012, of which 145 are provider-based outpatient rehabilitation clinics operated as departments of the inpatient rehabilitation hospitals we operated.

In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual limit for therapy expenses. Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) is able to request an exception from the therapy caps if the provision of therapy services was deemed to be medically necessary. Therapy cap exceptions have been available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity. The American Taxpayer Relief Act of 2012 extends the exceptions process for outpatient therapy caps through December 31, 2013. Unless Congress extends the exceptions process, the therapy caps will apply to all outpatient therapy services beginning January 1, 2014, except those services furnished and billed by outpatient hospital departments.

The Middle Class Tax Relief and Job Creation Act of 2012 made several changes to the exceptions process to the annual limit for therapy expenses. For any claim above the annual limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record. Effective October 1, 2012, all claims exceeding \$3,700 are subject to a manual medical review process. The \$3,700 threshold is applied separately to the combined physical therapy/speech therapy cap and the occupational therapy cap. The American Taxpayer Relief Act of 2012 extends through December 31, 2013 the requirement that Medicare perform manual medical review of therapy services when an exception is requested for cases in which the beneficiary has reached a specified dollar aggregate threshold. Effective October 1, 2012, all therapy claims, whether above or below the annual limit, must include the national provider identifier (NPI) of the physician responsible for certifying and periodically reviewing the plan of care.

55

Table of Contents

Multiple Procedure Payment Reduction

CMS adopted a multiple procedure payment reduction for therapy services in the final update to the Medicare physician fee schedule for calendar year 2011. This multiple procedure payment reduction policy became effective January 1, 2011 and applies to all outpatient therapy services paid under Medicare Part B. Furthermore, the multiple procedure payment reduction policy applies across all therapy disciplines occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the therapy procedure or unit of service with the highest Relative Value Unit, and then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012 the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increases the payment reduction to 50% effective April 1, 2013. Our outpatient rehabilitation therapy services are primarily offered in institutional settings and, as such, are subject to the applicable 25% payment reduction in the practice expense component for the second and subsequent therapy services furnished by us to the same patient on the same day until April 1, 2013 when the payment reduction will increase to 50%.

Budget Control Act of 2011

The Budget Control Act of 2011, enacted on August 2, 2011, increased the federal debt ceiling in connection with deficit reductions over the next ten years. The Budget Control Act of 2011 requires automatic reductions in federal spending by approximately \$1.2 trillion split evenly between domestic and defense spending. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. The American Taxpayer Relief Act of 2012 temporarily delays the automatic, across-the-board "sequestration" cuts in federal spending imposed by the Budget Control Act of 2011, which are expected to reduce Medicare payments by more than \$11 billion in fiscal year 2013 and \$123 billion over the period of fiscal years 2013 to 2021. Unless further legislation is enacted, we believe this will generally result in a 2% reduction to Medicare payments for services furnished on or after April 1, 2013, which reduction will have an adverse financial impact on our net operating revenues and profitability.

Development of New Specialty Hospitals and Clinics

In addition to the growth of our business through the acquisition and integration of other businesses, we have also grown our business through specialty hospital and outpatient rehabilitation facility development opportunities. Since our inception in 1997 through December 31, 2012, we have internally developed 64 specialty hospitals and 355 outpatient rehabilitation clinics. The SCHIP Extension Act as extended by PPACA instituted a moratorium on the development of new LTCHs through December 28, 2012. As a result, we stopped all new LTCH development during this period. Now that the moratorium on new LTCHs and satellites has expired, we will evaluate the addition of LTCH beds at certain of our hospitals. We will also continue to evaluate opportunities to develop new joint venture relationships with significant health systems and from time to time we may also develop new inpatient rehabilitation hospitals. We also intend to open new outpatient rehabilitation clinics in the local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth.

56

Table of Contents

Critical Accounting Matters

Merger Transactions

On February 24, 2005, EGL Acquisition Corp. was merged with and into Select, with Select continuing as the surviving corporation and a wholly owned subsidiary of Holdings. The merger was completed pursuant to an agreement and plan of merger, dated as of October 17, 2004, among EGL Acquisition Corp., Holdings and Select. We refer to the merger and the related transactions collectively as the "Merger."

As a result of the Merger transactions, the majority of Select's assets and liabilities were adjusted to their fair value as of February 25, 2005. The excess of the total purchase price over the fair value of Select's tangible and identifiable intangible assets was allocated to goodwill. Additionally, a portion of the equity related to our continuing stockholders was recorded at the stockholder's predecessor basis and a corresponding portion of the fair value of the acquired assets was reduced accordingly.

Sources of Revenue

Our net operating revenues are derived from a number of sources, including commercial, managed care, private and governmental payors. Our net operating revenues include amounts estimated by management to be reimbursable from each of the applicable payors and the federal Medicare program. Amounts we receive for treatment of patients are generally less than the standard billing rates. We account for the differences between the estimated reimbursement rates and the standard billing rates as contractual adjustments, which we deduct from gross revenues to arrive at net operating revenues.

Net operating revenues generated directly from the Medicare program from all segments represented approximately 47%, 48% and 47% of net operating revenues for the years ended December 31, 2012, 2011 and 2010, respectively. Approximately 60%, 61% and 61% of our specialty hospital revenues for the years ended December 31, 2012, 2011 and 2010, respectively, were received for services provided to Medicare patients.

Most of our specialty hospitals receive bi-weekly periodic interim payments from Medicare instead of being paid on an individual claim basis. Under a periodic interim payment methodology, Medicare estimates a hospital's claim volume based on historical trends and makes bi-weekly interim payments to us based on these estimates. Twice a year per hospital, Medicare reconciles the differences between the actual claim data and the estimated payments. To the extent our actual hospital's experience is different from the historical trends used by Medicare to develop the estimate, the periodic interim payment will result in our being either temporarily over-paid or under-paid for our Medicare claims. At each balance sheet date, we record any aggregate under-payment as an account receivable or any aggregate over-payment as a payable to third-party payors on our balance sheet. The timing of when we receive our bi-weekly periodic interim payments, in relation to our balance sheet date, can have an impact on our accounts receivable balance and our days sales outstanding as of the end of any reporting period.

Contractual Adjustments

Net operating revenues include amounts estimated by us to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for treatment of patients covered by these programs are generally less than the standard billing rates. Contractual allowances are calculated and recorded through our internally developed systems. In our specialty hospital segment our billing system automatically calculates estimated Medicare reimbursement and associated contractual allowances. For non-governmental payors in our specialty hospital segment, we either manually calculate the contractual allowance for each patient based upon the contractual provisions associated with the specific payor or where we have a relatively homogeneous patient population, we monitor individual payors' historical closed paid claims data and

57

Table of Contents

apply those payment rates to the existing patient population. The net payments are converted into per diem rates. The per diem rates are applied to unpaid patient days to determine the expected payment and a contractual adjustment is recorded to adjust the recorded amount to agree with the expected payment. Quarterly, we update our analysis of historical closed paid claims. In our outpatient segment, we perform provision testing, using internally developed systems, whereby we monitor a payors' historical paid claims data and compare it against the associated gross charges. This difference is determined as a percentage of gross charges and is applied against gross billing revenue to determine the contractual allowances for the period. Additionally, these contractual percentages are applied against the gross receivables on the balance sheet to determine that adequate contractual reserves are maintained for the gross accounts receivables reported on the balance sheet. We account for any difference as additional contractual adjustments to gross revenues to arrive at net operating revenues in the period that the difference is determined. We believe the processes described above and used in recording our contractual adjustments have resulted in reasonable estimates determined on a consistent basis.

Allowance for Doubtful Accounts

Substantially all of our accounts receivable are related to providing healthcare services to patients. Collection of these accounts receivable is our primary source of cash and is critical to our financial performance. Our primary collection risks relate to non-governmental payors who insure these patients, and deductibles, co-payments and self-insured amounts owed by the patient. Deductibles, co-payments and self-insured amounts are an immaterial portion of our net accounts receivable balance. At December 31, 2012, deductibles, co-payments and self-insured amounts owed by the patient accounted for approximately 0.2% of our net accounts receivable balance before doubtful accounts. Our general policy is to verify insurance coverage prior to the date of admission for a patient admitted to our hospitals, or in the case of our outpatient rehabilitation clinics, we verify insurance coverage prior to their first therapy visit. Our estimate for the allowance for doubtful accounts is calculated by providing a reserve allowance based upon the age of an account balance. Generally we reserve as uncollectible all governmental accounts over 365 days from discharge and non-governmental accounts over 180 days from discharge. This method is monitored based on our historical cash collections experience. Collections are impacted by the effectiveness of our collection efforts with non-governmental payors and regulatory or administrative disruptions with the fiscal intermediaries that pay our governmental receivables.

We estimate bad debts for total accounts receivable within each of our operating units. We believe our policies have resulted in reasonable estimates determined on a consistent basis. We have historically collected substantially all of our third-party insured receivables (net of contractual allowances) which include receivables from governmental agencies. Historically, there has not been a material difference between our bad debt allowances and the ultimate historical collection rates on accounts receivable. We review our overall reserve adequacy by monitoring historical cash collections as a percentage of net revenue less the provision for bad debts. Uncollected accounts are charged against the reserve when they are turned over to an outside collection agency, or when management determines that the balance is uncollectible, whichever occurs first.

The following table is an aging of our net (after allowances for contractual adjustments but before doubtful accounts) accounts receivable as of the dates indicated (in thousands):

	Balance as of December 31,							
		201	1			201	2	
			0	ver 180			O	ver 180
	0-1	80 Days		Days	0-1	80 Days		Days
Commercial insurance and other	\$	237,171	\$	35,801	\$	230,878	\$	31,441
Medicare and Medicaid		176,616		11,624		133,318		6,146
Total net accounts receivable	\$	413,787	\$	47,425	\$	364,196	\$	37,587

58

Table of Contents

The approximate percentage of total net accounts receivable (after allowance for contractual adjustments but before doubtful accounts) summarized by aging categories as of the dates indicated is as follows:

As of December 31,

	2011	2012
0 to 90 days	82.9%	83.0%
91 to 180 days	6.9%	7.6%
181 to 365 days	4.5%	4.8%
Over 365 days	5.7%	4.6%
Total	100.0%	100.0%

The approximate percentage of total net accounts receivable (after allowance for contractual adjustments but before doubtful accounts) summarized by insured status as of the dates indicated is as follows:

As	οf	D	ec	em	her	31.

	2011	2012
Commercial insurance and other	59.0%	65.1%
Medicare and Medicaid	40.8%	34.7%
Self-pay receivables (including deductibles and co-payments)	0.2%	0.2%
Total	100.0%	100.0%

Insurance

Under a number of our insurance programs, which include our employee health insurance program and certain components under our property and casualty insurance program, we are liable for a portion of our losses. In these cases we accrue for our losses under an occurrence based principle whereby we estimate the losses that will be incurred by us in a given accounting period and accrue that estimated liability. Where we have substantial exposure, we utilize actuarial methods in estimating the losses. In cases where we have minimal exposure, we will estimate our losses by analyzing historical trends. We monitor these programs quarterly and revise our estimates as necessary to take into account additional information. At December 31, 2012 and December 31, 2011, we have recorded a liability of \$92.5 million and \$85.7 million, respectively, for our estimated losses under these insurance programs.

Related Party Transactions

We are party to various rental and other agreements with companies affiliated with us through common ownership. Our payments to these related parties amounted to \$4.0 million for both the years ended December 31, 2012 and 2011. Our future commitments are related to commercial office space we lease for our corporate headquarters in Mechanicsburg, Pennsylvania. These future commitments as of December 31, 2012 amount to \$36.4 million through 2023. These transactions and commitments are described more fully in the notes to our consolidated financial statements included herein. The Company's practice is that any such transaction must receive the prior approval of both the audit and compliance committee of the board of directors and a majority of non-interested members of the board of directors. It is the Company's practice that an independent third-party appraisal supporting the amount of rent for such leased space is obtained prior to approving the related party lease of office space.

59

Table of Contents

Goodwill and Other Intangible Assets

Goodwill and certain other indefinite-lived intangible assets are subject to periodic impairment evaluations. Our most recent impairment assessment was completed during the fourth quarter of 2012, which indicated that there was no impairment with respect to goodwill or other recorded intangible assets. The majority of our goodwill resides in our specialty hospital reporting unit. In performing periodic impairment tests, the fair value of the reporting unit is compared to the carrying value, including goodwill and other intangible assets. If the carrying value exceeds the fair value, an impairment condition exists, which results in an impairment loss equal to the excess carrying value. Impairment tests are required to be conducted at least annually, or when events or conditions occur that might suggest a possible impairment. These events or conditions include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors; a current period operating or cash flow loss combined with a history of such losses or a projection of continuing losses; or a sale or disposition of a significant portion of a reporting unit. The occurrence of one of these events or conditions could significantly impact an impairment assessment, necessitating an impairment charge and adversely affecting our results of operations. For purposes of goodwill impairment assessment, we have defined our reporting units as specialty hospitals, outpatient rehabilitation clinics and contract therapy, with goodwill having been allocated among reporting units based on the relative fair value of those divisions when the Merger occurred in 2005 and based on subsequent acquisitions.

To determine the fair value of our reporting units, we use a discounted cash flow approach. Included in the discounted cash flow are assumptions regarding revenue growth rates, internal development of specialty hospitals and rehabilitation clinics, future Adjusted EBITDA margin estimates, future general and administrative expense rates and the weighted average cost of capital for our industry. We also must estimate residual values at the end of the forecast period and future capital expenditure requirements. Each of these assumptions requires us to use our knowledge of (1) our industry, (2) our recent transactions, and (3) reasonable performance expectations for our operations. If any one of the above assumptions changes or fails to materialize, the resulting decline in our estimated fair value could result in a material impairment charge to the goodwill associated with any one of the reporting units.

Realization of Deferred Tax Assets

Deferred tax assets and liabilities are required to be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Deferred tax assets are also required to be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we estimate our income taxes based on our actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. We also recognize as deferred tax assets the future tax benefits from net operating loss carry forwards. We evaluate the realizability of these deferred tax assets by assessing their valuation allowances and by adjusting the amount of such allowances, if necessary. Among the factors used to assess the likelihood of realization are our projections of future taxable income streams, the expected timing of the reversals of existing temporary differences, and the impact of tax planning strategies that could be implemented to avoid the potential loss of future tax benefits. However, changes in tax codes, statutory tax rates or future taxable income levels could materially impact our valuation of tax accruals and assets and could cause our provision for income taxes to vary significantly from period to period.

At December 31, 2012, we had deferred tax liabilities in excess of deferred tax assets of approximately \$71.6 million for both Holdings and Select principally due to depreciation deductions that have been accelerated for tax purposes. This amount includes approximately \$13.3 million of valuation reserves related primarily to state net operating losses.

60

Table of Contents

Uncertain Tax Positions

We record and review quarterly our uncertain tax positions. Reserves for uncertain tax positions are established for exposure items related to various federal and state tax matters. Income tax reserves are recorded when an exposure is identified and when, in the opinion of management, it is more likely than not that a tax position will not be sustained and the amount of the liability can be estimated. While we believe that our reserves for uncertain tax positions are adequate, the settlement of any such exposures at amounts that differ from current reserves may require us to materially increase or decrease our reserves for uncertain tax positions.

Stock Based Compensation

We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Our share-based compensation arrangements comprise both stock options and restricted share plans. We value employee stock options using the Black-Scholes option valuation method that uses assumptions that relate to the expected volatility of our common stock, the expected dividend yield of our stock, the expected life of the options and the risk free interest rate. Such compensation amounts, if any, are amortized over the respective vesting periods or period of service of the option grant. We value restricted stock grants by using the public market price of our stock on the date of grant.

61

Table of Contents

Operating Statistics

The following tables set forth operating statistics for our specialty hospitals and our outpatient rehabilitation clinics for each of the periods presented. The data in the tables reflect the changes in the number of specialty hospitals and outpatient rehabilitation clinics we operate that resulted from acquisitions, start-up activities, closures and sales. The operating statistics reflect data for the period of time these operations were managed by us.

	Year Ended December 31 2010	, Decem	Ended aber 31, 011	Year Ended December 31, 2012
Specialty hospital data ⁽¹⁾ :				
Number of hospitals owned start of period		94	116	115
Number of hospital start-ups		1		1
Number of hospitals acquired		23	1	1
Number of hospitals closed/sold		(2)	(2)	(1)
Number of hospitals owned end of period	1	16	115	116
Number of hospitals managed end of period		2	4	6
Total number of hospitals (all) end of period	1	.18	119	122
Long term acute care hospitals	1	.11	110	110
Rehabilitation hospitals		7	9	12
Available licensed beds ⁽²⁾	5,1	.63	5,135	5,138
Admissions ⁽²⁾	45,9	90	54,734	55,147
Patient days ⁽²⁾	1,119,5	566	1,330,890	1,345,430
Average length of stay (days) ⁽²⁾		24	24	24
Net revenue per patient day ⁽²⁾⁽³⁾	\$ 1,4	174 \$	1,497	\$ 1,534
Occupancy rate ⁽²⁾		67%	71%	71%
Percent patient days Medicar ²		64%	65%	64%
Outpatient rehabilitation data:				
Number of clinics owned start of period	8	383	875	850
Number of clinics acquired		1	15	12
Number of clinic start-ups		23	26	30
Number of clinics closed/sold	((32)	(66)	(25)
Number of clinics owned end of period	8	375	850	867
Number of clinics managed end of period		69	104	112
Total number of clinics (all) end of period	ç	944	954	979
Number of visits ⁽²⁾	4,567,1	.53	4,470,061	4,568,821
Net revenue per visit ⁽²⁾⁽⁴⁾		.01 \$		\$ 103

⁽¹⁾ Specialty hospitals consist of long term acute care hospitals and inpatient rehabilitation facilities.

⁽²⁾ Data excludes specialty hospitals and outpatient clinics managed by the Company.

Net revenue per patient day is calculated by dividing specialty hospital direct patient service revenues by the total number of patient days.

⁽⁴⁾Net revenue per visit is calculated by dividing outpatient rehabilitation clinic direct patient service revenue by the total number of visits. For purposes of this computation, outpatient rehabilitation clinic direct patient service revenue does not include managed clinics

or contract services revenue.

62

Table of Contents

Results of Operations

The following table outlines, for the periods indicated, selected operating data as a percentage of net operating revenues:

	Select Medical Holdings Corporation						
	Year Ended	Year Ended	Year Ended				
	December 31,	December 31,	December 31,				
	2010	2011	2012				
Net operating revenues	100.0%	100.0%	100.0%				
Cost of services ⁽¹⁾	82.9	82.3	82.9				
General and administrative	2.6	2.2	2.2				
Bad debt expense	1.7	1.8	1.3				
Depreciation and amortization	2.9	2.6	2.2				
Income from operations	9.9	11.1	11.4				
Loss on early retirement of debt		(1.1)	(0.2)				
Equity in earnings (losses) of unconsolidated subsidiaries	(0.0)	0.1	0.3				
Other income	0.0						
Interest expense, net	(4.7)	(3.5)	(3.2)				
Income before income taxes	5.2	6.6	8.3				
Income tax expense	1.7	2.5	3.1				
•							
Net income	3.5	4.1	5.2				
Net income attributable to non-controlling interests	0.2	0.2	0.2				
Č							
Net income attributable to Holdings	3.3%	3.9%	5.0%				
Net income Net income attributable to non-controlling interests	3.5 0.2	4.1 0.2	5.2 0.2				

	Select Medical Corporation					
	Year Ended	Year Ended	Year Ended			
	December 31,	December 31,	December 31,			
	2010	2011	2012			
Net operating revenues	100.0%	100.0%	100.0%			
Cost of services ⁽¹⁾	82.9	82.3	82.9			
General and administrative	2.6	2.2	2.2			
Bad debt expense	1.7	1.8	1.3			
Depreciation and amortization	2.9	2.6	2.2			
Income from operations	9.9	11.1	11.4			
Loss on early retirement of debt		(0.7)	(0.2)			
Equity in earnings (losses) of unconsolidated subsidiaries	(0.0)	0.1	0.3			
Other income	0.0					
Interest expense, net	(3.5)	(2.9)	(2.9)			
Income before income taxes	6.4	7.6	8.6			
Income tax expense	2.2	2.9	3.1			
•						
Net income	4.2	4.7	5.5			
Net income attributable to non-controlling interests	0.2	0.2	0.2			
Č						
Net income attributable to Select	4.0%	4.5%	5.3%			

Table of Contents

The following tables summarize selected financial data by business segment, for the periods indicated:

Select Medical Holdings Corporation

	% %								
		ear Ended cember 31, 2010		ear Ended cember 31, 2011	De	ear Ended cember 31, 2012	% Change 2010-2011	% Change 2011- 2012	
				(In th	ousa	ands)			
Net operating revenues:									
Specialty hospitals	\$	1,702,165	\$	2,095,519	\$	2,197,529	23.1%		
Outpatient rehabilitation		688,017		708,867		751,317	3.0	6.0	
Other ⁽²⁾		108		121		123	12.0	1.7	
Total company	\$	2,390,290	\$	2,804,507	\$	2,948,969	17.3%	5.2%	
1 3		, ,				, ,			
Income (loss) from operations:									
Specialty hospitals	\$	239,442	\$	311,705	\$	334,518	30.2%	7.3%	
Outpatient rehabilitation	Ψ	63,328	Ψ	67,377	Ψ	73,816	6.4	9.6	
Other ⁽²⁾		(66,633)		(68,363)		(71,475)	(2.6)	(4.6)	
Other		(00,033)		(00,303)		(71,473)	(2.0)	(4.0)	
Total company	\$	236,137	\$	310,719	\$	336,859	31.6%	8.4%	
Adjusted EBITDA:(3)									
Specialty hospitals	\$	284,558	\$	362,334	\$	381,354	27.3%	5.2%	
Outpatient rehabilitation	Ψ	83,772	Ψ	83,864	Ψ	87,024	0.1	3.8	
Other ⁽²⁾		(61,251)		(60,237)		(62,531)	1.7	(3.8)	
Office		(01,231)		(00,237)		(02,331)	1.7	(3.6)	
Total company	\$	307,079	\$	385,961	\$	405,847	25.7%	5.2%	
Adjusted EBITDA margins:(3)									
Specialty hospitals		16.7%	ó	17.3%	, D	17.4%			
Outpatient rehabilitation		12.2		11.8		11.6			
Other ⁽²⁾		N/M		N/M		N/M			
Total company		12.8%	ó	13.8%	ó	13.8%			
Total assets:									
Specialty hospitals	\$	2,162,726	\$	2,187,767	\$	2,143,906			
Outpatient rehabilitation		481,828		429,503		434,834			
Other ⁽²⁾		77,532		154,877		182,621			
Total company	\$	2,722,086	\$	2,772,147	\$	2,761,361			
Total company	Ψ	2,722,000	Ψ	2,772,147	Ψ	2,701,301			
Purchases of property and equipment, net:									
	¢	20.227	¢	20.464	¢	50.005			
Specialty hospitals	\$	39,237	\$	30,464	\$	50,005			
Outpatient rehabilitation		9,449		12,135		13,209			
Other ⁽²⁾		3,075		3,417		4,971			
Total company	\$	51,761	\$	46,016	\$	68,185			
			64						

Table of Contents

			Select Medi	cal (Corporation		
	ear Ended cember 31, 2010	Year Ended December 31, 2011 Year Ended December 31, 2012		% Change 2010- 2011	% Change 2011- 2012		
			(In th	ous	ands)		
Net operating revenues:							
Specialty hospitals	\$ 1,702,165	\$	2,095,519	\$	2,197,529	23.1%	
Outpatient rehabilitation	688,017		708,867		751,317	3.0	6.0
Other ⁽²⁾	108		121		123	12.0	1.7
Total company	\$ 2,390,290	\$	2,804,507	\$	2,948,969	17.3%	5.2%
Income (loss) from operations:							
Specialty hospitals	\$ 239,442	\$	311,705	\$	334,518	30.2%	7.3%
Outpatient rehabilitation	63,328		67,377		73,816	6.4	9.6
Other ⁽²⁾	(66,633)		(68,363)		(71,475)	(2.6)	(4.6)
Total company	\$ 236,137	\$	310,719	\$	336,859	31.6%	8.4%
Adjusted EBITDA:(3)							
Specialty hospitals	\$ 284,558	\$	362,334	\$	381,354	27.3%	5.2%
Outpatient rehabilitation	83,772		83,864		87,024	0.1	3.8
Other ⁽²⁾	(61,251)		(60,237)		(62,531)	1.7	(3.8)
Total company	\$ 307,079	\$	385,961	\$	405,847	25.7%	5.2%
Adjusted EBITDA margins:(3)							
Specialty hospitals	16.7%	,	17.3%	ó	17.4%		
Outpatient rehabilitation	12.2		11.8		11.6		
Other ⁽²⁾	N/M		N/M		N/M		
Total company	12.8%	Ď	13.8%	ó	13.8%		
Total assets:							
Specialty hospitals	\$ 2,162,726	\$	2,187,767	\$	2,143,906		
Outpatient rehabilitation	481,828		429,503		434,834		
Other ⁽²⁾	75,018		153,468		181,573		
Total company	\$ 2,719,572	\$	2,770,738	\$	2,760,313		
Purchases of property and equipment, net:							
Specialty hospitals	\$ 39,237	\$	30,464	\$	50,005		
Outpatient rehabilitation	9,449		12,135		13,209		
Other ⁽²⁾	3,075		3,417		4,971		
Total company	\$ 51,761	\$	46,016	\$	68,185		

N/M Not Meaningful.

(1)

Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense and other operating costs.

(2) Other includes our general and administrative services and non-healthcare services.

We define Adjusted EBITDA as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries, and other income (expense). We believe that the presentation

65

Table of Contents

of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our operating units. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

	Select Medical Holdings Corporation					
	Year Ended December 31,					
		2010		2011		2012
			(In	thousands)		
Net income	\$	82,364	\$	112,762	\$	153,893
Income tax expense		41,628		70,968		89,657
Other income		(632)				
Loss on early retirement of debt				31,018		6,064
Interest expense, net of interest income		112,337		98,894		94,950
Equity in (earnings) losses of unconsolidated subsidiaries		440		(2,923)		(7,705)
Stock compensation expense:						
Included in general and administrative		763		1,996		3,538
Included in cost of services		1,473		1,729		2,139
Depreciation and amortization		68,706		71,517		63,311
Adjusted EBITDA	\$	307,079	\$	385,961	\$	405,847

		Select	Med	lical Corpo	ratio	n
	Year Ended December 31,					
		2010	2011			2012
			(In	thousands)		
Net income	\$	100,477	\$	131,363	\$	161,167
Income tax expense		51,380		80,984		93,574
Other income		(632)				
Loss on early retirement of debt				20,385		6,064
Interest expense, net of interest income		84,472		80,910		83,759
Equity in (earnings) losses of unconsolidated subsidiaries		440		(2,923)		(7,705)
Stock compensation expense:						
Included in general and administrative		763		1,996		3,538
Included in cost of services		1,473		1,729		2,139
Depreciation and amortization		68,706		71,517		63,311
Adjusted EBITDA	\$	307,079	\$	385,961	\$	405,847
		66				

Table of Contents

Year Ended December 31, 2012 Compared to Year Ended December 31, 2011

In the following discussion, we address the results of operations of Select and Holdings. With the exception of interest expense, other income (expense), loss on early retirement of debt and income taxes, the results of operations of Holdings are identical to those of Select. Therefore, discussion related to net operating revenues, operating expenses, Adjusted EBITDA, income from operations, equity in earnings (losses) of unconsolidated subsidiaries and non-controlling interest is identical for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased by 5.2% to \$2,949.0 million for the year ended December 31, 2012 compared to \$2,804.5 million for the year ended December 31, 2011.

Specialty Hospitals. Our specialty hospital net operating revenues increased by 4.9% to \$2,197.5 million for the year ended December 31, 2012 compared to \$2,095.5 million for the year December 31, 2011. The growth in net operating revenue for the year ended December 31, 2012 resulted from increases in patient volumes, increases in both Medicare and non-Medicare reimbursement rates and revenues generated from contracted labor services provided to the Baylor JV. Our patient days increased 1.1% compared to the year ended December 31, 2011 to 1,345,430 days for the year ended December 31, 2012. Our specialty hospital occupancy was 71% for both the years ended December 31, 2012 and 2011. Our average net revenue per patient day was \$1,534 for the year ended December 31, 2012 compared to \$1,497 for the year ended December 31, 2011. For the year ended December 31, 2012, we experienced increases in both our Medicare and non-Medicare net revenue per patient day from the prior year. The increase in our Medicare net revenue per patient day was due to increases in our Medicare base rate. The increases in our non-Medicare net revenue per patient day resulted from increases in our non-government payment rates that have occurred through contract renewal and from Medicaid bonus payments we received during the three months ended June 30, 2012.

Outpatient Rehabilitation. Our outpatient rehabilitation net operating revenues increased 6.0% to \$751.3 million for the year ended December 31, 2012 compared to \$708.9 million for the year ended December 31, 2011. The net operating revenues generated by our outpatient rehabilitation clinics for the year ended December 31, 2012 increased 3.0% to \$561.4 million compared to \$545.1 million for the year ended December 31, 2011. The increase was principally related to volume growth in our owned outpatient rehabilitation clinics and revenues we generated from contract labor services provided to the Baylor JV. The number of patient visits in our owned outpatient rehabilitation clinics increased 2.2% for the year ended December 31, 2012 to 4,568,821 visits compared to 4,470,061 visits for the year ended December 31, 2011. Net revenue per visit in our owned outpatient rehabilitation clinics was \$103 for both the years ended December 31, 2012 and 2011. Our contract services business increased net operating revenues 16.0% to \$189.9 million compared to \$163.8 million for the year ended December 31, 2011, which primarily resulted from the addition of new contracts in the fourth quarter of 2011. During the fourth quarter of 2012, our outpatient rehabilitation operations in the mid-Atlantic and Northeastern states were adversely affected by hurricane Sandy. We currently estimate that the lost patient revenue from this event in the three months ended December 31, 2012 was approximately \$3.9 million, of which \$3.2 million occurred in our outpatient rehabilitation clinics and \$0.7 million occurred in our contract services business.

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense and bad debt expense. Our operating expenses increased by 5.2% to \$2,548.8 million for the year ended December 31, 2012 compared to \$2,422.3 million for the year ended December 31, 2011. As a percentage of our net operating revenues, our operating expenses were 86.4% for both the years ended December 31, 2012 and December 31, 2011. Our cost of services, a major component of which is labor expense, were \$2,443.6 million or 82.9% of net operating revenues for the year ended December 31, 2012 compared to \$2,308.6 million or 82.3% of net operating revenues for the year ended December 31, 2011. The increase in

67

Table of Contents

cost of services as a percentage of net operating revenues resulted primarily from increased relative labor costs in both our specialty hospital and our outpatient rehabilitation segments. Our specialty hospitals experienced an increase in relative labor costs due to the labor costs associated with the Baylor JV services agreement and increased staffing costs during the year ended December 31, 2012 compared to the year ended December 31, 2011. Our outpatient rehabilitation segment experienced an increase in relative labor costs associated with the Baylor JV services agreement and increased relative staffing costs of providing patient services in our outpatient rehabilitation clinics. Additionally, our outpatient rehabilitation segment experienced higher relative labor costs during the year ended December 31, 2012 as a result of hurricane Sandy, as we incurred continuing labor costs in our affected outpatient rehabilitation clinics without corresponding revenue. Facility rent expense, which is a component of cost of services, was \$124.2 million for year ended December 31, 2012 compared to \$118.4 million for the year ended December 31, 2011. General and administrative expenses were 2.2% of net operating revenue or \$66.2 million for the year ended December 31, 2012 compared to 2.2% of net operating revenue or \$62.4 million for the year ended December 31, 2011. This increase in general and administrative expense resulted principally from increases in executive compensation. Our bad debt expense was \$39.1 million or 1.3% of net operating revenues for the year ended December 31, 2012 compared to \$51.3 million or 1.8% for the year ended December 31, 2011. The decline in our bad debt expense was attributed to our favorable collections experience of accounts receivable in both our operating segments for the year ended December 31, 2012 as compared to the year ended December 31, 2011.

Adjusted EBITDA

Specialty Hospitals. Our Adjusted EBITDA for our specialty hospitals increased by 5.2% to \$381.4 million for the year ended December 31, 2012 compared to \$362.3 million for the year ended December 31, 2011. Our Adjusted EBITDA margins for the segment increased to 17.4% for the year ended December 31, 2012 from 17.3% for the year ended December 31, 2011. The increase in the Adjusted EBITDA for our specialty hospitals was primarily the result of both rate improvements and patient volume increases discussed above under "Net Operating Revenues" and a reduction in bad debt expense discussed above under "Operating Expenses." The increase in the Adjusted EBITDA margin is principally due to the decline in bad debt expense, offset in part by increases in cost of services as discussed above under "Operating Expenses."

Outpatient Rehabilitation. Adjusted EBITDA for our outpatient rehabilitation segment increased 3.8% to \$87.0 million for the year ended December 31, 2012 compared to \$83.9 million for the year ended December 31, 2011. Our Adjusted EBITDA margins decreased to 11.6% for the year ended December 31, 2012 from 11.8% for the year ended December 31, 2011. Our Adjusted EBITDA in our outpatient rehabilitation segment was adversely affected by hurricane Sandy as discussed above under "Net Operating Revenues." The Adjusted EBITDA in our outpatient rehabilitation clinics increased by \$1.3 million to \$72.9 million for the year ended December 31, 2012 compared to \$71.6 for the year ended December 31, 2011. Our Adjusted EBITDA margins for our outpatient rehabilitation clinics decreased to 13.0% for the year ended December 31, 2012 from 13.1% for the year ended December 31, 2011. The decrease in our Adjusted EBITDA margin in our outpatient rehabilitation clinics was principally due to the incurrence of labor costs in the outpatient rehabilitation clinics affected by hurricane Sandy without any corresponding patient revenue as discussed above under "Net Operating Revenues." The Adjusted EBITDA in our contract services business increased by \$1.8 million to \$14.1 million for the year ended December 31, 2012 compared to \$12.3 million for the year ended December 31, 2011. The Adjusted EBITDA margins for our contract services business declined to 7.4% for the year ended December 31, 2012 compared to 7.5% for the year ended December 31, 2011. The decline in Adjusted EBITDA margins for our contract services business was principally due to increased labor costs associated with new business and lower productivity resulting from regulatory changes that became effective on October 1, 2011.

Other. The Adjusted EBITDA loss was \$62.5 million for the year ended December 31, 2012 compared to an Adjusted EBITDA loss of \$60.2 million for the year ended December 31, 2011 and is

68

Table of Contents

principally related to increases in executive compensation that are a component of our general and administrative expense.

Income from Operations

For the year ended December 31, 2012 we had income from operations of \$336.9 million compared to \$310.7 million for the year ended December 31, 2011. The increase in our income from operations resulted principally from increases in our operating performance of our specialty hospital and outpatient rehabilitation segments described above and a decline in depreciation and amortization expense.

Loss on Early Retirement of Debt

Select Medical Corporation. On September 12, 2012 we redeemed an aggregate of \$275.0 million principal amount of Select's 7⁵/s% senior subordinated notes at a redemption price of 101.271% of the principal amount. We recognized a loss on early retirement of debt of \$6.1 million for the year ended December 31, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

On June 1, 2011, we refinanced our senior secured credit facility. A portion of the proceeds from this transaction were used to repurchase and retire \$266.5 million of Select's 75/8% senior subordinated notes. We recognized a loss on early retirement of debt of \$20.4 million for the year ended December 31, 2011, which included the write-off of unamortized deferred financing costs and tender premiums.

Select Medical Holdings Corporation. On September 12, 2012 we redeemed an aggregate of \$275.0 million principal amount of Select's $7^5/8\%$ senior subordinated notes at a redemption price of 101.271% of the principal amount. We recognized a loss on early retirement of debt of \$6.1 million for the year ended December 31, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

On June 1, 2011, we refinanced our senior secured credit facility. A portion of the proceeds from this transaction were used to repurchase and retire \$266.5 million of Select's 75/8% senior subordinated notes and \$150.0 million to repurchase and retire our 10% senior subordinated notes. We recognized a loss on early retirement of debt of \$31.0 million for the year ended December 31, 2011, which included the write-off of unamortized deferred financing costs, tender premiums and original issue discount.

Equity in Earnings of Unconsolidated Subsidiaries

For the year ended December 31, 2012, we had equity in earnings of unconsolidated subsidiaries of \$7.7 million compared to equity in earnings of unconsolidated subsidiaries of \$2.9 million for the year ended December 31, 2011. The increase in our equity in earnings of unconsolidated subsidiaries resulted principally from an increase in the income contribution from the Baylor JV.

Interest Expense

Select Medical Corporation. Interest expense was \$83.8 million for the year ended December 31, 2012 compared to \$81.2 million for the year ended December 31, 2011. The increase in interest expense resulted primarily from the refinancing of \$150.0 million of Holdings' debt, for which Select was not previously obligated through indebtedness incurred by Select under the new senior secured credit facility on June 1, 2011.

Select Medical Holdings Corporation. Interest expense was \$95.0 million for the year ended December 31, 2012 compared to \$99.2 million for the year ended December 31, 2011. The decrease in interest expense resulted primarily from the lower interest rates on the portions of the debt that were refinanced on June 1, 2011, lower interest rates on portions of the debt that we refinanced in the third quarter of 2012 and lower average debt balances during the year ended December 31, 2012 compared to the year ended December 31, 2011.

69

Table of Contents

Income Taxes

Select Medical Corporation. We recorded income tax expense of \$93.6 million for the year ended December 31, 2012. The expense represented an effective tax rate of 36.7%. We recorded income tax expense of \$81.0 million for the year ended December 31, 2011. The expense represented an effective tax rate of 38.1%. Select Medical Corporation is part of the consolidated federal tax return for Select Medical Holdings Corporation. We allocate income taxes between Select and Holdings for purposes of financial statement presentation. Because Holdings is a passive investment company incorporated in Delaware, it does not incur any state income tax expense or benefit on its specific income or loss and, as such, receives a tax allocation equal to the federal statutory rate of 35% on its specific income or loss. Based upon the relative size of Holdings' income or loss, this can cause the effective tax rate for Select to differ from the effective tax rate for the consolidated company.

Select Medical Holdings Corporation. We recorded income tax expense of \$89.7 million for the year ended December 31, 2012. The expense represented an effective tax rate of 36.8%. We recorded income tax expense of \$71.0 million for the year ended December 31, 2011. The expense represented an effective tax rate of 38.6%. The decline in our effective tax rate is primarily a consequence of an Internal Revenue Service penalty abatement and a lower effective state tax rate.

Non-Controlling Interests

Non-controlling interests in consolidated earnings were \$5.7 million for the year ended December 31, 2012 and \$4.9 million for the year ended December 31, 2011.

Year Ended December 31, 2011 Compared to Year Ended December 31, 2010

Net Operating Revenues

Our net operating revenues increased by 17.3% to \$2,804.5 million for the year ended December 31, 2011 compared to \$2,390.3 million for the year ended December 31, 2010.

Specialty Hospitals. Our specialty hospital net operating revenues increased by 23.1% to \$2,095.5 million for the year ended December 31, 2011 compared to \$1,702.2 million for the year December 31, 2010. The Regency hospitals acquired on September 1, 2010 contributed \$339.6 million of net operating revenues in 2011 and provided \$245.7 million of the \$393.4 million increase in net operating revenues for 2011. The remaining increase primarily resulted from an increase in patient volumes in our other specialty hospitals. Our patient days increased 18.9% to 1,330,890 days for 2011, which was principally related to the addition of the Regency hospitals. The Regency hospitals contributed a net increase in patient days of 146,065 days. Excluding the effect of the Regency hospitals, patient days would have increased 6.2% in 2011 over 2010 as a result of similar increases in both Medicare and non-Medicare volumes. The occupancy percentage increased to 71% for 2011 from 67% for 2010. Our average net revenue per patient day was \$1,497 for 2011 compared to \$1,474 for 2010. The increase in our net revenue per patient day was principally due to increases in our average Medicare net revenue per patient day.

Outpatient Rehabilitation. Our outpatient rehabilitation net operating revenues increased 3.0% to \$708.9 million for the year ended December 31, 2011 compared to \$688.0 million for the year ended December 31, 2010. The net operating revenues generated by our outpatient rehabilitation clinics in 2011 grew approximately 2.3% compared to 2010. The increase was principally related to revenues we are generating from services provided to the Baylor JV. The number of patient visits in our owned outpatient rehabilitation clinics decreased 2.1% for 2011 to 4,470,061 visits compared to 4,567,153 visits for 2010. The decrease in visits, which also slowed our revenue growth, resulted primarily from the 18 clinics in the Dallas-Fort Worth metroplex that were contributed to the Baylor JV, which is accounted for as an unconsolidated joint venture. Net revenue per visit in our clinics increased 2.0% to \$103 for 2011,

70

Table of Contents

compared to \$101 for 2010. Our contract services business experienced an increase in net operating revenues of approximately 5.4% compared to 2010 which resulted from the addition of new contracts.

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense and bad debt expense. Our operating expenses increased by \$336.9 million to \$2,422.3 million for the year ended December 31, 2011 compared to \$2,085.4 million for the year ended December 31, 2010. As a percentage of our net operating revenues, our operating expenses were 86.4% for the year ended December 31, 2011 compared to 87.2% for the year ended December 31, 2010. Our cost of services, a major component of which is labor expense, were \$2,308.6 million for the year ended December 31, 2011 compared to \$1,982.2 million for the year ended December 31, 2010. The principal cause of the increase in cost of services resulted from the addition of the Regency hospitals. Additionally facility rent expense, which is a component of cost of services, was \$118.4 million for year ended December 31, 2011 compared to \$118.3 million for the year ended December 31, 2010. General and administrative expenses were 2.2% of net operating revenue or \$62.4 million for the year ended December 31, 2011 compared to 2.6% of net operating revenue or \$62.1 million for the year ended December 31, 2010. In 2010, our general and administrative expenses included \$9.0 million of non-recurring costs related to the transition and closing of the Regency corporate office and a \$4.8 million charge due to an increase in employee healthcare costs. Additionally, in 2010 there was no incentive compensation paid to our executive officers. In 2011, our general and administrative expenses included increased legal expenses of approximately \$7.8 million primarily related to the Columbus qui tam matter and increased compensation costs of approximately \$8.1 million related to executive incentive compensation. These cost increases in 2011 were offset by gains of \$5.4 million on the sale of assets. Our bad debt expense as a percentage of net operating revenues remained relatively stable at 1.8% for the year ended December 31, 2011 compared to 1.7% for the year ended December 31, 2010.

Adjusted EBITDA

Specialty Hospitals. Adjusted EBITDA for our specialty hospitals increased by 27.3% to \$362.3 million for the year ended December 31, 2011 compared to \$284.6 million for the year ended December 31, 2010. Our Adjusted EBITDA margins increased to 17.3% for the year ended December 31, 2011 from 16.7% for the year ended December 31, 2010. For the year ended December 31, 2011, the Regency hospitals acquired on September 1, 2010 contributed \$45.9 million of the \$77.8 million increase in specialty hospital Adjusted EBITDA for 2011. Excluding the effect of the Regency hospitals in both periods, the Adjusted EBITDA margin would have been 18.0% and 17.7% for 2011 and 2010, respectively. In addition to the contribution from the Regency hospitals, the increase in the Adjusted EBITDA for the remainder of our specialty hospitals was primarily the result of an increase in patient volumes and an increase in our Medicare net revenue per patient day described above under "Net Operating Revenues Specialty Hospitals."

Outpatient Rehabilitation. Adjusted EBITDA for our outpatient rehabilitation segment was \$83.9 million for the year ended December 31, 2011 compared to \$83.8 million for the year ended December 31, 2010. Our Adjusted EBITDA margins decreased to 11.8% for the year ended December 31, 2011 from 12.2% for the year ended December 31, 2010. The principal reason for the decrease in the Adjusted EBITDA margin for the segment was related to our contract services business. We experienced a decline in the Adjusted EBITDA and Adjusted EBITDA margin of our contract services business that resulted from (1) the loss of significant contracts during the second quarter of 2010 that had generated higher Adjusted EBITDA margins and (2) higher labor costs for the treatment models required by RUGS IV/MDS 3.0 rules that became effective on October 1, 2010. The Adjusted EBITDA in our outpatient rehabilitation clinics increased by \$6.4 million for the year ended December 31, 2011 compared to the year ended December 31, 2010. Additionally, our Adjusted EBITDA margins for our outpatient rehabilitation clinics grew to 13.0% for the year ended December 31, 2011 from 12.1% for the year ended December 31,

71

Table of Contents

2010. The increase in our Adjusted EBITDA and Adjusted EBITDA margin in our rehabilitation clinics was principally due to an improvement in the performance in the clinics acquired in 2007 from HealthSouth Corporation and the increase in our net revenue per visit.

Other. The Adjusted EBITDA loss was \$60.2 million for the year ended December 31, 2011 compared to an Adjusted EBITDA loss of \$61.3 million for the year ended December 31, 2010 and is primarily related to our general and administrative expenses, as described under "Operating Expenses."

Income from Operations

For the year ended December 31, 2011 we had income from operations of \$310.7 million compared to \$236.1 million for the year ended December 31, 2010. The increase in income from operations resulted primarily from the Regency hospitals acquired on September 1, 2010 which contributed \$41.3 million of the \$74.6 million increase in income from operations for the year ended December 31, 2011, and improved operating performance at our other specialty hospitals.

Loss on Early Retirement of Debt

Select Medical Corporation. On June 1, 2011 we refinanced our senior secured credit facility. We recognized a loss on early retirement of debt of \$20.4 million for the year ended December 31, 2011 which included the write-off of unamortized deferred financing costs and tender premiums.

Select Medical Holdings Corporation. On June 1, 2011 we refinanced our senior secured credit facility. We recognized a loss on early retirement of debt of \$31.0 million for the year ended December 31, 2011, which included the write-off of unamortized deferred financing costs, tender premiums and original issue discount.

Interest Expense

Select Medical Corporation. Interest expense was \$81.2 million for the year ended December 31, 2011 compared to \$84.5 million for the year ended December 31, 2010. The decrease in interest expense resulted primarily from the expiration of interest rate swaps in 2010 that carried higher fixed interest rates, which was offset in part by the refinancing of \$150.0 million of Holdings' debt, for which Select was not previously obligated through indebtedness incurred by Select under the new senior secured credit facility on June 1, 2011.

Select Medical Holdings Corporation. Interest expense was \$99.2 million for the year ended December 31, 2011 compared to \$112.3 million for the year ended December 31, 2010. The decrease in interest expense resulted primarily from the expiration of interest rate swaps in 2010 that carried higher fixed interest rates and lower interest rates on the portions of the debt that were refinanced on June 1, 2011.

Income Taxes

Select Medical Corporation. We recorded income tax expense of \$81.0 million for the year ended December 31, 2011. The expense represented an effective tax rate of 38.1%. We recorded income tax expense of \$51.4 million for the year ended December 31, 2010. The expense represented an effective tax rate of 33.8%. Select Medical Corporation is part of the consolidated federal tax return for Select Medical Holdings Corporation. We allocate income taxes between Select and Holdings for purposes of financial statement presentation. Because Holdings is a passive investment company incorporated in Delaware, it does not incur any state income tax expense or benefit on its specific income or loss and, as such, receives a tax allocation equal to the federal statutory rate of 35% on its specific income or loss. Based upon the relative size of Holdings' income or loss, this can cause the effective tax rate for Select to differ from the effective tax rate for the consolidated company. The analysis in the following paragraph discusses the change in our consolidated tax rate.

72

Table of Contents

Select Medical Holdings Corporation. We recorded income tax expense of \$71.0 million for the year ended December 31, 2011. The expense represented an effective tax rate of 38.6%. We recorded income tax expense of \$41.6 million for the year ended December 31, 2010. The expense represented an effective tax rate of 33.6%. Although our effective tax rate for the year ended December 31, 2011 approximates our statutory tax rate, the rate was affected by two significant items that offset each other in the effective rate. We experienced an increase in our effective tax rate from a difference between the tax accounting basis and the financial accounting basis associated with a hospital exchange that occurred in early 2011 and an increase in our reserves for uncertain tax positions resulting from the settlement costs associated with the Columbus matter. These increases were offset by a release in reserves for uncertain tax positions associated with the tax basis of an acquisition we consummated in 1999. During 2011, additional information was discovered that further supported the tax basis of entities acquired through this acquisition and resulted in a change in the estimates related to this tax uncertainty. Our low effective tax rate for the year ended December 31, 2010 is below the statutory rate due to the reversal of certain valuation allowances that had been provided on losses in previous years. A substantial portion of this reversal in our valuation allowance relates to our ability to utilize a Federal capital loss generated in 2007 to offset a taxable capital gain on a recently completed transaction.

Non-Controlling Interests

Non-controlling interests in consolidated earnings were \$4.9 million for the year ended December 31, 2011 and \$4.7 million for the year ended December 31, 2010.

Liquidity and Capital Resources

Years Ended December 31, 2010, 2011 and 2012

	Select Medical Holdings Corporation						Select Medical Corporation						
	Year Ended December 31,							Year Ended December 31,					
		2010		2011		2012		2010		2011		2012	
			thousands)		(In thousands)								
Cash flows provided by operating													
activities	\$	144,537	\$	217,128	\$	298,682	\$	170,064	\$	240,053	\$	309,371	
Cash flows used in investing activities		(216,998)		(54,735)		(72,406)		(216,998)		(54,735)		(72,406)	
Cash flows used in financing													
activities		(6,854)		(154,715)		(198,175)		(32,381)		(177,640)		(208,864)	
Net increase (decrease) in cash and cash equivalents		(79,315)		7,678		28,101		(79,315)		7,678		28,101	
Cash and cash equivalents at beginning of period		83,680		4,365		12,043		83,680		4,365		12,043	
Cash and cash equivalents at end of period	\$	4,365	\$	12,043	\$	40,144	\$	4,365	\$	12,043	\$	40,144	

Operating activities for Select provided \$309.4 million of cash flows for the year ended December 31, 2012. The increase in cash flow provided by operating activities is principally related to a reduction in our days sales outstanding. Our days sales outstanding were 45 days at December 31, 2012 compared to 53 days at December 31, 2011. The reduction in days sales outstanding is primarily due to timing of the periodic interim payments we receive from Medicare for the services provided at our specialty hospitals and a reduction in our non-Medicare receivables.

73

Table of Contents

Operating activities for Select provided \$240.1 million for the year ended December 31, 2011. The increase in cash flow provided by operating activities for the year ended December 31, 2011 is principally related to the increase in our income from operations. Additionally, we were able to offset the cash impact of an increase in our tax expense through an one-time deferral of income effectuated through a tax accounting change related to how we recognize our specialty hospital Medicare revenues for tax reporting purposes. This tax accounting change had the effect of deferring \$16.5 million of tax liability in 2011. Our days sales outstanding were 53 days at December 31, 2011 compared to 51 days at December 31, 2010. The increase is principally related to the timing and settlement of our Medicare accounts receivable for services provided at our specialty hospitals.

Operating activities for Select provided \$170.1 million for the year ended December 31, 2010. The decrease in cash flow provided by operating activities in comparison to our operating cash flow provided by operating activities for the year ended December 31, 2009 is principally related to the increase in our accounts receivable at December 31, 2010. Our days sales outstanding were 51 days at December 31, 2010 compared to 49 days at December 31, 2009 and falls within our historical range of days sales outstanding.

The operating cash flow of Select exceeds the operating cash flow of Holdings by \$10.7 million, \$22.9 million and \$25.5 million for the years ended December 31, 2012, 2011 and 2010, respectively. The difference relates to interest payments on Holdings' indebtedness.

Investing activities used \$72.4 million, \$54.7 million and \$217.0 million of cash flow for the years ended December 31, 2012, 2011, and 2010, respectively. Of this amount, we incurred acquisition related payments of \$6.0 million, \$0.9 million and \$165.8 million, respectively in 2012, 2011 and 2010. The acquisition payments for 2012 related principally to several small acquisitions of clinics in our outpatient rehabilitation segment. The acquisition payments for 2011 relate primarily to small acquisitions of outpatient businesses and specialty hospitals. The acquisition payments in 2010 related principally to the acquisition of Regency which was \$165.6 million. Investing activities also used cash for the purchases of property and equipment of \$68.2 million, \$46.0 million and \$51.8 million in 2012, 2011, and 2010, respectively. We sold business units and real property which generated \$16.5 million, \$7.9 million and \$0.6 million in cash during the years ended December 31, 2012, 2011 and 2010, respectively. Investment in businesses relates to equity investments in unconsolidated businesses. The \$14.7 million of investments for the year ended December 31, 2012 and \$15.7 million of investments for the year ended December 31, 2011 related primarily to our investment in the Baylor JV partnership units. In addition, Select purchased minority investment interests in other healthcare related businesses that provide specialized technology, services to healthcare entities, and other healthcare services during the year ended December 31, 2012.

Financing activities for Select used \$208.9 million of cash flow for the year ended December 31, 2012. The primary use of cash related to dividends paid to Holdings of \$268.5 million principally to fund the payment of dividends to stockholders on December 12, 2012, fund interest payments, and the repurchase of common stock. Select also used \$6.5 million for debt issuances costs and paid \$3.3 million in distributions to non-controlling interests, offset in part by net borrowings of debt of \$66.4 million, \$1.2 million of proceeds from bank overdrafts and \$1.8 million of equity investment made by Holdings.

Financing activities for Select used \$177.6 million of cash flow for the year ended December 31, 2011. The primary use of cash related to dividends paid to Holdings of \$245.7 million to fund interest payments, repurchase of common stock and the repurchase of all \$150.0 million principal amount of Holdings 10% senior subordinated notes, \$18.6 million of debt issuance costs, repayment of bank overdrafts of \$2.2 million and \$4.6 million in distributions to non-controlling interests offset by net borrowings of debt of \$93.2 million.

Financing activities for Select used \$32.4 million of cash flow for the year ended December 31, 2010. The primary usage of cash was related to dividends paid to Holdings of \$69.7 million to fund interest payments and stock repurchases and was offset by a net borrowing under our revolving senior secured credit facility.

74

Table of Contents

The difference in cash flows used in financing activities of Holdings compared to Select of \$10.7 million, \$22.9 million and \$25.5 million for the years ended December 31, 2012, 2011 and 2010, respectively, relates to dividends paid by Select to Holdings to service Holdings' interest obligations related to its indebtedness.

Capital Resources

Select Medical Corporation. Select had net working capital of \$63.2 million at December 31, 2012 compared to net working capital of \$97.3 million at December 31, 2011.

Select Medical Holdings Corporation. Holdings had net working capital of \$65.2 million at December 31, 2012 compared to net working capital of \$99.5 million at December 31, 2011.

On June 1, 2011, Select entered into a new senior secured credit agreement that originally provided for \$1.15 billion in senior secured credit facilities comprised of an \$850.0 million, seven-year term loan facility, which we refer to as the Original Term Loan, and a \$300.0 million, five-year revolving credit facility, including a \$75.0 million sublimit for the issuance of standby letters of credit and a \$25.0 million sublimit for swingline loans. Borrowings under the senior secured credit facilities are guaranteed by Holdings and substantially all of Select's current domestic subsidiaries and will be guaranteed by Select's future domestic subsidiaries and secured by substantially all of Select's existing and future property and assets and by a pledge of Select's capital stock, the capital stock of Select's domestic subsidiaries and up to 65% of the capital stock of Select's foreign subsidiaries, if any.

On August 13, 2012, Select entered into an additional credit extension amendment to its senior secured credit facilities providing for a \$275.0 million additional term loan tranche, which we refer to as the Series A Tranche B Term Loan, to Select at the same interest rate and with the same term as the Original Term Loan.

Borrowings under the Original Term Loan and the Series A Tranche B Term Loan will bear interest at a rate equal to Adjusted LIBO plus 3.75%, or Alternate Base Rate plus 2.75%.

Borrowings under the revolving credit facility will bear interest at a rate equal to Adjusted LIBO plus a percentage ranging from 2.75% to 3.75%, or Alternate Base Rate plus a percentage ranging from 1.75% to 2.75%, in each case based on Select's leverage ratio (the ratio of indebtedness to consolidated EBITDA, as defined in the senior secured credit agreement). The applicable margin percentage for revolving loans as of December 31, 2012 was (1) 3.25% for Adjusted LIBO loans and (2) 2.25% for Alternate Base Rate loans.

The Original Term Loan and the Series A Tranche B Term Loan amortize in equal quarterly installments on the last day of each March, June, September and December in aggregate annual amounts equal to \$11.3 million. The balance of the Original Term Loan and the Series A Tranche B Term Loan will be payable on June 1, 2018 and the revolving credit facility will be payable on June 1, 2016.

On February 20, 2013, Select entered into an additional credit extension amendment to its senior secured credit facilities providing for a \$300.0 million additional term loan tranche, which we refer to as the Series B Tranche B Term Loan, to Select.

Borrowings under the Series B Tranche B Term Loan will bear interest at a rate equal to Adjusted LIBO plus 3.25%, or Alternate Base Rate plus 2.25%. The Series B Tranche B Term Loan amortizes in equal quarterly installments on the last day of each March, June, September and December in aggregate annual amounts equal to \$3.0 million. The balance of the Series B Tranche B Term Loan will be payable on February 20, 2016.

"Adjusted LIBO" is defined as, with respect to any interest period, the London interbank offered rate for such interest period, adjusted for any applicable statutory reserve requirements; provided that Adjusted LIBO, when used in reference to the Original Term Loan and Series A Tranche B Term Loan, will at no time be less than 1.75% per annum.

75

Table of Contents

"Alternate Base Rate" is defined as the highest of (a) the administrative agent's Prime Rate, (b) the Federal Funds Effective Rate plus ¹/₂ of 1.00% and (c) the Adjusted LIBO from time to time for an interest period of one month, plus 1.00%.

Select will be required to prepay borrowings under the senior secured credit facilities with (1) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and the payment of certain indebtedness secured by liens subject to a first lien intercreditor agreement, (2) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (3) 50% of excess cash flow (as defined in the credit agreement) if Select's leverage ratio is greater than 3.75 to 1.00 and 25% of excess cash flow if Select's leverage ratio is less than or equal to 3.75 to 1.00 and greater than 3.25 to 1.00, in each case, reduced by the aggregate amount of term loans optionally prepaid during the applicable fiscal year. Select will not be required to prepay borrowings with excess cash flow if Select's leverage ratio is less than or equal to 3.25 to 1.00.

The senior secured credit facilities require Select to maintain a leverage ratio (based upon the ratio of indebtedness to consolidated EBITDA, as defined in the credit agreement), which is tested quarterly, and prohibits Select from making capital expenditures in excess of \$125.0 million in any fiscal year (subject to a 50% carry-over provision). As of December 31, 2012, Select was required to maintain its leverage ratio at less than 4.75 to 1.00, and Select's leverage ratio was 3.18 to 1.00 as of December 31, 2012. Failure to comply with these covenants would result in an event of default under the senior secured credit facilities and, absent a waiver or an amendment from the lenders, preclude Select from making further borrowings under the revolving credit facility and permit the lenders to accelerate all outstanding borrowings under the senior secured credit facilities.

The senior secured credit facilities also contain a number of affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The senior secured credit facilities contain events of default for non-payment of principal and interest when due, cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

In June 2011, Select used borrowings under the senior secured credit facilities to refinance all of its outstanding indebtedness under its existing senior secured credit facilities, to repurchase \$266.5 million aggregate principal amount of its 75/8% senior subordinated notes due 2015 and to repay all of Holdings' 10% senior subordinated notes due 2015.

In August 2012, Select used borrowings under the senior secured credit facilities to repurchase \$275.0 million aggregate principal amount of its 7⁵/₈% senior subordinated notes due 2015.

Select intends to use borrowings under the Series B Tranche B Term Loan to redeem all of its outstanding 75/8% senior subordinated notes due 2015, to finance Holdings redemption of all of Holdings' senior floating rate notes due 2015 and to reduce a portion of the balance outstanding under its revolving credit facility. On February 20, 2013, Select and Holdings each instructed U.S. Bank Trust National Association, as trustee, to deliver an irrevocable notice of redemption to the holders of all of Select's outstanding 75/8% senior subordinated notes due 2015 and all of Holdings' outstanding senior floating rate notes due 2015, respectively, all of which will be redeemed at 100% of the principal amount plus any accrued and unpaid interest to the redemption date on or about March 22, 2013.

As of December 31, 2012, we had outstanding borrowings of \$1,096.6 million (net of unamortized original issue discount of \$14.2 million) under the term loans and outstanding borrowings of \$130.0 million under the revolving loan portion of our senior secured credit facilities. As of December 31, 2012, we had \$135.9 million of availability under our revolving credit facility (after giving effect to \$34.1 million of outstanding letters of credit).

76

Table of Contents

On February 24, 2005, EGL Acquisition Corp. issued and sold \$660.0 million in aggregate principal amount of 75/8% senior subordinated notes due 2015, which Select assumed in connection with the Merger. The net proceeds of the offering were used to finance a portion of the funds needed to consummate the Merger with EGL Acquisition Corp. The notes were issued under an indenture between EGL Acquisition Corp. and U.S. Bank Trust National Association, as trustee. Interest on the notes is payable semi-annually in arrears on February 1 and August 1 of each year. The notes are guaranteed by all of Select's wholly-owned subsidiaries, subject to certain exceptions.

During 2008, we repurchased and retired senior subordinated notes having a carrying value of \$2.0 million. During 2009, we repurchased and retired senior subordinated notes having a carrying value of \$46.5 million.

On June 1, 2012, Select used a portion of the proceeds from its senior secured credit facilities to repurchase \$266.5 million aggregate principal amount of its $7^5/8\%$ senior subordinated notes.

On September 12, 2012, Select used the proceeds of the incremental term loans and cash on hand to redeem \$275.0 million aggregate principal amount of its 75/8% senior subordinated notes.

On September 29, 2005, Holdings sold \$175.0 million of senior floating rate notes due 2015, which bear interest at a rate per annum, reset semi-annually, equal to the 6-month LIBOR plus 5.75%. Interest is payable semi-annually in arrears on March 15 and September 15 of each year, with the principal due in full on September 15, 2015. The senior floating rate notes are general unsecured obligations of Holdings and are not guaranteed by Select or any of its subsidiaries. The net proceeds of the issuance of the senior floating rate notes, together with cash was used to reduce the amount of our preferred stock, to make a payment to participants in our long-term incentive plan and to pay related fees and expenses.

During 2009, we repurchased and retired senior floating rate notes having a carrying value of \$7.7 million.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Holdings has authorized a program to repurchase up to \$350.0 million worth of shares of our common stock. The program will remain in effect until March 31, 2014, unless extended by the board of directors. During the year ended December 31, 2012, Holdings has repurchased 5,725,782 shares at a cost of \$46.8 million and since the inceptions of the program has repurchased 22,490,389 shares under the program at a cost of \$163.6 million, which includes related transaction costs. We anticipate funding this program through available operating cash flow and borrowings under our senior secured credit facility.

We believe our internally generated cash flows and borrowing capacity under our senior secured credit facility will be sufficient to finance operations over the next twelve months

We routinely pursue opportunities to develop new joint ventures relationships with significant health systems, and from time to time we may also develop new inpatient rehabilitation hospitals. With the expiration on December 28, 2012 of the moratorium on new LTCHs and new LTCH beds, we are evaluating the addition of new LTCH beds at certain of our hospitals. We also intend to open new outpatient rehabilitation clinics in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow our network of specialty hospitals through opportunistic acquisitions.

Commitments and Contingencies

The following tables summarize contractual obligations at December 31, 2012, and the effect such obligations are expected to have on liquidity and cash flow in future periods. Reserves for uncertain tax positions of \$15.4 million have been excluded from the tables below as we cannot reasonably estimate the amounts or periods in which these liabilities will be paid.

77

Table of Contents

Select Medical Holdings Corporation:

Contractual Obligations	Total	2013	20	014-2016	2	017-2018	A	fter 2018
			(in	thousands)			
7 ⁵ /8% senior subordinated notes ⁽¹⁾	\$ 70,000	\$	\$	70,000	\$		\$	
Senior secured credit facility ⁽²⁾⁽³⁾	1,226,641	8,584		155,860		1,062,197		
Senior floating rate notes ⁽¹⁾	167,300			167,300				
Other debt obligations	6,302	3,062		1,794		46		1,400
Total debt	1,470,243	11,646		394,954		1,062,243		1,400
Interest ⁽⁴⁾	382,820	82,966		217,041		82,757		56
Letters of credit outstanding	34,072			34,072				
Purchase obligations	6,240	3,479		2,358		403		
Construction contracts	7,246	7,246						
Naming, promotional and sponsorship								
agreement	42,977	2,870		9,017		6,365		24,725
Operating leases	675,028	121,272		223,326		74,840		255,590
Related party operating leases	36,436	3,481		9,910		6,992		16,053
Total contractual cash obligations	\$ 2,655,062	\$ 232,960	\$	890,678	\$	1,233,600	\$	297,824

Select Medical Corporation:

Contractual Obligations	Total	2013	20	14-2016	2	2017-2018	Af	fter 2018
			(in	thousands)			
7 ⁵ /8% senior subordinated notes ⁽¹⁾	\$ 70,000	\$	\$	70,000	\$		\$	
Senior secured credit facility ⁽²⁾⁽³⁾	1,226,641	8,584		155,860		1,062,197		
Other debt obligations	6,302	3,062		1,794		46		1,400
Total debt	1,302,943	11,646		227,654		1,062,243		1,400
Interest ⁽⁴⁾	353,704	72,209		198,682		82,757		56
Letters of credit outstanding	34,072			34,072				
Purchase obligations	6,240	3,479		2,358		403		
Construction contracts	7,246	7,246						
Naming, promotional and sponsorship								
agreement	42,977	2,870		9,017		6,365		24,725
Operating leases	675,028	121,272		223,326		74,840		255,590
Related party operating leases	36,436	3,481		9,910		6,992		16,053
Total contractual cash obligations	\$ 2,458,646	\$ 222,203	\$	705,019	\$	1,233,600	\$	297,824

Table of Contents 87

(2)

78

On February 20, 2013, Select and Holdings each instructed U.S. Bank Trust National Association, as trustee, to deliver an irrevocable notice of redemption to the holders of all of Select's outstanding 75/8% senior subordinated notes due 2015 and all of Holdings' outstanding senior floating rate notes due 2015, respectively, all of which will be redeemed on or about March 22, 2013 using a portion of the proceeds from the Series B Tranche B Term Loan.

Reflects the balance sheet liability of the senior secured credit facility calculated in accordance with GAAP. The balance sheet liability so reflected is less than the \$1,125.1 million aggregate principal amount of term loans that were issued with original issue discount. The remaining unamortized original issue discount on the term loans was \$14.2 million at December 31, 2012. Interest on the

Table of Contents

senior secured credit facility accrued on the full principal amount thereof and Holdings will be obligated to repay the full principal thereof at maturity or upon any mandatory or voluntary prepayment thereof.

- (3) The balance of the term loans will be payable on June 1, 2018 and the revolving credit facility will be payable on June 1, 2016.
- The interest obligation for the senior secured credit facility term loans was calculated using the average interest rate at December 31, 2012 of 5.5% and the revolving portion was calculated at the average interest rate at December 31, 2012 of 4.3%. The interest obligation was calculated using the stated interest rate for the 75/8% senior subordinated notes, 6.4% for the senior floating rate notes and 6.0% for the other debt obligations.

Inflation

The healthcare industry is labor intensive and susceptible to wage increases during periods of inflation and when labor shortages occur in the marketplace. In addition, suppliers which include pharmaceutical costs, pass along rising costs to us in the form of higher prices. Our ability to pass on increased costs associated with providing healthcare to Medicare and Medicaid patients is limited due to federal and state laws that established fixed reimbursement rates. In recent years, inflation has not had a material impact on our results of operations. We cannot predict the impact that future economic conditions may have on our ability to contain or offset future cost increases.

Recent Accounting Pronouncements

In July 2012, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2012-02, "Intangibles Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment," ("Update 2012-02"). In accordance with Update 2012-02, an entity has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If the entity determines that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, the entity will be required to perform the quantitative impairment test. Update 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. However, early adoption is permitted. Update 2012-02 will not have an impact on our consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05, "Comprehensive Income (Topic 220) Presentation of Comprehensive Income" ("Update 2011-05") that improves the comparability, consistency and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders' equity. Update 2011-05 requires that all non-owner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income ("OCI") to net income, in both net income and OCI. Update 2011-05 does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, Update 2011-05 does not affect the calculation or reporting of earnings per share. Update 2011-05 was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 and is to be applied retrospectively. With the adoption of Update 2011-05, the Company opted to change its presentation of its components of other comprehensive income to a single continuous statement of operations and other comprehensive income.

79

Table of Contents

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

We are subject to interest rate risk in connection with our long-term indebtedness. In 2012, our principal interest rate exposure related to the loans outstanding under Select's senior secured credit facility and Holdings' senior floating rate notes. As of December 31, 2012, we had \$1,110.9 million (excluding unamortized original issue discount) in term loans and \$130.0 million in revolving loans outstanding under our senior secured credit facility and \$167.3 million in senior floating rate notes outstanding, which bear interest at variable rates. Each eighth of a point change in interest rates on the variable rate portion of our long-term indebtedness would result in a \$1.8 million annual change in interest expense. However, because the variable interest rate for our \$1,110.9 million in term loans is subject to an Adjusted LIBO Rate floor of 1.75% until the Adjusted LIBO Rate exceeds 1.75%, our interest rate on this indebtedness is effectively fixed at 5.50%.

Following the redemption of all of Holdings' outstanding senior floating rate notes due 2015, our principal interest rate exposure will relate to the loans outstanding under Select's senior secured credit facility. After giving effect to the borrowings under the Series B Tranche B Term Loan, the repayment of a portion of our revolving loans, and the redemption of all of Holdings' senior floating rate notes, we will have \$1,410.9 million (excluding unamortized original issue discount) in term loans and \$75.0 million in revolving loans outstanding under our senior secured credit facility. Each eighth of a point change in interest rates on the variable rate portion of our Original Term Loan and Series A Tranche B Term Loan would result in a \$1.4 million annual change in interest expense. However, because the variable interest rate for our term loans is subject to an Adjusted LIBO Rate floor of 1.75% until the Adjusted LIBO Rate exceeds 1.75%, our interest rate on this indebtedness is effectively fixed at 5.50%. Each eighth of a point change in interest rates on our \$300.0 million Series B Tranche B Term Loan and \$75.0 million in revolving loans outstanding would result in a \$0.5 million annual change in interest expense.

Item 8. Financial Statements and Supplementary Data.

See Consolidated Financial Statements and Notes thereto commencing at Page F-1.

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective as of December 31, 2012 to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized and reported within the time periods specified in the relevant SEC rules and forms.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the fourth quarter of the year ended December 31, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

80

Table of Contents

Management's Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining an adequate system of internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria on Internal Control Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission, or "COSO," as of December 31, 2012. Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2012. This assessment was based on criteria for effective internal control over financial reporting described in "Internal Control Integrated Framework," issued by COSO. Based on this assessment, management concludes that, as of December 31, 2012, internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles. The effectiveness of the Company's internal control over financial reporting as of December 31, 2012 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm as stated in their report which appears herein.

Item 9B. Other Information.

None.

81

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The information regarding directors and nominees for directors of the Company, including identification of the audit committee and audit committee financial expert, and Compliance with Section 16(a) of the Exchange Act is presented under the headings "Corporate Governance Committees of the Board of Directors," "Election of Directors Directors and Nominees" and "Section 16(a) Beneficial Ownership Reporting Compliance" in the Company's definitive proxy statement for use in connection with the 2013 Annual Meeting of Stockholders (the "Proxy Statement") to be filed within 120 days after the end of the Company's fiscal year ended December 31, 2012. The information contained under these headings is incorporated herein by reference. Information regarding the executive officers of the Company is included in this Annual Report on Form 10-K under Item 1 of Part I as permitted by Instruction 3 to Item 401(b) of Regulation S-K.

We have adopted a written code of business conduct and ethics, known as our code of conduct, which applies to all of our directors, officers, and employees, as well as a code of ethics applicable to our senior financial officers, including our chief executive officer, our chief financial officer and our chief accounting officer. Our code of conduct and code of ethics for senior financial officers are available on our Internet website, www.selectmedicalholdings.com. Our code of conduct and code of ethics for senior financial officers may also be obtained by contacting investor relations at (717) 972-1100. Any amendments to our code of conduct or code of ethics for senior financial officers or waivers from the provisions of the codes for our chief executive officer, our chief financial officer and our chief accounting officer will be disclosed on our Internet website promptly following the date of such amendment or waiver.

Item 11. Executive Compensation.

Information concerning executive compensation is presented under the headings "Executive Compensation" and "Compensation Committee Report" in the Proxy Statement. The information contained under these headings is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Information with respect to security ownership of certain beneficial owners and management is set forth under the heading "Security Ownership of Certain Beneficial Owners and Directors and Officers" in the Proxy Statement. The information contained under this heading is incorporated herein by reference.

Equity Compensation Plan Information

Set forth in the table below is a list of all of our equity compensation plans and the number of securities to be issued on exercise of equity rights, average exercise price, and number of securities that

82

Number of

Table of Contents

would remain available under each plan if outstanding equity rights were exercised as of December 31, 2012.

	Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants	Weighted-Average Exercise Price of Outstanding Options, Warrants	Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in
Disco Codessore	and Rights	and Rights	Column (a))
Plan Category	and Rights (a)	and Rights (b)	Column (a)) (c)
Equity compensation plans approved by security holders:	U	U	` '/
	U	U	` '/
Equity compensation plans approved by security holders:	U	(b)	` '/
Equity compensation plans approved by security holders: Select Medical Holdings Corporation 2005 Equity	(a)	(b)	(c)
Equity compensation plans approved by security holders: Select Medical Holdings Corporation 2005 Equity Incentive Plan	(a)	(b) \$ 8.40	(c)

Item 13. Certain Relationships, Related Transactions and Director Independence.

Information concerning related transactions is presented under the heading "Certain Relationships, Related Transactions and Director Independence" in the Proxy Statement. The information contained under this heading is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services.

Information concerning principal accountant fees and services is presented under the heading "Ratification of Appointment of Independent Registered Public Accounting Firm" in the Proxy Statement. The information contained under this heading is incorporated herein by reference.

Table of Contents

PART IV

Item 15. Exhibits and Financial Statement Schedules.

- (a) The following documents are filed as part of this report:
 - 1) Financial Statements: See Index to Financial Statements appearing on page F-1 of this report.
 - 2) Financial Statement Schedule: See Schedule II Valuation and Qualifying Accounts appearing on page F-54 of this report.
 - 3) The following exhibits are filed as part of, or incorporated by reference into, this report:

Number Description

- 2.1 Purchase and Sale Agreement by and among Regency Hospital Company, L.L.C., the Sellers named therein, the Representative named therein, Intensiva Healthcare Corporation and Select Medical Corporation, dated June 18, 2010, incorporated herein by reference to Exhibit 2.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on June 23, 2010 (Reg. Nos. 001-34465 and 001-31441).
- Amendment No. 1 to Purchase and Sale Agreement by and among Regency Hospital Company, L.L.C., Waud Capital Partners, L.L.C. and Intensiva Healthcare Corporation, dated September 1, 2010, incorporated herein by reference to Exhibit 2.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on September 7, 2010 (Reg. Nos. 001-34465 and 001-31441).
- 3.1 Amended and Restated Certificate of Incorporation of Select Medical Corporation, incorporated by reference to Exhibit 3.1 of Select Medical Corporation's Form S-4 filed June 15, 2005 (Reg. no. 001-31441).
- 3.2 Form of Restated Certificate of Incorporation of Select Medical Holdings Corporation, incorporated by reference to Exhibit 3.3 of Select Medical Holdings Corporation's Form S-1/A filed September 21, 2009 (Reg No. 333-152514).
- 3.3 Amended and Restated Bylaws of Select Medical Corporation, as amended, incorporated by reference to Exhibit 3.2 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
- 3.4 Amended and Restated Bylaws of Select Medical Holdings Corporation, as amended, incorporated by reference to Exhibit 3.1 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
- 4.1 Registration Rights Agreement, dated as of February 24, 2005, among Select Medical Holdings Corporation, Welsh, Carson, Anderson & Stowe IX, L.P., WCAS Capital Partners IV, L.P., each of the entities and individuals listed on Schedule I thereto and each of the other entities and individuals from time to time listed on Schedule II thereto, incorporated by reference to Exhibit 10.77 of Select Medical Holdings Corporation's Form S-4 filed April 13, 2006 (Reg. No. 333-133284).

84

Table of Contents

Number	Description
10.1	Credit Agreement, dated as of June 1, 2011, among Select Medical Holdings Corporation, Select Medical Corporation, JPMorgan Chase Bank, N.A., as Administrative and Collateral Agent, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Goldman Sachs Bank USA, as Co-Syndication Agents and Morgan Stanley Senior Funding, Inc. and Wells Fargo Bank, National Association, LLC, as Co-Documentation Agents and the other lenders party thereto, incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on June 2, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.2	Employment Agreement, dated as of March 1, 2000, between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.16 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.3	Amendment No. 1 to Employment Agreement, dated as of August 8, 2000, between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.17 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.4	Amendment No. 2 to Employment Agreement, dated as of February 23, 2001, between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.47 of Select Medical Corporation's Registration Statement on Form S-1 March 30, 2001 (Reg. No. 333-48856).
10.5	Amendment No. 3 to Employment Agreement, dated as of April 24, 2001, between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.50 of Select Medical Corporation's Registration Statement on Form S-4 filed June 26, 2001 (Reg. No. 333-63828).
10.6	Amendment No. 4 to Employment Agreement, dated as of September 17, 2001, between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.52 of Select Medical Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 (Reg. No. 000-32499).
10.7	Amendment No. 5 to Employment Agreement, dated as of February 24, 2005, between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.10 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.8	Employment Agreement, dated as of March 1, 2000, between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.14 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.9	Amendment No. 1 to Employment Agreement, dated as of August 8, 2000, between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.15 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.10	Amendment No. 2 to Employment Agreement, dated as of February 23, 2001, between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.48 of Select Medical Corporation's Registration Statement on Form S-1 filed March 30, 2001 (Reg. No. 333-48856).
10.11	Amendment No. 3 to Employment Agreement, dated as of September 17, 2001, between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.53 of Select Medical Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 (Reg. No. 000-32499). 85

Table of Contents

Number	Description
10.12	Amendment No. 4 to Employment Agreement, dated as of December 10, 2004, between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 99.3 of Select Medical Corporation's Current Report on Form 8-K filed December 16, 2004 (Reg. No. 001-31441).
10.13	Amendment No. 5 to Employment Agreement, dated as of February 24, 2005, between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.16 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.14	Employment Agreement, dated as of March 1, 2000, between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.19 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.15	Amendment No. 1 to Employment Agreement, dated as of August 8, 2000, between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.20 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.16	Amendment No. 2 to Employment Agreement, dated as of February 23, 2001, between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.49 of Select Medical Corporation's Registration Statement on Form S-1 filed March 30, 2001 (Reg. No. 333-48856).
10.17	Amendment No. 3 to Employment Agreement, dated as of December 10, 2004, between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 99.2 of Select Medical Corporation's Current Report on Form 8-K filed December 16, 2004 (Reg. No. 001-31441).
10.18	Amendment No. 4 to Employment Agreement, dated as of February 24, 2005, between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.21 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.19	Amendment No. 5 to Employment Agreement, dated as of April 27, 2005, between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.46 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.20	Amendment No. 6 to Employment Agreement, dated as of February 13, 2008, between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.27 of Select Medical Holdings Corporation's Form S-1 filed July 24, 2008 (Reg. No. 333-152514).
10.21	Amendment No. 1 to Restricted Stock Award Agreement, dated as of February 13, 2008, between Select Medical Holdings Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.29 of Select Medical Holdings Corporation's Form S-1 filed July 24, 2008 (Reg. No. 333-152514).
10.22	Change of Control Agreement, dated as of March 1, 2000, between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.11 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.23	Amendment to Change of Control Agreement, dated as of February 23, 2001, between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.52 of Select Medical Corporation's Registration Statement on Form S-1 filed March 30, 2001 (Reg. No. 333-48856).

Table of Contents

Number	Description
10.24	Second Amendment to Change of Control Agreement, dated as of February 24, 2005, between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.24 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.25	Change of Control Agreement, dated as of March 1, 2000, between Select Medical Corporation and James J. Talalai, incorporated by reference to Exhibit 10.58 of Select Medical Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 (Reg. No. 000-32499).
10.26	Amendment to Change of Control Agreement, dated as of February 23, 2001, between Select Medical Corporation and James J. Talalai, incorporated by reference to Exhibit 10.59 of Select Medical Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 (Reg. No. 000-32499).
10.27	Second Amendment to Change of Control Agreement, dated as of February 24, 2005, between Select Medical Corporation and James J. Talalai, incorporated by reference to Exhibit 10.35 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.28	Change of Control Agreement, dated as of March 1, 2000, between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.22 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).
10.29	Amendment to Change of Control Agreement, dated as of February 23, 2001, between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.54 of Select Medical Corporation's Registration Statement on Form S-1 filed March 30, 2001 (Reg. No. 333-48856).
10.30	Second Amendment to Change of Control Agreement, dated as of February 24, 2005, between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.39 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.31	Change of Control Agreement, dated as of March 1, 2000, between Select Medical Corporation and Scott A. Romberger, incorporated by reference to Exhibit 10.56 of Select Medical Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 (Reg. No. 000-32499).
10.32	Amendment to Change of Control Agreement, dated as of February 23, 2001, between Select Medical Corporation and Scott A. Romberger, incorporated by reference to Exhibit 10.57 of Select Medical Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 (Reg. No. 000-32499).
10.33	Second Amendment to Change of Control Agreement, dated as of February 24, 2005, between Select Medical Corporation and Scott A. Romberger, incorporated by reference to Exhibit 10.42 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.34	Form of Unit Award Agreement, incorporated by reference to Exhibit 10.54 of Select Medical Holdings Corporation's Form S-1 filed July 24, 2008 (Reg. No. 333-152514).
10.35	Office Lease Agreement, dated as of June 17, 1999, between Select Medical Corporation and Old Gettysburg Associates III, incorporated by reference to Exhibit 10.27 of Select Medical Corporation's Registration Statement on Form S-1 filed October 27, 2000 (Reg. No. 333-48856).

Table of Contents

Number	Description
10.36	First Addendum to Lease Agreement, dated as of April 25, 2008, between Old Gettysburg Associates III and Select Medical Corporation, incorporated by reference to Exhibit 10.65 of Select Medical Holdings Corporation's Form S-1 filed July 24, 2008 (Reg. No. 333-152514).
10.37	Second Addendum to Lease Agreement, dated as of November 1, 2012, between Old Gettysburg Associates III LP and Select Medical Corporation.
10.38	Office Lease Agreement, dated August 25, 2006, between Old Gettysburg Associates IV, L.P. and Select Medical Corporation, incorporated by reference to Exhibit 10.1 of Select Medical Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 (Reg. No. 001-31441).
10.39	First Addendum to Lease Agreement, dated as of November 1, 2012, between Old Gettysburg Associates IV LP and Select Medical Corporation.
10.40	Office Lease Agreement, dated November 1, 2012, by and between Select Medical Corporation and Old Gettysburg Associates.
10.41	Office Lease Agreement, dated November 1, 2012, by and between Select Medical Corporation and Old Gettysburg Associates II, LP.
10.42	Naming, Promotional and Sponsorship Agreement, dated as of October 1, 1997, between NovaCare, Inc. and the Philadelphia Eagles Limited Partnership, assumed by Select Medical Corporation in a Consent and Assumption Agreement dated November 19, 1999 by and among NovaCare, Inc., Select Medical Corporation and the Philadelphia Eagles Limited Partnership, incorporated by reference to Exhibit 10.36 of Select Medical Corporation's Registration Statement on Form S-1 filed December 7, 2000 (Reg. No. 333-48856).
10.43	First Amendment to Naming, Promotional and Sponsorship Agreement, dated as of January 1, 2004, between Select Medical Corporation and Philadelphia Eagles, LLC, incorporated by reference to Exhibit 10.63 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.44	Select Medical Holdings Corporation 2005 Equity Incentive Plan, as amended and restated, incorporated by reference to Exhibit 10.88 of Select Medical Holdings Corporation's Form S-1/A filed September 9, 2009 (Reg. No. 333-152514).
10.45	Select Medical Holdings Corporation 2011 Equity Incentive Plan, incorporated by reference to Exhibit A to Select Medical Holdings Corporation's Definitive Proxy Statement on Schedule 14A filed on March 25, 2011 (Reg. No. 333-174393).
10.46	Select Medical Holdings Corporation 2005 Equity Incentive Plan for Non-Employee Directors, as amended and restated, incorporated by reference to Exhibit 10.89 of Select Medical Holdings Corporation's Form S-1/A filed September 9, 2009 (Reg. No. 333-152514).
10.47	Amendment No. 6 to Employment Agreement between Select Medical Corporation and Rocco A. Ortenzio, incorporated by reference to Exhibit 10.95 of Select Medical Holdings Corporation's Form S-1/A filed June 18, 2009 (Reg. No. 333-152514).
10.48	Amendment No. 6 to Employment Agreement between Select Medical Corporation and Robert A. Ortenzio, incorporated by reference to Exhibit 10.96 of Select Medical Holdings Corporation's Form S-1/A filed June 18, 2009 (Reg. No. 333-152514).
10.49	Amendment No. 7 to Employment Agreement between Select Medical Corporation and Patricia A. Rice, incorporated by reference to Exhibit 10.97 of Select Medical Holdings Corporation's Form S-1/A filed June 18, 2009 (Reg. No. 333-152514). 88

Table of Contents

Number	Description
10.50	Third Amendment to Change of Control Agreement between Select Medical Corporation and Michael E. Tarvin, incorporated by reference to Exhibit 10.100 of Select Medical Holdings Corporation's Form S-1/A filed June 18, 2009 (Reg. No. 333-152514).
10.51	Third Amendment to Change of Control Agreement between Select Medical Corporation and James J. Talalai, incorporated by reference to Exhibit 10.101 of Select Medical Holdings Corporation's Form S-1/A filed June 18, 2009 (Reg. No. 333-152514).
10.52	Third Amendment to Change of Control Agreement between Select Medical Corporation and Scott A. Romberger, incorporated by reference to Exhibit 10.102 of Select Medical Holdings Corporation's Form S-1/A filed June 18, 2009 (Reg. No. 333-152514).
10.53	Third Amendment to Change of Control Agreement between Select Medical Corporation and Martin F. Jackson, incorporated by reference to Exhibit 10.103 of Select Medical Holdings Corporation's Form S-1/A filed June 18, 2009 (Reg. No. 333-152514).
10.54	Indenture governing 75/8% Senior Subordinated Notes due 2015 among Select Medical Corporation, the Guarantors named therein and U.S. Bank Trust National Association, dated February 24, 2005, incorporated by reference to Exhibit 4.4 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.55	Form of 7 ⁵ /8% Senior Subordinated Notes due 2015 (included in Exhibit 4.4), incorporated by reference to Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.56	Exchange and Registration Rights Agreement, dated as of February 24, 2005, by and among Select Medical Corporation, the Guarantors named therein, Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc., Wachovia Capital Markets, LLC, CIBC World Markets Corp. and PNC Capital Markets, Inc., incorporated by reference to Exhibit 4.6 of Select Medical Corporation's Form S-4 filed June 16, 2005 (Reg. No. 333-125846).
10.57	Registration Rights Agreement, dated as of February 24, 2005, between Select Medical Holdings Corporation, WCAS Capital Partners IV, L.P., Rocco A. Ortenzio, Robert A. Ortenzio, John M. Ortenzio, Martin J. Ortenzio, Martin J. Ortenzio, Martin J. Ortenzio Descendants Trust and Ortenzio Family Foundation, incorporated by reference to Exhibit 10.78 of Select Medical Holdings Corporation's Form S-4 filed April 13, 2006 (Reg. No. 333-133284).
10.58	Indenture governing Senior Floating Rate Notes due 2015 among Select Medical Holdings Corporation and U.S. Bank Trust National Association, dated September 29, 2005, incorporated by reference to Exhibit 4.7 of Select Medical Holdings Corporation's Form S-4 filed April 13, 2006 (Reg. No. 333-133284).
10.59	Form of Senior Floating Rate Notes due 2015 (included in Exhibit 4.7), incorporated by reference to Select Medical Holdings Corporation's Form S-4 filed April 13, 2006 (Reg. No. 333-133284).
10.60	Exchange and Registration Rights Agreement, dated as of September 29, 2005, by and among Select Medical Holdings Corporation, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wachovia Capital Markets, LLC and J.P. Morgan Securities Inc., incorporated by reference to Exhibit 4.9 of Select Medical Holdings Corporation's Form S-4 filed April 13, 2006 (Reg. No. 333-133284).
10.61	Form of Restricted Stock Agreement under the 2005 Equity Incentive Plan, incorporated by reference to Exhibit 10.119 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 17, 2010 (Reg. Nos. 001-34465 and 001-31441).

Table of Contents

Number	Description
10.62	Second Addendum to Lease Agreement, dated August 1, 2010, by and between Old Gettysburg Associates II and Select Medical Corporation, incorporated by reference to Exhibit 10.1 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
10.63	Restricted Stock Award Agreement, dated August 11, 2010, by and between Select Medical Holdings Corporation and Bryan C. Cressey, incorporated by reference to Exhibit 10.2 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
10.64	Restricted Stock Award Agreement, dated August 11, 2010, by and between Select Medical Holdings Corporation and James E. Dalton, Jr., incorporated by reference to Exhibit 10.3 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
10.65	Restricted Stock Award Agreement, dated August 11, 2010, by and between Select Medical Holdings Corporation and James S. Ely, III, incorporated by reference to Exhibit 10.4 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
10.66	Restricted Stock Award Agreement, dated August 11, 2010, by and between Select Medical Holdings Corporation and William H. Frist, M.D., incorporated by reference to Exhibit 10.5 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
10.67	Restricted Stock Award Agreement, dated August 11, 2010, by and between Select Medical Holdings Corporation and Leopold Swergold, incorporated by reference to Exhibit 10.6 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on November 12, 2010 (Reg. Nos. 001-34465 and 001-31441).
10.68	Employment Agreement, dated September 13, 2010, by and between Select Medical Corporation and David S. Chernow, incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on September 15, 2010. (Reg. Nos. 001-34465 and 001-31441).
10.69	Restricted Stock Award Agreement, dated September 13, 2010, by and between Select Medical Holdings Corporation and David S. Chernow, incorporated herein by reference to Exhibit 10.2 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select filed on September 15, 2010. (Reg. Nos. 001-34465 and 001-31441).
10.70	Amendment No. 1 to Employment Agreement, dated March 21, 2011, between Select Medical Corporation and David S. Chernow, incorporated herein by reference to Exhibit 10.8 of the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation filed on May 5, 2011. (Reg. Nos. 001-34465 and 001-31441).
10.71	Amendment No. 7 to Employment Agreement, dated November 10, 2010, by and between Select Medical Corporation and Rocco A. Ortenzio, incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select filed on November 15, 2010. (Reg. Nos. 001-34465 and 001-31441).
10.72	Amendment No. 7 to Employment Agreement, dated November 10, 2010, by and between Select Medical Corporation and Robert A. Ortenzio, incorporated herein by reference to Exhibit 10.2 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select filed on November 15, 2010. (Reg. Nos. 001-34465 and 001-31441).

Table of Contents

Number	Description
10.73	Amendment No. 8 to Employment Agreement, dated November 10, 2010, by and between Select Medical Corporation and Patricia A. Rice, incorporated herein by reference to Exhibit 10.3 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select filed on November 15, 2010. (Reg. Nos. 001-34465 and 001-31441).
10.74	Fourth Amendment to Change of Control Agreement, dated March 8, 2011, between Select Medical Corporation and Martin F. Jackson, incorporated herein by reference to Exhibit 10.111 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 9, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.75	Amendment No. 8 to Employment Agreement, dated March 8, 2011, between Select Medical Corporation and Robert A. Ortenzio, incorporated herein by reference to Exhibit 10.112 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 9, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.76	Amendment No. 8 to Employment Agreement, dated March 8, 2011, between Select Medical Corporation and Rocco A. Ortenzio, incorporated herein by reference to Exhibit 10.113 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 9, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.77	Amendment No. 9 to Employment Agreement, dated March 8, 2011, between Select Medical Corporation and Patricia A. Rice, incorporated herein by reference to Exhibit 10.114 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 9, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.78	Fourth Amendment to Change of Control Agreement, dated March 8, 2011, between Select Medical Corporation and Scott A. Romberger, incorporated herein by reference to Exhibit 10.115 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 9, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.79	Fourth Amendment to Change of Control Agreement, dated March 8, 2011, between Select Medical Corporation and James J. Talalai, incorporated herein by reference to Exhibit 10.116 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 9, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.80	Fourth Amendment to Change of Control Agreement, dated March 8, 2011, between Select Medical Corporation and Michael E. Tarvin, incorporated herein by reference to Exhibit 10.117 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 9, 2011 (Reg. Nos. 001-34465 and 001-31441).
10.81	Restrictive Covenants Agreement Letter, dated December 15, 2011, by and between Select Medical Corporation and James J. Talalai, incorporated herein by reference to Exhibit 10.106 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 2, 2012 (Reg. Nos. 001-34465 and 001-31441).
10.82	Form of Restricted Stock Award Agreement under the Select Medical Holdings Corporation 2011 Equity Incentive Plan, incorporated herein by reference to Exhibit 10.107 of the Annual Report on Form 10-K of Select Medical Holdings Corporation and Select Medical Corporation filed on March 2, 2012 (Reg. Nos. 001-34465 and 001-31441).

Table of Contents

Additional Credit Extension Amendment, dated as of August 13, 2012, among Select Medical Holdings Corporation, Select Medical Corporation, the subsidiaries of Select Medical Corporation named therein and the financial institutions party therete incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation Select Medical Corporation filed on August 14, 2012 (Reg. Nos. 001-34465 and 001-31441). 10.84 Amendment No. 1 to the Credit Agreement, dated as of August 8, 2012, among Select Medical Holdings Corporation, Select Medical Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Report Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on August 14, 2012 (Reg. Nos. 001-34465 and 001-31441). 10.85 Amendment No. 2 to the Credit Agreement, dated as of November 6, 2012, among Select Medical Holdings Corporation, Select Medical Corporation and JPMorgan Chase Bank, N.A. 10.86 Additional Credit Extension Amendment, dated as of February 20, 2013, among Select Medical Holdings Corporation, Select Medical Corporation, the subsidiaries of Select Medical Corporation named therein and the financial institutions party therete incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441). 10.87 Amendment No. 3 to the Credit Agreement, dated as of February 15, 2013, among Select Medical Holdings Corporation Select Medical Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Report Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441) 10.88 Statement of Ratio of Earnings to Fixed Charges. 21.1 Subsidiaries of Select Medical Holdings Corporation. 22.1 Certification of Chief Executive Officer pu	
 Medical Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Reports Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on August 14, 2012 (Reg. Nos. 001-34465 and 001-31441). 10.85 Amendment No. 2 to the Credit Agreement, dated as of November 6, 2012, among Select Medical Holdings Corporation, Select Medical Corporation and JPMorgan Chase Bank, N.A. 10.86 Additional Credit Extension Amendment, dated as of February 20, 2013, among Select Medical Holdings Corporation, Select Medical Corporation, the subsidiaries of Select Medical Corporation named therein and the financial institutions party therete incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441). 10.87 Amendment No. 3 to the Credit Agreement, dated as of February 15, 2013, among Select Medical Holdings Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Report Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441) 12 Statement of Ratio of Earnings to Fixed Charges. 21.1 Subsidiaries of Select Medical Holdings Corporation. 23 Consent of PricewaterhouseCoopers LLP. 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 	nereto,
 Medical Corporation and JPMorgan Chase Bank, N.A. Additional Credit Extension Amendment, dated as of February 20, 2013, among Select Medical Holdings Corporation, Select Medical Corporation, the subsidiaries of Select Medical Corporation named therein and the financial institutions party thereto incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441). Amendment No. 3 to the Credit Agreement, dated as of February 15, 2013, among Select Medical Holdings Corporation, Sel Medical Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Report Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441) Statement of Ratio of Earnings to Fixed Charges. Subsidiaries of Select Medical Holdings Corporation. Consent of PricewaterhouseCoopers LLP. Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 	
 Medical Corporation, the subsidiaries of Select Medical Corporation named therein and the financial institutions party therete incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441). 10.87 Amendment No. 3 to the Credit Agreement, dated as of February 15, 2013, among Select Medical Holdings Corporation, Sel Medical Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Report Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441) Statement of Ratio of Earnings to Fixed Charges. Subsidiaries of Select Medical Holdings Corporation. Consent of PricewaterhouseCoopers LLP. Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 	ı, Select
Medical Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Repo Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on February 20, 2013 (Reg. Nos. 001-34465 and 001-31441) Statement of Ratio of Earnings to Fixed Charges. Subsidiaries of Select Medical Holdings Corporation. Consent of PricewaterhouseCoopers LLP. Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	nereto,
 Subsidiaries of Select Medical Holdings Corporation. Consent of PricewaterhouseCoopers LLP. Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 	
Consent of PricewaterhouseCoopers LLP. Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	
31.2 Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxlev Act of 2	
1	t of 2002.
Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	
The following financial information from the Registrant's Annual Report on Form 10-K for the year ended December 31, 201 formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations and Comprehensi Income for the years ended December 31, 2012, 2011 and 2010 (ii) Consolidated Balance Sheets as of December 31, 2012 at 2011, (iii) Consolidated Statements of Cash Flows for the years ended December 31, 2012, 2011 and 2010, (iv) Consolidated Statements of Changes in Equity and Income for the years ended December 31, 2012, 2011 and 2010 and (v) Notes to Consolidated Financial Statements.*	nensive 12 and

XBRL information is furnished and not filed herewith, is not part of a registration statement or prospectus for purposes of section 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

92

Table of Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL HOLDINGS CORPORATION SELECT MEDICAL CORPORATION

By: /s/ MICHAEL E. TARVIN

Michael E. Tarvin

(Executive Vice President, General Counsel and Secretary)

Date: February 26, 2013

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated as of February 26, 2013.

/s/ Rocco A. Ortenzio	/s/ Robert A. Ortenzio
Rocco A. Ortenzio Director and Executive Chairman	Robert A. Ortenzio Director and Chief Executive Officer (principal executive officer)
/s/ Martin F. Jackson	/s/ Scott A. Romberger
Martin F. Jackson Executive Vice President and Chief Financial Officer (principal financial officer)	Scott A. Romberger Senior Vice President, Controller and Chief Accounting Officer (principal accounting officer)
/s/ Russell L. Carson	/s/ Bryan C. Cressey
Russell L. Carson Director	Bryan C. Cressey Director
/s/ James E. Dalton, Jr.	/s/ James S. Ely III
James E. Dalton, Jr. Director	James S. Ely III Director
/s/ William H. Frist, M.D.	/s/ Thomas A. Scully
William H. Frist, M.D. Director	Thomas A. Scully Director
/s/ Leopold Swergold	
Leopold Swergold Director	93

Table of Contents

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION INDEX TO FINANCIAL STATEMENTS

Reports of Independent Registered Public Accounting Firm	<u>F-2</u>	
Consolidated Balance Sheets	<u>F-4</u>	
Consolidated Statements of Operations and Comprehensive Income	<u>F-5</u>	
Consolidated Statements of Changes in Equity and Income	<u>F-7</u>	
Consolidated Statements of Cash Flows	F-9	
Notes to Consolidated Financial Statements	<u>F-11</u>	
Financial Statements Schedule II Valuation and Qualifying Accounts	F-54	
F-1		

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholder of Select Medical Corporation:

In our opinion, the consolidated financial statements listed in the accompanying index present fairly, in all material respects, the financial position of Select Medical Corporation and its subsidiaries at December 31, 2012 and December 31, 2011, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2012 in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion the financial statement schedule listed in the accompanying index presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements. Also, in our opinion, the Company maintained effective internal control over financial reporting as of December 31, 2012 based on criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for these financial statements and financial statement schedule, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting appearing under item 9A. Our responsibility is to express opinions on these financial statements, on the financial statement schedule, and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP Philadelphia, Pennsylvania February 26, 2013

F-2

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Select Medical Holdings Corporation:

In our opinion, the consolidated financial statements listed in the accompanying index present fairly, in all material respects, the financial position of Select Medical Holdings Corporation and its subsidiaries at December 31, 2012 and December 31, 2011, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2012 in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion the financial statement schedule listed in the accompanying index presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements, Also, in our opinion, the Company maintained effective internal control over financial reporting as of December 31, 2012 based on criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for these financial statements and financial statement schedule, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting appearing under item 9A. Our responsibility is to express opinions on these financial statements, on the financial statement schedule, and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP Philadelphia, Pennsylvania February 26, 2013

F-3

Table of Contents

PART I FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Balance Sheets (in thousands, except share and per share amounts)

	Select Medical Holdings Corporation			Select Medical Corporation				
	December 31, December 31, 2011 2012			December 31, 2011		December 31, 2012		
ASSE	TS	2011				2011		
Current Assets:								
Cash and cash equivalents	\$	12,043	\$	40,144	\$	12,043	\$	40,144
Accounts receivable, net of allowance for doubtful accounts of \$47,469								
and \$41,854 in 2011 and 2012, respectively		413,743		359,929		413,743		359,929
Current deferred tax asset		18,305		17,877		18,305		17,877
Prepaid income taxes		9,497		3,895		9,497		3,895
Other current assets		29,822		31,818		29,822		31,818
Total Current Assets		483,410		453,663		483,410		453,663
Property and equipment, net		510,028		501,552		510,028		501,552
Goodwill		1,631,716		1,640,534		1,631,716		1,640,534
Other identifiable intangibles		72,123		71,745		72,123		71,745
Assets held for sale		2,742		2,742		2,742		2,742
Other assets		72,128		91,125		70,719		90,077
Total Assets	\$	2,772,147	\$	2,761,361	\$	2,770,738	\$	2,760,313
LIABILITIES A	. ND]	EQUITY						
Current Liabilities:								
Bank overdrafts	\$	16,609	\$	17,836	\$	16,609	\$	17,836
Current portion of long-term debt and notes payable		10,848		11,646		10,848		11,646
Accounts payable		95,618		89,547		95,618		89,547
Accrued payroll		82,888		88,586		82,888		88,586
Accrued vacation		51,250		55,714		51,250		55,714
Accrued interest		15,096		22,016		11,980		18,759
Accrued restructuring		5,027		1,726		5,027		1,726
Accrued other		101,076		100,314		106,316		105,554
Due to third party payors		5,526		1,078		5,526		1,078
Total Current Liabilities		383,938		388,463		386,062		390,446
Long-term debt, net of current portion		1,385,950		1,458,597		1,218,650		1,291,297
Non-current deferred tax liability		82,028		89,510		82,028		89,510
Other non-current liabilities		64,905		68,502		64,905		68,502
Total Liabilities		1,916,821		2,005,072		1,751,645		1,839,755
Redeemable non-controlling interests		8,988		10,811		8,988		10,811
Stockholders' Equity:		3,700		10,011		0,700		10,011
Common stock of Holdings, \$0.001 par value, 700,000,000 shares								
authorized, 145,268,190 shares and 140,589,256 shares issued and								
outstanding in 2011 and 2012, respectively		145		141				
Common stock of Select, \$0.01par value, 100 shares issued and								
outstanding						0		0

Edgar Filing: CHINA TELECOM CORP LTD - Form 20-F

Capital in excess of par Retained earnings	493,828 325,706	473,697 243,210	848,844 134,602	859,839 21,478
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity Non-controlling interests	819,679 26,659	717,048 28,430	983,446 26,659	881,317 28,430
Total Equity	846,338	745,478	1,010,105	909,747
Total Liabilities and Equity	\$ 2,772,147	\$ 2,761,361	\$ 2,770,738	\$ 2,760,313

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Select Medical Holdings Corporation Consolidated Statements of Operations and Comprehensive Income (in thousands, except per share amounts)

	For the Year Ended December 31,								
		2010		2011		2012			
Net operating revenues	\$	2,390,290	\$	2,804,507	\$	2,948,969			
Costs and expenses:									
Cost of services		1,982,179		2,308,570		2,443,550			
General and administrative		62,121		62,354		66,194			
Bad debt expense		41,147		51,347		39,055			
Depreciation and amortization		68,706		71,517		63,311			
Total costs and expenses		2,154,153		2,493,788		2,612,110			
•						· ·			
Income from operations		236,137		310,719		336,859			
Other income and expense:									
Loss on early retirement of debt				(31,018)		(6,064)			
Equity in earnings (losses) of unconsolidated subsidiaries		(440)		2,923		7,705			
Other income		632							
Interest income				322					
Interest expense		(112,337)		(99,216)		(94,950)			
Income before income taxes		123,992		183,730		243,550			
Income tax expense		41,628		70,968		89,657			
•									
Net income		82,364		112,762		153,893			
Less: Net income attributable to non-controlling interests		4,720		4,916		5,663			
C									
Net income attributable to Select Medical Holdings Corporation		77,644		107,846		148,230			
Other comprehensive income:		ŕ		·		·			
Unrealized gain on interest rate swap, net of tax		8,914							
		ŕ							
Comprehensive income attributable to Select Medical Holdings Corporation	\$	86,558	\$	107,846	\$	148,230			
compressions to moonid analogues to below incomes.	Ψ	00,000	Ψ	107,010	Ψ	1.0,200			
Income per common share:									
Basic	\$	0.49	\$	0.71	\$	1.05			
Diluted	\$	0.48	\$	0.71	\$	1.05			

The accompanying notes are an integral part of these consolidated financial statements.

F-5

Table of Contents

Select Medical Corporation Consolidated Statements of Operations and Comprehensive Income (in thousands)

	For the Year Ended December 31,									
		2010		2012						
Net operating revenues	\$	2,390,290	\$	2,804,507	\$	2,948,969				
Costs and expenses:										
Cost of services		1,982,179		2,308,570		2,443,550				
General and administrative		62,121		62,354		66,194				
Bad debt expense		41,147		51,347		39,055				
Depreciation and amortization		68,706		71,517		63,311				
Total costs and expenses		2,154,153		2,493,788		2,612,110				
•		, ,		, ,		, ,				
Income from operations		236,137		310,719		336,859				
Other income and expense:		230,137		310,717		330,037				
Loss on early retirement of debt				(20,385)		(6,064)				
Equity in earnings (losses) of unconsolidated subsidiaries		(440)		2,923		7,705				
Other income		632		,		,,,,,,,				
Interest income				322						
Interest expense		(84,472)		(81,232)		(83,759)				
•		, , ,								
Income before income taxes		151,857		212,347		254,741				
Income tax expense		51,380		80,984		93,574				
•										
Net income		100,477		131,363		161,167				
Less: Net income attributable to non-controlling interests		4,720		4,916		5,663				
C		,		,		,				
Net income attributable to Select Medical Corporation		95,757		126,447		155,504				
Other comprehensive income:		,,,,,,,		220,111		200,001				
Unrealized gain on interest rate swap, net of tax		8,914								
G		-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,								
Comprehensive income attributable to Select Medical Corporation	\$	104,671	\$	126,447	\$	155,504				

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Select Medical Holdings Corporation Consolidated Statement of Changes in Equity and Income (in thousands)

Select Medical Holdings Corporation Stockholders

				Common	Commor Stock	Ca	pital in		Accumu Othe Compreh	er ensive	
		prehensivo Income	e Total	Stock Issued	Par Value	Ex	cess of Par	Retained Earnings	Incon (Loss		controlling
Balance at December 31, 2009		income	\$ 760,302			\$		\$ 166,036		3,914) \$	24,372
Net income	\$	80,482	80,482	2				77,644			2,838
Net income attributable to redeemable	÷										
non-controlling interests		1,882									
Unrealized gain on interest rate swap,											
net of tax		8,914	8,914	1					8	3,914	
Total comprehensive income	\$	91,278	\$ 89,396	5							
Issuance and vesting of restricted stock			1,068	3 1,380	1		1,067				
Repurchase of common shares			(44,144		(7)		(30,660)	(13,477)			
Stock option expense			1,168		(1)	,	1,168	(15,177)			
Exercise of stock options			242		1		241				
Reclassification of deemed dividend				31			(14,836)	14,836			
Distributions to non-controlling							(= 1,000)	- 1,000			
interests			(1,419	9)							(1,419)
Other			563					125			438
Balance at December 31, 2010			\$ 807,176	5 154,519	\$ 155	\$	535,628	\$ 245.164	\$	\$	26,229
Net income	\$	111,197	111,197		Ψ 100	Ψ	000,020	107,846	Ψ	Ψ	3,351
Net income attributable to redeemable		, , , ,	, .					,			. ,
non-controlling interests		1,565									
Total comprehensive income	\$	112,762	\$ 111,197	7							
Issuance and vesting of restricted stock			2,527	7 565	0		2,527				
Repurchase of common shares			(72,804	(9,870)	(10))	(45,733)	(27,061)			
Stock option expense			1,198	3			1,198				
Exercise of stock options			208	54	0		208				
Distributions to non-controlling											
interests			(2,688	3)							(2,688)
Other			(476	5)				(243)			(233)
Balance at December 31, 2011			\$ 846,338	3 145,268	\$ 145	\$	493,828	\$ 325,706	\$	\$	26,659
Net income	\$	151,948	151,948	3				148,230			3,718
Net income attributable to redeemable non-controlling interests	:	1,945									
Total comprehensive income	\$	153,893	\$ 151,948	3							
D' ' 1 '			(010.00)	2)				(210.000)			
Dividends paid to common stockholders	è		(210,888	/			4 472	(210,888)			
Issuance and vesting of restricted stock			4,472		(F)	`	4,472	(10.690)			
Repurchase of common shares Stock option expense			1,205	, , ,	(5)	,	(27,208)	(19,689)			
Exercise of stock options			1,203		1		1,205 1,816				
Distributions to non-controlling			1,01	501	1		1,010				
interests			(1,884	1)							(1,884)
Purchase of non-controlling interests			(479				(416)				(63)
Acquisitions of non-controlling interests	s		(17)				(110)				(03)
Other			(149	9)				(149)			
			(,	,				(/)			

Balance at December 31, 2012

\$ 745,478 140,589

140,589 \$ 141 \$ 473,697 \$ 243,210 \$

\$ 28,430

The accompanying notes are an integral part of these consolidated financial statements.

F-7

Select Medical Corporation

Consolidated Statement of Changes in Equity and Income (in thousands)

Select Medical Corporation Stockholders

					5	CIC		cuit	car corpor	ation Stock		ccumulated		
						Con	nmoi	1			А	Other		
					Common				apital in		Cor	mprehensiv	e	
	Com	prehensiv	e		Stock		ar		Excess of	Retained	<u></u>	•		controlling
		Income		Total	Issued		alue		Par	Earnings		(Loss)		iterests
Balance at December 31, 2009			\$	1,058,378	0	\$	0	\$	822,664	\$ 220,256	\$	(8,914)	\$	24,372
Net income	\$	98,595		98,595						95,757				2,838
Net income attributable to redeemable														
non-controlling interests		1,882												
Unrealized gain on interest rate swap, net of tax		8,914		8,914								8,914		
Total comprehensive income	\$	109,391	\$	107,509										
Federal tax benefit of losses contributed by														
Holdings				9,752					9,752					
Additional investment by Holdings				242					242					
Net change in dividends payable to Holdings				300						300				
Dividends declared and paid to Holdings				(69,671))					(69,671)			
Contribution related to restricted stock awards and														
stock option issuances by Holdings				2,236					2,236					
Distributions to non-controlling interests				(1,419))									(1,419)
Other				563						125				438
Balance at December 31, 2010			\$	1,107,890	0	\$	0	\$	834,894	\$ 246,767	\$		\$	26,229
Net income	\$	129,798	Ċ	129,798					,	126,447	·			3,351
Net income attributable to redeemable														
non-controlling interests		1,565												
Total comprehensive income	\$	131,363	\$	129,798										
Federal tax benefit of losses contributed by														
Holdings				10,016					10,016					
Additional investment by Holdings				208					208	7.260				
Net change in dividends payable to Holdings				7,360						7,360				
Dividends declared and paid to Holdings				(245,729))					(245,729)			
Contribution related to restricted stock awards and stock option issuances by Holdings				3,726					3,726					
Distributions to non-controlling interests				(2,688)					3,720					(2,688)
Other				(476)						(243	١			(233)
Other				(470))					(243)	,			(233)
Balance at December 31, 2011			\$	1,010,105	0	\$	0	\$	848,844	\$ 134,602	\$		\$	26,659
Net income	\$	159,222		159,222						155,504				3,718
Net income attributable to redeemable														
non-controlling interests		1,945												
Total comprehensive income	\$	161,167	\$	159,222										
Federal tax benefit of losses contributed by Holdings				3,917					3,917					
Additional investment by Holdings				1,817					1,817					
Dividends declared and paid to Holdings				(268,479)					1,017	(268,479)			
Contribution related to restricted stock awards and				, ,						,.,.				
stock option issuances by Holdings				5,677					5,677					
Distributions to non-controlling interests				(1,884)										(1,884)
Purchase of non-controlling interests				(479))				(416)					(63)
Other				(149))					(149)			

Balance at December 31, 2012 \$ 909,747 0 \$ 0 \$ 859,839 \$ 21,478 \$ \$ 28,430

The accompanying notes are an integral part of these consolidated financial statements.

F-8

Select Medical Holdings Corporation Consolidated Statements of Cash Flows (in thousands)

	For the Year Ended December 31,						
	2010	2011	2012				
Operating activities							
Net income	\$ 82,364	\$ 112,762	\$ 153,893				
Adjustments to reconcile net income to net cash provided by operating activities:							
Depreciation and amortization	68,706	71,517	63,311				
Provision for bad debts	41,147	51,347	39,055				
Equity in losses (earnings) of unconsolidated subsidiaries	440	(2,923)	(7,705)				
Loss on early retirement of debt		31,018	6,064				
Loss (gain) from disposal or sale of assets	484	(4,966)	(5,906)				
Gain from interest rate swaps	(632)						
Non-cash stock compensation expense	2,236	3,725	5,677				
Amortization of debt discount and issuance costs	9,043	8,007	7,566				
Deferred income taxes	9,450	35,305	7,909				
Changes in operating assets and liabilities, net of effects from acquisition of businesses:							
Accounts receivable	(64,329)	(111,126)	15,158				
Other current assets	1,595	(1,201)	(1,607)				
Other assets	(6,782)	(2,081)	5,862				
Accounts payable	(7,161)	20,629	(6,117)				
Due to third-party payors	(1,902)	227	(4,448)				
Accrued expenses	9,878	4,888	19,970				
•							
Net cash provided by operating activities	144,537	217,128	298,682				
Investing activities							
Purchases of property and equipment	(51,761)	(46,016)	(68,185)				
Investment in businesses, net of distributions		(15,699)	(14,689)				
Acquisition of businesses, net of cash acquired	(165,802)	(899)	(6,043)				
Proceeds from sale of assets	565	7,879	16,511				
Net cash used in investing activities	(216,998)	(54,735)	(72,406)				
Financing activities							
Borrowings on revolving credit facilities	227,000	735,000	495,000				
Payments on revolving credit facilities	(202,000)	(720,000)	(405,000)				
Borrowings on 2011 credit facility term loans, net of discount		841,500	266,750				
Payments on 2011 credit facility term loans		(4,250)	(9,875)				
Payments on 2005 credit facility term loans, net of premium	(1,223)	(484,633)					
Repurchase of 10% senior subordinated notes		(150,000)					
Repurchase of 75/8% senior subordinated notes, net of premiums		(273,941)	(278,495)				
Borrowings of other debt	6,347	7,055	8,281				
Principal payments on other debt	(7,436)	(7,499)	(10,295)				
Debt issuance costs		(18,556)	(6,527)				
Proceeds from (repayment of) bank overdrafts	18,792	(2,183)	1,227				
Dividends paid to common stockholders			(210,888)				
Repurchase of common stock	(44,144)	(72,804)	(46,902)				
Proceeds from issuance of common stock	241	208	1,817				
Distributions to non-controlling interests	(4,431)	(4,612)	(3,268)				
	(, /	,,- ,	(,)				
Net cash used in financing activities	(6,854)	(154,715)	(198,175)				
Net increase (decrease) in cash and cash equivalents	(79,315)	7,678	28,101				

Edgar Filing: CHINA TELECOM CORP LTD - Form 20-F

Cash and cash equivalents at beginning of period		83,680		4,365		12,043
Cash and cash equivalents at end of period	•	1 365	Φ	12.043	•	40.144
Cash and Cash equivalents at end of period	φ	4,303	φ	12,043	φ	40,144
Supplemental Cash Flow Information						
Cash paid for interest	\$	105,939	\$	107,488	\$	80,722
Cash paid for taxes	\$	37,809	\$	39,000	\$	77,614

The accompanying notes are an integral part of these consolidated financial statements.

F-9

Select Medical Corporation

Consolidated Statements of Cash Flows (in thousands)

	For the Year Ended December 31,						
		2012					
Operating activities							
Net income	\$	100,477	\$	131,363	\$	161,167	
Adjustments to reconcile net income to net cash provided by operating activities:							
Depreciation and amortization		68,706		71,517		63,311	
Provision for bad debts		41,147		51,347		39,055	
Equity in losses (earnings) of unconsolidated subsidiaries		440		(2,923)		(7,705)	
Loss on early retirement of debt				20,385		6,064	
Loss (gain) from disposal or sale of assets		484		(4,966)		(5,906)	
Non-cash gain from interest rate swaps		(632)					
Non-cash stock compensation expense		2,236		3,725		5,677	
Amortization of debt discount and issuance costs		6,599		6,700		7,190	
Deferred income taxes		9,450		35,305		7,909	
Changes in operating assets and liabilities, net of effects from acquisition of businesses: Accounts receivable		(64,329)		(111,126)		15,158	
Other current assets		1,595		(1,201)		(1,607)	
Other assets		(6,771)		(2,068)		5,877	
Accounts payable		(7,161)		20,629		(6,117)	
Due to third-party payors		(1,902)		227		(4,448)	
Accrued expenses		19,725		21,139		23,746	
Net cash provided by operating activities		170,064		240,053		309,371	
Investing activities							
Purchases of property and equipment		(51,761)		(46,016)		(68,185)	
Investment in businesses, net of distributions				(15,699)		(14,689)	
Acquisition of businesses, net of cash acquired		(165,802)		(899)		(6,043)	
Proceeds from sale of assets		565		7,879		16,511	
Net cash used in investing activities		(216,998)		(54,735)		(72,406)	
Financing activities							
Borrowings on revolving credit facilities		227,000		735,000		495,000	
Payments on revolving credit facilities		(202,000)		(720,000)		(405,000)	
Borrowings on 2011 credit facility term loans, net of discount				841,500		266,750	
Payments on 2011 credit facility term loans				(4,250)		(9,875)	
Payments on 2005 credit facility term loans, net of premium		(1,223)		(484,633)			
Repurchase of 75/8% senior subordinated notes, net of premiums				(273,941)		(278,495)	
Borrowings of other debt		6,347		7,055		8,281	
Principal payments on other debt		(7,436)		(7,499)		(10,295)	
Debt issuance costs				(18,556)		(6,527)	
Proceeds from (repayment of) bank overdrafts		18,792		(2,183)		1,227	
Equity investment by Holdings		241		208		1,817	
Dividends paid to Holdings		(69,671)		(245,729)		(268,479)	
Distributions to non-controlling interests		(4,431)		(4,612)		(3,268)	
Net cash used in financing activities		(32,381)		(177,640)		(208,864)	
Net increase (decrease) in cash and cash equivalents		(79,315)		7,678		28,101	
Cash and cash equivalents at beginning of period		83,680		4,365		12,043	
offer group at columning or beyon		02,000		.,505		12,013	

Cash and cash equivalents at end of period	\$ 4,365	\$ 12,043	\$ 40,144
Supplemental Cash Flow Information			
Cash paid for interest	\$ 80,424	\$ 84,575	\$ 70,047
Cash paid for taxes	\$ 37,809	\$ 39,000	\$ 77,614

The accompanying notes are an integral part of these consolidated financial statements.

F-10

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Significant Accounting Policies

Business Description

Select Medical Corporation ("Select") was formed in December 1996 and commenced operations during February 1997 upon the completion of its first acquisition. Select Medical Holdings Corporation ("Holdings") was formed in October 2004 for the purpose of affecting a leveraged buyout of Select, which was a publicly traded entity. On February 24, 2005, Select merged with a subsidiary of Holdings, which resulted in Select becoming a wholly-owned subsidiary of Holdings (the "Merger"). On September 30, 2009 Holdings completed its initial public offering of common stock at a price to the public of \$10.00 per share. Generally accepted accounting principles ("GAAP") require that any amounts recorded or incurred (such as goodwill and compensation expense) by the parent as a result of the Merger or for the benefit of the subsidiary be "pushed down" and recorded in Select's consolidated financial statements. Holdings and Select and their subsidiaries are collectively referred to as the "Company." The consolidated financial statements of Holdings include the accounts of its wholly-owned subsidiary Select. Holdings conducts substantially all of its business through Select and its subsidiaries.

The Company provides long term acute care hospital services and inpatient acute rehabilitative hospital care through its specialty hospital segment and provides physical, occupational and speech rehabilitation services through its outpatient rehabilitation segment. The Company's specialty hospital segment consists of hospitals designed to serve the needs of long term stay acute patients and hospitals designed to serve patients that require intensive medical rehabilitation care. Patients are typically admitted to the Company's specialty hospitals from general acute care hospitals. These patients have specialized needs, and serious and often complex medical conditions such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders and cancer. The Company's outpatient rehabilitation segment consists of clinics and contract services that provide physical, occupational and speech rehabilitation services. The Company's outpatient rehabilitation patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living. The Company operated 118, 119 and 122 specialty hospitals at December 31, 2010, 2011 and 2012, respectively. At December 31, 2010, 2011 and 2012, the Company operated 944, 954, and 979 outpatient clinics, respectively. At December 31, 2010, 2011 and 2012, the Company had facilities in the District of Columbia and 41, 39 and 39 states, respectively.

Reclassifications

Certain reclassifications have been made to prior-year amounts in order to conform to the current-year presentation.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company, its majority owned subsidiaries, limited liability companies and limited partnerships the Company and its subsidiaries control through ownership of general and limited partnership or membership interests. All significant intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and

F-11

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost which approximates market value.

Accounts Receivable and Allowance for Doubtful Accounts

The Company reports accounts receivable at estimated net realizable values. Substantially all of the Company's accounts receivable are related to providing healthcare services to patients whose costs are primarily paid by federal and state governmental authorities, managed care health plans, commercial insurance companies and workers' compensation programs. Collection of these accounts receivable is the Company's primary source of cash and is critical to its operating performance. The Company's primary collection risks relate to non-governmental payors who insure these patients and deductibles, co-payments and amounts owed by the patient. Deductibles, co-payments and amounts owed by the patient are an immaterial portion of the Company's net accounts receivable balance and accounted for approximately 0.2% of the net accounts receivable balance before doubtful accounts at both December 31, 2011 and December 31, 2012. The Company's general policy is to verify insurance coverage prior to the date of admission for a patient admitted to the Company's hospitals or in the case of the Company's outpatient rehabilitation clinics, the Company verifies insurance coverage prior to their first therapy visit. The Company's estimate for the allowance for doubtful accounts is calculated by providing a reserve allowance based upon the age of an account balance. Generally the Company has reserved as uncollectible all governmental accounts over 365 days and non-governmental accounts over 180 days from discharge. This method is monitored based on historical cash collections experience. Collections are impacted by the effectiveness of the Company's governmental receivables.

The Company has historically collected substantially all of its third-party insured receivables (net of contractual allowances) which include receivables from governmental agencies. The Company reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of net revenue less the provision for bad debts.

Uncollected accounts are written off the balance sheet when they are turned over to an outside collection agency, or when management determines that the balance is uncollectible, whichever occurs first.

Property and Equipment

Property and equipment are stated at cost net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets or the term of the lease, as appropriate. The general range of useful lives is as follows:

T 1 11'		_
Leasehold improvements		5 years
Furniture and equipment	3	20 years
Buildings		40 years
Building Improvements	5	25 years
Land Improvements	2	25 years
		F-12

Table of Contents

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The Company reviews the realizability of long-lived assets whenever events or circumstances occur which indicate recorded costs may not be recoverable. Gains or losses related to the retirement or disposal of property and equipment are reported as a component of income from operations.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash balances and trade receivables. The Company invests its excess cash with large financial institutions. The Company grants unsecured credit to its patients, most of who reside in the service area of the Company's facilities and are insured under third-party payor agreements. Because of the geographic diversity of the Company's facilities and non-governmental third-party payors, Medicare represents the Company's only significant concentration of credit risk.

Income Taxes

Deferred tax assets and liabilities are recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As part of the process of preparing its consolidated financial statements, the Company estimates income taxes based on its actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for book and tax purposes. The Company also recognizes as deferred tax assets the future tax benefits from net operating loss carry forwards. The Company evaluates the realizability of these deferred tax assets by assessing their valuation allowances and by adjusting the amount of such allowances, if necessary. Among the factors used to assess the likelihood of realization are projections of future taxable income streams, the expected timing of the reversals of existing temporary differences, and the impact of tax planning strategies that could be implemented to avoid the potential loss of future tax benefits.

Reserves for uncertain tax positions are established for exposure items related to various federal and state tax matters. Income tax reserves are recorded when an exposure is identified and when, in the opinion of management, it is more likely than not that a tax position will not be sustained and the amount of the liability can be estimated.

Intangible Assets

Goodwill and certain other indefinite-lived intangible assets are not amortized, but instead are subject to periodic impairment evaluations. In performing the quantitative periodic impairment tests, the fair value of the reporting unit is compared to its carrying value, including goodwill and other intangible assets. If the carrying value exceeds the fair value, an impairment condition exists, which results in an impairment loss equal to the excess carrying value.

To determine the fair value of its reporting units, the Company uses a discounted cash flow approach. Included in this analysis are assumptions regarding revenue growth rate, future Adjusted EBITDA margin estimates, future general and administrative expense rates and the industry's weighted average cost of capital and industry specific market comparable Adjusted EBITDA multiples. The Company also must estimate residual values at the end of the forecast period and future capital expenditure requirements. Each of these assumptions requires the Company to use its knowledge of (1) its industry, (2) its recent transactions, and (3) reasonable performance expectations for its operations. If any one of the above assumptions changes or fails to materialize, the resulting decline in the Company's estimated fair value could result in a material impairment charge to the goodwill associated with any one of the reporting units.

F-13

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Impairment tests are required to be conducted at least annually, or when events or conditions occur that might suggest a possible impairment. These events or conditions include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors; a current period operating or cash flow loss combined with a history of such losses or a projection of continuing losses; or a sale or disposition of a significant portion of a reporting unit. The occurrence of one of these events or conditions could significantly impact an impairment assessment, necessitating an impairment charge. For purposes of goodwill impairment assessment, the Company has defined its reporting units as specialty hospitals, outpatient rehabilitation clinics and contract therapy with goodwill having been allocated among reporting units based on the relative fair value of those divisions when the Merger occurred in 2005 and based on subsequent acquisitions and dispositions. The Company's most recent impairment assessment was completed during the fourth quarter of 2012 utilizing financial information as of October 1, 2012 and indicated that there was no impairment with respect to goodwill or other recorded intangible assets.

Identifiable assets and liabilities acquired in connection with business combinations accounted for under the purchase method are recorded at their respective fair values. Deferred income taxes have been recorded to the extent of differences between the fair value and the tax basis of the assets acquired and liabilities assumed. Company management has allocated the intangible assets between identifiable intangibles and goodwill. At December 31, 2012, intangible assets other than goodwill consist of the values assigned to trademarks, certificates of need and accreditations. Management believes that the estimated useful lives established are reasonable based on the economic factors applicable to each of the intangible assets.

The approximate useful life of each class of intangible assets is as follows:

Trademarks	Indefinite
Certificates of need	Indefinite
Accreditations	Indefinite

The Company reviews the realizability of intangible assets whenever events or circumstances occur which indicate recorded amounts may not be recoverable.

If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying amount of the assets and their estimated fair value.

Due to Third-Party Payors

Due to third-party payors represents the difference between amounts received under interim payment plans from Medicare and Medicaid for services rendered and amounts estimated to be reimbursed by those third-party payors upon settlement of cost reports.

Insurance Risk Programs

Under a number of the Company's insurance programs, which include the Company's employee health insurance program, its workers' compensation, professional liability insurance programs and certain components under its property and casualty insurance program, the Company is liable for a portion of its losses. In these situations the Company accrues for its losses under an occurrence-based approach whereby the Company estimates the losses that will be incurred in a respective accounting period and accrues that estimated liability. Where the Company has substantial exposure, actuarial methods are utilized in estimating the losses. In cases where the Company has minimal exposure, losses are estimated by analyzing

F-14

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

historical trends. These programs are monitored quarterly and estimates are revised as necessary to take into account additional information. Provisions for losses for professional liability risks retained by the Company at December 31, 2011 and 2012 have been discounted at 3%. At December 31, 2011 and 2012 respectively, the Company had recorded a liability of \$85.7 million and \$92.5 million related to these programs. If the Company did not discount the provisions for losses for professional liability risks, the aggregate liability for all of the insurance risk programs would be approximately \$88.6 million and \$95.6 million at December 31, 2011 and 2012, respectively.

Equity Method Investments

Investments in equity method investees are accounted for using the equity method based upon the level of ownership and/or the Company's ability to exercise significant influence over the operating and financial policies of the investee. Investments of this nature are recorded at original cost and adjusted periodically to recognize the Company's proportionate share of the investees' net income or losses after the date of investment. When net losses from an investment accounted for under the equity method exceeds its carrying amount, the investment balance is reduced to zero. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company's share of that net income exceeds the share of the net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. The Company evaluates its investments in companies accounted for using the equity method for impairment when there is evidence or indicators that a decrease in value may be other than temporary.

Non-Controlling Interests

The interests held by other parties in subsidiaries, limited liability companies and limited partnerships owned and controlled by the Company are reported as either redeemable non-controlling interests outside of stockholders' equity or as non-controlling interests in the stockholders' equity section of the consolidated balance sheets. The minority ownership interests that are reflected as redeemable non-controlling interests on our consolidated balance sheets consist of those outside owners that have certain "put rights," that are currently exercisable, and that, if exercised, require us to purchase the minority member's interest. Those redeemable non-controlling interests that are currently redeemable or considered probable of becoming redeemable have been adjusted to their approximate redemption values. As of December 31, 2011 and December 31, 2012, we believe the redemption values of the non-controlling ownership interests approximates the fair value of those interests classified as redeemable non-controlling interests. The non-controlling interests' balances reported in the stockholders' equity section of our consolidated balance sheets were \$26.7 million and \$28.4 million as of December 31, 2011 and December 31, 2012, respectively.

Net income attributable to non-controlling interests was \$4.7 million, \$4.9 million and \$5.7 million for the years ended December 31, 2010, December 31, 2011, and December 31, 2012, respectively. Non-controlling interests reported in the consolidated statement of operations and comprehensive income reflect the respective interests in the income or loss of the subsidiaries, attributable to the other parties, the effect of which is removed from the Company's consolidated statement of operations and comprehensive income.

During 2012, the amounts related to redeemable non-controlling interests have been reclassified on the consolidated balance sheets at December 31, 2011 and the consolidated statement of changes in equity and income for the years ended December 31, 2010 and December 31, 2011 from non-controlling interests to redeemable non-controlling interests. The redeemable non-controlling interests' balances reported on our consolidated balance sheets were \$9.0 million and \$10.8 million as of December 31, 2011 and December 31, 2012, respectively.

F-15

Table of Contents

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Revenue Recognition

Net operating revenues consists primarily of patient service revenues and revenues generated from therapy services provided to healthcare institutions under contractual arrangements and are recognized as services are rendered.

Patient service revenue is reported net of provisions for contractual allowances from third-party payors and patients. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established billing rates. The differences between the estimated program reimbursement rates and the standard billing rates are accounted for as contractual adjustments, which are deducted from gross revenues to arrive at net operating revenues. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, per diem and per visit payments. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. Accounts receivable resulting from such payment arrangements are recorded net of contractual allowances.

A significant portion of the Company's net operating revenues are generated directly from the Medicare program. Net operating revenues generated directly from the Medicare program represented approximately 47%, 48% and 47% of the Company's net operating revenues for the years ended December 31, 2010, 2011 and 2012, respectively. Approximately 32% and 29% of the Company's accounts receivable (after allowances for contractual adjustments but before doubtful accounts) at December 31, 2011 and 2012, respectively, are from this payor source. As a provider of services to the Medicare program, the Company is subject to extensive regulations. The inability of any of the Company's specialty hospitals or clinics to comply with regulations can result in significant changes in that specialty hospital's or clinic's net operating revenues generated from the Medicare program.

Revenues generated under contractual arrangements are comprised primarily of billings for services rendered to nursing homes, hospitals, schools and other third parties.

Fair Value Measurements

The Company measures interest rate swap agreements at fair value at each balance sheet date. The Company determines the fair value of interest rate swap agreements based on financial models that consider current and future market interest rates and adjustments for non-performance risk. The Company considers those inputs utilized in the valuation process to be Level 2 in the fair value hierarchy. Level 2 in the fair value hierarchy is defined as inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company's last interest rate swap agreement matured on November 22, 2010.

Financial Instruments and Hedging

The Company has in the past entered into interest rate swap agreements to manage interest rate risk on a portion of its long-term borrowings. Interest rate swap agreements were limited in use and not entered into for speculative purposes. All interest rate swap agreements were recognized at fair value on the balance sheet. The effective portion of gains or losses on interest rate swap agreements designated as hedges, were initially deferred in stockholders' equity as a component of other comprehensive income. These deferred gains or losses were subsequently reclassified into earnings as an adjustment to interest expense over the same period in which the related interest payments being hedged are recognized in expense. The ineffective portion of changes in fair value of the interest rate swap agreements were

F-16

Table of Contents

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

immediately recognized in the other income and expense section of the consolidated statement of operations.

Stock Based Compensation

The Company measures the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognizes the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements comprise both stock options and restricted share plans. Employee stock options are valued using the Black-Scholes option valuation method which uses assumptions that relate to the expected volatility of the Company's common stock, the expected dividend yield of the Company's stock, the expected life of the options and the risk free interest rate. Such compensation amounts, if any, are amortized over the respective vesting periods or periods of service of the option grant. The Company values restricted stock grants by using the public market price of its stock on the date of grant.

Recent Accounting Pronouncements

In July 2012, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2012-02, "Intangibles Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment," ("Update 2012-02"). In accordance with Update 2012-02, an entity has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If the entity determines that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, the entity will be required to perform the quantitative impairment test. Update 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. However, early adoption is permitted. Update 2012-02 will not have an impact on the Company's consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05, "Comprehensive Income (Topic 220) Presentation of Comprehensive Income" ("Update 2011-05") that improves the comparability, consistency and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders' equity. Update 2011-05 requires that all non-owner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income ("OCI") to net income, in both net income and OCI. Update 2011-05 does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, Update 2011-05 does not affect the calculation or reporting of earnings per share. Update 2011-05 was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 and is to be applied retrospectively. With the adoption of Update 2011-05, the Company opted to change its presentation of its components of other comprehensive income to a single continuous statement of operations and other comprehensive income.

2. Acquisitions

For the Year Ended December 31, 2010

On September 1, 2010, Select completed the acquisition of all the issued and outstanding equity securities of Regency Hospital Company, L.L.C. ("Regency") an operator of long term acute care

F-17

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

hospitals, for \$210.0 million, including certain assumed liabilities. The amount paid at closing was reduced by \$33.1 million for certain assumed liabilities, payments to employees, payments for the purchase of non-controlling interests and an estimated working capital adjustment. The purchase price was subject to a final settlement of net working capital which occurred during the year ended December 31, 2011. Regency operated a network of 23 long term acute care hospitals located in nine states. The results of operations of Regency have been included in the Company's consolidated financial statements since September 1, 2010 and consisted of net operating revenues of \$94.4 million and a pre-tax loss of \$12.9 million for the four months ended December 31, 2010. Regency's operations have been included in the specialty hospitals segment.

The purchase price was allocated to tangible and identifiable intangible assets and liabilities based upon estimates of fair value, with the remainder allocated to goodwill. The factors that were considered when deciding to acquire Regency and determining the purchase price that resulted in goodwill included the historical earnings of the acquired long term acute care hospitals, general and administrative cost saving opportunities that could be achieved by utilizing the Company's infrastructure and the benefits that could be achieved by having a larger network of long term acute care hospitals.

The purchase price allocation reflecting the finalization of the intangible asset valuation and the post-closing settlement of working capital which occurred during the year ended December 31, 2011 is as follows (in thousands):

Cash paid, net of cash acquired of \$11.3 million	\$ 161,445
Fair value of net tangible assets acquired:	
Accounts receivable	22,749
Other current assets	5,053
Property and equipment	82,688
Other assets	3,379
Current liabilities	(48,136)
Other liabilities	(1,528)
Net tangible assets acquired	64,205
Tradename	9,851
Accreditations	822
Certificates of need	475
Goodwill	86,092
	\$ 161,445

Also, during the year ended December 31, 2010, the Company purchased an outpatient rehabilitation business for approximately \$0.2 million in cash.

For the Year Ended December 31, 2011

The Company exchanged one of its long term acute care hospitals and paid \$2.0 million in cash for an entity that operates an inpatient rehabilitation hospital and paid \$2.3 million in cash and issued a \$1.0 million note for an outpatient rehabilitation business. In addition during 2011, the Company purchased non-controlling interests for \$0.5 million in cash. As described above, the Company completed the post-closing settlement of net working capital with the seller of Regency resulting in the receipt of \$3.9 million in cash.

F-18

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Year Ended December 31, 2012

The Company paid \$5.9 million in cash and issued \$1.8 million in notes for the purchase of several outpatient rehabilitation businesses. In addition during 2012, the Company purchased non-controlling interests for \$0.1 million in cash.

For the Veer Ended

Information with respect to all businesses acquired in purchase transactions is as follows:

	December 31,						
		2010		2011	2	2012	
		(In	the	ousands)	,		
Cash paid (net of cash acquired)	\$	165,802	\$	899	\$	6,043	
Notes issued				1,020		1,844	
		165,802		1,919		7,887	
Contingent consideration						1,500	
Liabilities assumed		48,479		701		107	
		214,281		2,620		9,494	
Fair value of assets acquired, principally accounts receivable and property and equipment		113,894		767		1,313	
Trademark		16,529					
Accreditations		856					
Certificates of need		456					
Non-controlling interests		(437)		(602)		(970)	
Cost in excess of fair value of net assets acquired (goodwill)	\$	82,983	\$	2,455	\$	9,151	

The following pro forma unaudited results of operations have been prepared assuming the acquisition of Regency occurred at the beginning of the period presented. The acquisitions of the other businesses acquired are not reflected in this pro forma information as their impact is not material. These results are not necessarily indicative of results of future operations nor of the results that would have actually occurred had the acquisition been consummated as of the beginning of the period presented.

	Unaud for the Decem	o-Forma ited Results Year Ended ber 31, 2010 sands, except	
	per share data)		
Net revenue	\$	2,625,235	
Net income:			
Select Medical Corporation	\$	98,463	
Select Medical Holdings Corporation	\$	80,378	
Income per common share of Select Medical Holdings Corporation:			
Basic	\$	0.47	
Diluted	\$	0.47	
	F-19		

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

3. Significant Transactions

On April 1, 2011, the Company entered into a joint venture with Baylor Health Care System. The joint venture consists of a partnership between Baylor Institute for Rehabilitation and a wholly-owned subsidiary of the Company ("BIR"). The Company contributed several businesses to the joint venture, including its Frisco inpatient rehabilitation hospital and certain Texas-based outpatient rehabilitation clinics. A gain of \$1.2 million was recognized on this contribution and is included in the general and administrative line item on the consolidated statement of operations for the year ended December 31, 2011. In 2011, the Company invested \$13.5 million in cash which consisted of the purchase of partnership units for \$7.6 million and working capital investments of \$5.9 million and in 2012, the Company invested an additional \$7.8 million. The Company owns a 49.0% non-controlling interest in the partnership and is accounting for the investment using the equity method.

4. Property and Equipment

Property and equipment consists of the following:

	December 31,			
	2011			2012
		(In thou	usan	ids)
Land	\$	69,904	\$	68,573
Leasehold improvements		120,369		128,468
Buildings		361,081		352,677
Furniture and equipment		225,363		246,858
Construction-in-progress		9,686		21,648
		786,403		818,224
Less: accumulated depreciation		276,375		316,672
Total property and equipment	\$	510,028	\$	501,552

Depreciation expense was \$64.1 million, \$69.8 million and \$62.5 million for the years ended December 31, 2010, 2011 and 2012, respectively.

F-20

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

5. Intangible Assets

Intangible assets consist of the following:

	As of December 31, 2011			
	Gross Carrying Amount			cumulated nortization
		(In thous	ands))
Amortized intangible assets				
Non-compete agreements	\$	25,909	\$	(25,569)
Indefinite-lived intangible assets				
Goodwill	\$	1,631,716		
Trademarks		57,709		
Certificates of need		11,914		
Accreditations		2,160		
Total	\$	1,703,499		

	As of December 31, 2012 Gross Carrying Accumulate Amount Amortizatio			umulated
		(In thous	sands)	
Amortized intangible assets				
Non-compete agreements	\$	25,909	\$	(25,909)
Indefinite-lived intangible assets				
Goodwill	\$	1,640,534		
Trademarks		57,709		
Certificates of need		11,914		
Accreditations		2,122		
Total	\$	1,712,279		

The Company's accreditations and trademarks have renewal terms. The costs to renew these intangibles are expensed as incurred. At December 31, 2012, the accreditations and trademarks have a weighted average time until next renewal of 1.5 years and 7.5 years, respectively.

Amortization expense for intangible assets with finite lives follows:

Amortization expense for the Company's intangible assets primarily relates to the amortization of the value associated with the non-compete agreements entered into in connection with the acquisitions of the outpatient rehabilitation division of HealthSouth Corporation, Kessler Rehabilitation Corporation and

F-21

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

SemperCare Inc. and the value assigned to the Company's contract therapy relationships. During 2010 the non-compete agreement related to the acquisition of Kessler Rehabilitation Corporation and the Company's contract therapy relationships were fully amortized, during 2011 the non-compete agreement related to the acquisition of SemperCare Inc. was fully amortized and during 2012 the non-compete agreement related to the acquisition of substantially all of the outpatient rehabilitation division of HealthSouth Corporation.

The changes in the carrying amount of goodwill for the Company's reportable segments for the years ended December 31, 2011 and 2012 are as follows:

	Specialty Hospitals		atient ilitation	Total
		(In tho	usands)	
Balance as of January 1, 2011	\$ 1,330,609	\$	300,643	\$ 1,631,252
Goodwill revision ⁽¹⁾	7,114			7,114
Goodwill acquired during year ⁽²⁾	(1,420)		3,875	2,455
Goodwill allocated to dispositions during the year	(2,750)		(6,355)	(9,105)
Balance as of December 31, 2011	\$ 1,333,553	\$	298,163	\$ 1,631,716
Goodwill acquired during year			9,151	9,151
Other	(333)			(333)
Balance as of December 31, 2012	\$ 1,333,220	\$	307,314	\$ 1,640,534

⁽¹⁾During 2011, the Company made a revision to the Regency purchase price allocation resulting from the finalization of the intangible asset valuations.

6. Restructuring Reserves

In connection with the acquisition of substantially all of the outpatient rehabilitation division of HealthSouth Corporation, the Company recorded an estimated liability of \$18.7 million in 2007 for business restructuring which was accounted for as additional purchase price. This reserve primarily included costs associated with workforce reductions and lease termination costs in accordance with the Company's restructuring plan.

In connection with the acquisition of all the issued and outstanding equity securities of Regency (Note 2) an operator of long term acute care hospitals, the Company recorded an estimated liability of \$4.3 million in 2010 for business restructuring related to lease termination costs.

F-22

⁽²⁾During 2011, the Company completed the post-closing settlement of net working capital with the seller of Regency for \$3.9 million in cash received.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The following summarizes the Company's restructuring activity:

	Lease		
	Termination Costs		
	(In th	ousands)	
January 1, 2010	\$	4,256	
2010 acquisition restructuring reserve		4,308	
Amounts paid in 2010		(1,649)	
Accretion expense		541	
Revision of estimate		(702)	
December 31, 2010		6,754	
Amounts paid in 2011		(1,930)	
Accretion expense		423	
Revision of estimate		(220)	
December 31, 2011		5,027	
Amounts paid in 2012		(1,493)	
Accretion expense		237	
Revision of estimate		(2,045)	
December 31, 2012	\$	1,726	

The Company expects to pay out the remaining lease termination costs through 2014 for the acquisition of the outpatient rehabilitation division of HealthSouth Corporation and through 2015 for the Regency acquisition.

7. Long-Term Debt and Notes Payable

The components of long-term debt and notes payable are shown in the following tables:

	Holdings				
	December 31,				
	2011 2012				
		(In tho	usan	ıds)	
7 ⁵ / ₈ % senior subordinated notes	\$	345,000	\$	70,000	
Senior secured credit facilities:					
Revolving loan		40,000		130,000	
Term loans ⁽¹⁾		837,974		1,096,641	
Senior floating rate notes		167,300		167,300	
Other		6,524		6,302	
Total debt		1,396,798		1,470,243	
Less: current maturities		10,848		11,646	
Total long-term debt	\$	1,385,950	\$	1,458,597	
				F-23	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select December 31,

	Determiner 31,			
	2011			2012
		(In tho	usan	ıds)
7 ⁵ / ₈ % senior subordinated notes	\$	345,000	\$	70,000
Senior secured credit facilities:				
Revolving loan		40,000		130,000
Term loans ⁽¹⁾		837,974		1,096,641
Other		6,524		6,302
Total debt		1,229,498		1,302,943
Less: current maturities		10,848		11,646
Total long-term debt	\$	1,218,650	\$	1,291,297

(1) Presented net of unamortized discount of \$7.8 million and \$14.2 million at December 31, 2011 and 2012, respectively.

Senior Secured Credit Facilities

On June 1, 2011, Select entered into a new senior secured credit agreement that originally provided \$1.15 billion in senior secured credit facilities, comprised of an \$850.0 million, seven-year term loan facility and a \$300.0 million, five-year revolving credit facility, including a \$75.0 million sublimit for the issuance of standby letters of credit and a \$25.0 million sublimit for swingline loans.

Select used borrowings under the senior secured credit facilities to refinance all of its outstanding indebtedness under its previously existing senior secured credit facilities, to repurchase \$266.5 million aggregate principal amount of its $7^5/8\%$ senior subordinated notes due 2015 and to repay all \$150.0 million of Holdings' 10% senior subordinated notes due 2015. Select recognized a loss on early retirement of debt for the year ended December 31, 2011 of \$20.4 million related to these transactions. Holdings recognized a loss on early retirement of debt for the year ended December 31, 2011 of \$31.0 million related to these transactions. Borrowings under the senior secured credit facilities are guaranteed by Holdings and substantially all of Select's current domestic subsidiaries and will be guaranteed by Select's future domestic subsidiaries and secured by substantially all of Select's existing and future property and assets and by a pledge of Select's capital stock, the capital stock of Select's domestic subsidiaries and up to 65% of the capital stock of Select's foreign subsidiaries, if any.

On August 13, 2012, Select entered into an additional credit extension amendment to its senior secured credit facilities providing for a \$275.0 million additional term loan tranche to Select at the same interest rate and with the same term as the then existing term loan facility.

Borrowings under the senior secured credit facilities will bear interest at a rate equal to:

in the case of the term loans, Adjusted LIBO plus 3.75%, or Alternate Base Rate plus 2.75%; and

in the case of the revolving loans, Adjusted LIBO plus a percentage ranging from 2.75% to 3.75%, or Alternate Base Rate plus a percentage ranging from 1.75% to 2.75%, in each case based on Select's leverage ratio (the ratio of indebtedness to consolidated EBITDA, as defined in the senior secured credit agreement).

F-24

Table of Contents

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

"Adjusted LIBO" is defined as, with respect to any interest period, the London interbank offered rate for such interest period, adjusted for any applicable statutory reserve requirements; provided that Adjusted LIBO, when used in reference to the term loans, will at no time be less than 1.75% per annum.

"Alternate Base Rate" is defined as the highest of (a) the administrative agent's Prime Rate, (b) the Federal Funds Effective Rate plus ¹/₂ of 1.00% and (c) the Adjusted LIBO from time to time for an interest period of one month, plus 1.00%.

As of December 31, 2012, the applicable margin percentage for revolving loans was (1) 2.25% for Alternate Base Rate loans and (2) 3.25% for Adjusted LIBO loans.

The term loans amortize in equal quarterly installments on the last day of each March, June, September and December in aggregate amounts equal to \$2.8 million. The balance of the term loans will be payable on June 1, 2018, however if on the 90th day prior to the scheduled final maturity date of Select's 75/8% senior subordinated notes due 2015 (the "Tranche B Trigger Date") more than \$60.0 million in aggregate principal amount of Select's 75/8% senior subordinated notes due 2015 are outstanding, the maturity date for the term loans will be the Tranche B Trigger Date. Similarly, the revolving credit facility will be payable on June 1, 2016, however if on the 90th day prior to the scheduled final maturity date of Select's 75/8% senior subordinated notes due 2015 (the "Revolving Trigger Date") more than \$60.0 million in aggregate principal amount of Select's 75/8% senior subordinated notes due 2015 are outstanding, the maturity date for the revolving credit facility will be the Revolving Trigger Date.

Select will be required to prepay borrowings under the senior secured credit facilities with (1) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and the payment of certain indebtedness secured by liens subject to a first lien intercreditor agreement, (2) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (3) 50% of excess cash flow (as defined in the senior secured credit agreement) if Select's leverage ratio is greater than 3.75 to 1.00 and 25% of excess cash flow if Select's leverage ratio is less than or equal to 3.75 to 1.00 and greater than 3.25 to 1.00, in each case, reduced by the aggregate amount of term loans optionally prepaid during the applicable fiscal year. Select will not be required to prepay borrowings with excess cash flow if Select's leverage ratio is less than or equal to 3.25 to 1.00.

The senior secured credit facilities require Select to maintain a leverage ratio, which is tested quarterly and becomes more restrictive over time, and prohibits Select from making capital expenditures in excess of \$125.0 million in any fiscal year (subject to a 50% carry-over provision). Failure to comply with these financial covenants would result in an event of default under the senior secured credit facilities and, absent a waiver or an amendment from the lenders, preclude Select from making further borrowings under the revolving credit facility and permit the lenders to accelerate all outstanding borrowings under the senior secured credit facilities. As of December 31, 2012, Select was in compliance with all financial covenants related to the senior secured credit facilities.

The senior secured credit facilities also contain a number of affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The senior secured credit facilities contain events of default for non-payment of principal and interest when due, cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

F-25

Table of Contents

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Senior Subordinated Notes

On February 24, 2005, EGL Acquisition Corp. sold \$660.0 million of 75/8% senior subordinated notes due 2015 which Select assumed in the Merger. The net proceeds of the offering were used to finance a portion of the Merger consideration, refinance certain of Select's existing indebtedness, and pay related fees and expenses. The senior subordinated notes are unconditionally guaranteed on a senior subordinated basis by all of Select's wholly-owned subsidiaries (the "Subsidiary Guarantors"). Certain of Select's subsidiaries that were not wholly-owned by Select did not guarantee the senior subordinated notes (the "Non-Guarantor Subsidiaries"). The guarantees of the senior subordinated notes are subordinated in right of payment to all existing and future senior indebtedness of the Subsidiary Guarantors, including any borrowings or guarantees by those subsidiaries under the senior secured credit facility. The senior subordinated notes rank equally in right of payment with all of Select's existing and future senior subordinated indebtedness and senior to all of Select's existing and future subordinated indebtedness. The senior subordinated notes were not guaranteed by Holdings.

Select is entitled at its option, effective February 1, 2013 to redeem all or a portion of the senior subordinated notes at face value plus accrued interest to the redemption date.

Select is not required to make any mandatory redemption or sinking fund payments with respect to the senior subordinated notes. However, upon the occurrence of any change of control of Select, each holder of the senior subordinated notes shall have the right to require Select to repurchase such notes at a purchase price in cash equal to 101% of the principal amount thereof on the date of purchase plus accrued and unpaid interest, if any, to the date of purchase.

The indenture governing the senior subordinated notes contains customary events of default and affirmative and negative covenants that, among other things, limit Select's ability and the ability of its restricted subsidiaries to incur or guarantee additional indebtedness, pay dividends or make other equity distributions, purchase or redeem capital stock, make certain investments, enter into arrangements that restrict dividends from subsidiaries, transfer and sell assets, engage in certain transactions with affiliates and effect a consolidation or merger. As of December 31, 2012, Select was in compliance with all debt covenants related to the senior subordinated notes.

In 2008 and 2009 Select repurchased a total of \$48.5 million aggregate principal amount of the senior subordinated notes. In connection with Select entering into a new senior secured agreement on June 1, 2011, Select repurchased \$266.5 million aggregate principal amount of the senior subordinated notes and on September 12, 2012, Select redeemed \$275.0 million aggregate principal amount of the senior subordinated notes.

Senior Floating Rate Notes

On September 29, 2005, Holdings, whose primary asset is its investment in Select, issued \$175.0 million of senior floating rate notes, due 2015. The senior floating rate notes are senior unsecured obligations of Holdings and bear interest at a floating rate, reset semi-annually, equal to 6-month LIBOR plus 5.75%. The senior floating rate notes are not guaranteed by Select or any of its subsidiaries.

Payment of interest expense on the senior floating rate notes is expected to be funded through periodic dividends from Select. The terms of Select's senior secured credit facility, as well as the indenture governing Select's 75/8% senior subordinated notes, and certain other agreements, restrict Select and certain of its subsidiaries from making payments or transferring assets to Holdings, including dividends, loans or other distributions. Such restrictions include prohibition of dividends in an event of default and limitations on the total amount of dividends paid to Holdings. In the event these agreements do not permit such subsidiaries to provide Holdings with sufficient distributions to fund interest and principal payments

F-26

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

on the senior floating rate notes when due, Holdings may default on its notes unless other sources of funding are available.

Holdings is entitled at its option to redeem all or a portion of the senior floating rate notes at face value plus accrued interest to the redemption date.

Holdings is not required to make any mandatory redemption or sinking fund payments with respect to the senior floating rate notes. However, upon the occurrence of any change of control of Holdings, each holder of the senior floating rate notes shall have the right to require Holdings to repurchase such notes at a purchase price in cash equal to 101% of the principal amount thereof on the date of purchase plus accrued and unpaid interest, if any, to the date of purchase.

The indenture governing the senior floating rate notes contains customary events of default and affirmative and negative covenants that, among other things, limit Holdings' ability and the ability of its restricted subsidiaries, including Select, to: incur additional indebtedness and issue or sell preferred stock; pay dividends on, redeem or repurchase capital stock; make certain investments; create certain liens; sell certain assets; incur obligations that restrict the ability of its subsidiaries to make dividends or other payments; guarantee indebtedness; engage in transactions with affiliates; create or designate unrestricted subsidiaries; and consolidate, merge or transfer all or substantially all of its assets and the assets of its subsidiaries on a consolidated basis. As of December 31, 2012, Holdings was in compliance with all debt covenants related to the senior floating rate notes.

In 2009 Holdings repurchased a total of \$7.7 million aggregate principal amount of the senior floating rate notes.

Maturities of Long-Term Debt and Notes Payable

Maturities of the Company's long-term debt for the years after 2012 are approximately as follows:

	Hold	Holdings		Select	
		(In thousands)			
2013	\$	11,646	\$	11,646	
2014		9,530		9,530	
2015	2	46,740		79,440	
2016	1	38,684		138,684	
2017		8,701		8,701	
2018 and beyond	1.0	54.942		1.054.942	

8. Stockholders' Equity

Common Stock

The board of directors of Holdings has authorized a program to repurchase up to \$250.0 million worth of shares of its common stock. The program will remain in effect until March 31, 2013, unless extended by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as the Company deems appropriate. Funding for this program has come from cash on hand and borrowings under the revolving credit facility. The Company repurchased 6,905,700 shares at a cost of \$44.1 million, 9,858,907 shares at a cost of \$72.7 million and 5,725,782 shares at a cost of \$46.8 million which includes transaction costs for the years ended December 31, 2010, 2011 and 2012, respectively.

F-27

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The Company granted 1,380,000 shares, 565,000 shares and 761,500 shares of restricted stock for the years ended December 31, 2010, 2011 and 2012, respectively and issued 64,181 shares, 53,932 shares and 301,208 shares of common stock related to the exercise of stock options and for the years ended December 31, 2010, 2011 and 2012, respectively. Also, 10,860 shares and 15,860 shares of stock were forfeited for the years ended December 31, 2011 and 2012, respectively.

9. Stock Option and Restricted Stock Plans

On February 25, 2005, Holdings adopted the Select Medical Holdings Corporation 2005 Equity Incentive Plan. On May 13, 2011, the Select Medical Holdings Corporation 2005 Equity Incentive Plan was frozen and Holdings adopted the 2011 Select Medical Holdings Corporation 2011 Equity Incentive Plan. The Select Medical Holdings Corporation 2005 Equity Incentive Plan and the Select Medical Holdings Corporation 2011 Equity Incentive Plan are referred to as the "Plans." The Plans provide for grants of restricted stock and stock options of Holdings. On November 8, 2005 the board of directors of Holdings adopted a director equity incentive plan ("Director Plan") and on August 12, 2009, the board of directors and stockholders of Holdings approved an amendment and restatement of the Director Plan. This amendment authorized Holdings to issue under the Director Plan options to purchase up to 75,000 shares of its common stock and restricted stock awards covering up to 150,000 shares of its common stock.

The options under the Plans and Director Plan generally vest over five years and have an option term not to exceed ten years. The fair value of the options granted was estimated using the Black-Scholes option pricing model assuming an expected volatility of 36%, no dividend yield, an expected life of five years and a risk free rate of 3.4% in 2010 and expected volatility of 36%, no dividend yield, an expected life of five years and a risk free rate of 3.3% for 2011. There were no options granted under the Plans or Director Plan during the year ended December 31, 2012. The following is a summary of stock option grants under the Plans and Director Plan from January 1, 2010 through December 31, 2012:

	Number of Options Granted	Exercise Price	Fair Value of Common Stock
	(Share am	ounts in thou	sands)
February 10, 2010	30	\$ 8.90	\$ 8.90
May 11, 2010	10	8.66	8.66
August 11, 2010	15	6.94	6.94
March 3, 2011	88	7.66	7.66
May 13, 2011	20	9.00	9.00
August 3, 2011	10	7.14	7.14
			F-28

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Stock option transactions and other information related to the Plans are as follows:

					ghted erage
	Pri	ce Per Share	Shares	Exerci	se Price
		(Share am	ounts in tho	usands)	
Balance, January 1, 2011	\$	3.33-10.00	2,716	\$	8.09
Granted		7.14-9.00	118		7.84
Exercised		3.33-8.33	(54)		3.86
Canceled		7.66-10.00	(50)		8.40
Balance, December 31, 2011	\$	3.33-10.00	2,730	\$	8.16
Granted					
Exercised		3.33-10.00	(280)		6.07
Canceled		7.66-10.00	(27)		8.18
Balance, December 31, 2012	\$	3.33-10.00	2,423	\$	8.40

Additional information with respect to the outstanding options as of December 31, 2012 for the Plans is as follows:

Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life (Share amounts in thousands)	Number Exercisable
\$ 3.00 4.00	220	2.14	220
6.00 7.00	9	7.61	
7.01 8.00	79	8.22	16
8.01 9.00	667	4.35	618
9.01 10.00	1,448	6.80	865

The weighted average remaining contractual term for all outstanding options is 5.75 years and the weighted average remaining contractual term of exercisable options is 5.24 years.

The total intrinsic value of options exercised for the years ended December 31, 2012, 2011, and 2010 was \$1.1 million, \$0.2 million and \$0.3 million respectively. The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2012 was \$2.6 million and \$2.2 million, respectively.

F-29

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Transactions and other information related to the Director Plan are as follows:

	Pri	ce Per Share	Shares	Weighted Exercise	8
		(Share a	ousands)		
Balance, January 1, 2011	\$	3.33-10.00	63	\$	7.62
Granted					
Exercised					
Balance, December 31, 2011	\$	3.33-10.00	63	\$	7.62
Granted					
Exercised		3.33-8.33	(21)		5.47
Balance, December 31, 2012	\$	3.33-10.00	42	\$	8.69

Additional information with respect to the outstanding options as of December 31, 2012 for the Director Plan is as follows:

			Weighted Average			
Ex	ercise Price	Number Outstanding	Remaining Contractual Life	Number Exercisable		
			(Share amounts in thousands)			
\$	3.00 4.00	6	2.61	6		
	8.00 9.00	9	4.37	9		
	9.01 10.00	27	6.12	19		

The weighted average remaining contractual term for all outstanding options is 5.24 years and the weighted average remaining contractual term of exercisable options is 5.01 years.

The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2012 was approximately \$46.5 thousand.

F-30

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The following is a summary of restricted stock issuances from January 1, 2010 through December 31, 2012:

	Number of Shares Issued	Fair Value of Common Stock								
	(Share amounts in thousands)									
August 11, 2010	30	\$ 6.94								
September 13, 2010	1,000	7.48								
November 11, 2010	300	6.29								
December 17, 2010	50	7.07								
August 3, 2011	25	7.14								
November 3, 2011	190	8.61								
December 15, 2011	350	8.57								
March 26, 2012	65	8.33								
May 2, 2012	129	8.67								
August 7, 2012	38	11.84								
October 30, 2012	530	10.75								

Stock compensation expense for each of the next five years, based on restricted stock awards granted as of December 31, 2012, is estimated to be as follows:

	2	013	2	2014	2	2015	2	2016	20)17
				(Iı	n the	ousands)			
Stock compensation expense	\$	6.012	\$	5.391	\$	3.734	\$	1.512	\$	53

The Company recognized the following stock compensation expense related to restricted stock and stock option awards:

				Year Er mber 31		l			
	2	2010	2	2011	2	2012			
	(In thousands)								
Stock compensation expense:									
Included in general and administrative	\$	763	\$	1,996	\$	3,538			
Included in cost of services		1,473		1,729		2,139			
Total	\$	2,236	\$	3,725	\$	5,677			
				F-:	31				

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

10. Income Taxes

Significant components of the Company's tax provision for the years ended December 31, 2010, 2011, and 2012 are as follows:

	Holdings For the Year Ended December 31,						Select For the Year Ended December 31,					
		2010		2011		2012		2010	2011			2012
		(In thousands)						(In thousands)				
Current:												
Federal	\$	25,102	\$	29,991	\$	70,159	\$	34,854	\$	40,007	\$	74,076
State and local		7,076		5,672		11,589		7,076		5,672		11,589
Total current		32,178		35,663		81,748		41,930		45,679		85,665
Deferred		9,450		35,305		7,909		9,450		35,305		7,909
Total income tax provision	\$	41.628	\$	70.968	\$	89,657	\$	51,380	\$	80.984	\$	93.574
provision	φ	71,020	φ	10,900	φ	09,037	φ	51,560	φ	00,704	φ	93,374

The differences between the expected income tax provision and income taxes computed at the federal statutory rate of 35% were as follows:

	For th	Holdings e Year End cember 31,	ed	Select For the Year Ended December 31,						
	2010	2011	2012	2010	2011	2012				
Expected federal tax rate	35.0%	35.0%	35.0%	35.0%	35.0%	35.0%				
State and local taxes, net of federal										
benefit	4.6	4.5	4.2	3.7	3.9	4.0				
Other permanent differences	0.9	1.0	0.6	0.8	0.9	0.6				
Valuation allowance	(4.8)	(0.5)	(0.6)	(4.0)	(0.4)	(0.6)				
Uncertain tax positions	(0.8)	(3.6)	(0.5)	(0.7)	(3.1)	(0.5)				
IRS audit settlements			(0.6)			(0.5)				
Non-controlling interest	(1.3)	(1.1)	(0.9)	(1.1)	(0.9)	(0.9)				
Sale of entities		3.1			2.7					
Other		0.2	(0.4)	0.1		(0.4)				
Total	33.6%	38.6%	36.8%	33.8%	38.1%	36.7%				
F-32										

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

A summary of deferred tax assets and liabilities for Holdings and Select is as follows:

	Dec	ember 31,	2011	December 31, 2012					
	Total	Current	Non-Current	Total	Current	Non-Current			
			(In the	ousands)					
Deferred tax assets									
Allowance for doubtful									
accounts	\$ 2,183	\$ 2,183	\$	\$ 1,496	\$ 1,496	\$			
Compensation and benefit related									
accruals	42,302	35,831	6,471	45,784	38,254	7,530			
Malpractice insurance	14,409	3,762	10,647	17,005	5,003	12,002			
Restructuring reserve	1,988	1,988		679	679				
Net operating loss									
carryforwards	26,941	853	26,088	24,543	777	23,766			
Other	2,475	2,117	358	1,025	996	29			
Stock options	1,927		1,927	4,089		4,089			
Excess capital loss	270		270						
Uncertain tax positions	3,096		3,096	2,661		2,661			
Total deferred tax assets	95,591	46,734	48,857	97,282	47,205	50,077			
Deferred tax liabilities									
Deferred income	(31,660)	(24,698	(6,962)	(33,188)	(26,253)	(6,935)			
Other	(2,048)	(356	(1,692)	(1,311)	(118	(1,193)			
Depreciation and									
amortization	(109,873)		(109,873)	(121,075)		(121,075)			
Total deferred tax									
liabilities	(143,581)	(25,054	(118,527)	(155,574)	(26,371)	(129,203)			
Net deferred taxes before									
valuation allowance	(47,990)	21,680	(69,670)	(58,292)	20,834	(79,126)			
Valuation allowance	(15,733)	(3,375	(12,358)	(13,341)	(2,957)	(10,384)			
Net deferred taxes	\$ (63,723)	\$ 18,305	\$ (82,028)	\$ (71,633)	\$ 17,877	\$ (89,510)			

The valuation allowance as of December 31, 2012 is primarily attributable to the uncertainty regarding the realization of state net operating losses and other net deferred tax assets of loss entities. The net deferred tax liabilities at December 31, 2011 and 2012 of approximately \$63.7 million and \$71.6 million, respectively, consist of items which have been recognized for tax reporting purposes, but which will increase tax on returns to be filed in the future, and include the use of net operating loss carryforwards. The Company has performed the required assessment of positive and negative evidence regarding the realization of the deferred tax assets. This assessment included a review of legal entities with three years of cumulative losses, estimates of projected future taxable income and the impact of tax-planning strategies that management plans to implement. Although realization is not assured, based on the Company's assessment, it has concluded that it is more likely than not that such assets, net of the determined valuation allowance, will be realized.

F-33

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The total state net operating losses are approximately \$545.1 million. State net operating loss carry forwards expire and are subject to gross valuation allowances as follows (in thousands):

	et Operating Losses	 Valuation lowance
2013	\$ 40,220	\$ 40,054
2014	7,780	6,247
2015	9,513	8,334
2016	8,525	8,302
Thereafter through 2032	479,046	339,030

Reserves for Uncertain Tax Positions:

The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. Significant judgment is required in evaluating the Company's tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. The Company establishes reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when it is believed that certain positions might be challenged despite the Company's belief that its tax return positions are fully supportable. The Company adjusts these reserves in light of changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.

The reconciliation of the Company's unrecognized tax benefits is as follows (in thousands):

Gross tax contingencies January 1, 2010	\$ 22,735
Acquired contingencies Regency Management Company	915
Reductions for tax positions taken in prior periods due primarily to statute expiration	(2,972)
Additions for existing tax positions taken	1,632
Gross tax contingencies December 31, 2010	22,310
Reductions for tax positions taken in prior periods due primarily to statute expiration	(2,706)
Reductions for tax positions taken in prior periods due to change in estimate	(7,012)
Additions for existing tax positions taken	3,064
Gross tax contingencies December 31, 2011	15,656
Reductions for tax positions taken in prior periods due primarily to statute expiration	(2,516)
Additions for existing tax positions taken	750
Gross tax contingencies December 31, 2012	\$ 13,890

In 2011, the Company recognized \$7.0 million of income tax benefits based on new information discovered by the Company which substantiates previously unrecognized tax benefits from an acquisition which occurred in 1999.

F-34

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

As of December 31, 2011 and 2012, the Company had \$15.6 million and \$13.9 million of unrecognized tax benefits, respectively, all of which, if fully recognized, would affect the Company's effective income tax rate.

As of December 31, 2012, changes to the Company's gross unrecognized tax benefits that are reasonably possible in the next 12 months are not material. The Company's policy is to include interest related to income taxes in income tax expense. As of December 31, 2011 and December 31, 2012, the Company had accrued interest related to income taxes of \$1.3 million and \$1.5 million, net of federal income taxes, respectively. Interest recognized for the years ended December 31, 2010, 2011 and 2012 was \$0.4 million, \$0.4 million, and \$0.5 million, net of federal income tax benefits, respectively.

The Company has substantially concluded all U.S. federal income tax matters for years through 2008. The statute for the 2006 U.S. federal income tax return is closed with the exception of a capital loss carryback made to this tax year. Substantially all material state, local and foreign income tax matters have been concluded for years through 2007.

11. Retirement Savings Plan

The Company sponsors a defined contribution retirement savings plan for substantially all of its employees. Employees who are not classified as HCE's (highly compensated employees) may contribute up to 30% of their salary; HCE's may contribute up to 6% of their salary. The Plan provides a discretionary company match which is determined annually. Currently, the Company matches 25% of the first 6% of compensation employees contribute to the plan. The employees vest in the employer contributions over a three-year period beginning on the employee's hire date. The expense incurred by the Company related to this plan was \$6.0 million, \$7.6 million and \$8.2 million during the years ended December 31, 2010, 2011 and 2012, respectively.

12. Segment Information

The Company's reportable segments consist of (i) specialty hospitals and (ii) outpatient rehabilitation. Other activities include our corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The outpatient rehabilitation reportable segment has two operating segments: outpatient rehabilitation clinics and contract therapy. These operating segments are aggregated for reporting purposes as they have common economic characteristics and provide a similar service to a similar patient base. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries and other income (expense).

F-35

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The following table summarizes selected financial data for the Company's reportable segments:

	Specialty Hospitals	(r Ended Decem Outpatient ehabilitation	Other			Total			
		(In thousands)								
Net revenue	\$ 1,702,165	\$	688,017	\$	108	\$	2,390,290			
Adjusted EBITDA	284,558		83,772		(61,251)		307,079			
Total assets ⁽¹⁾ :										
Select Medical Corporation	2,162,726		481,828		75,018		2,719,572			
Select Medical Holdings Corporation	2,162,726		481,828		77,532		2,722,086			
Capital expenditures	39,237		9,449		3,075		51,761			

	Year Ended December 31, 2011									
	Specialty Hospitals		Outpatient Rehabilitation			Other	Total			
				(In thousa	nds)					
Net revenue	\$	2,095,519	\$	708,867	\$	121	\$	2,804,507		
Adjusted EBITDA		362,334		83,864		(60,237)		385,961		
Total assets ⁽¹⁾ :										
Select Medical Corporation		2,187,767		429,503		153,468		2,770,738		
Select Medical Holdings Corporation		2,187,767		429,503		154,877		2,772,147		
Capital expenditures		30,464		12,135		3,417		46,016		

	Year Ended December 31, 2012							
	Specialty Hospitals		Outpatient Rehabilitation		Other			Total
	(In thousands)							
Net revenue	\$	2,197,529	\$	751,317	\$	123	\$	2,948,969
Adjusted EBITDA		381,354		87,024		(62,531)		405,847
Total assets ⁽¹⁾ :								
Select Medical Corporation		2,143,906		434,834		181,573		2,760,313
Select Medical Holdings Corporation		2,143,906		434,834		182,621		2,761,361
Capital expenditures		50,005		13,209		4,971		68,185

⁽¹⁾ The specialty hospital segment includes \$11.3 million, \$2.7 million and \$2.7 million in real estate assets held for sale on December 31, 2010, 2011 and 2012, respectively.

F-36

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Year Ended December 31, 2010									
		pecialty lospitals		tpatient ibilitation		Other				
				(In	thousands	s)			
Adjusted EBITDA	\$	284,558	\$	83,772	\$	(61,251)				
Depreciation and amortization		(45,116)		(20,444)		(3,146)				
Stock compensation expense						(2,236)				
								Select		
							I	Medical		Select
							F	Holdings	I	Medical
							Co	rporation	Co	rporation
Income (loss) from operations	\$	239,442	\$	63,328	\$	(66,633)	\$	236,137	\$	236,137
Equity in losses of unconsolidated										
subsidiaries								(440)		(440)
Other income								632		632
Interest expense, net								(112,337)		(84,472)
Income before income taxes							\$	123,992	\$	151,857

		Year Ended December 31, 2011								
	Specialty Hospitals	Outpatient Rehabilitation	Other							
		(In thousands)							
Adjusted EBITDA	\$ 362,334	\$ 83,864	\$ (60,237)							
Depreciation and amortization	(50,629	(16,487)	(4,401)							
Stock compensation expense			(3,725)							
				Calast						

				Select Medical Holdings Corporation		Select Medical orporation
Income (loss) from operations	\$ 311,705	\$ 67,377	\$ (68,363)	\$	310,719	\$ 310,719
Loss on early retirement of debt					(31,018)	(20,385)
Equity in earnings of unconsolidated						
subsidiaries					2,923	2,923
Interest expense, net					(98,894)	(80,910)
Income before income taxes				\$	183,730	\$ 212,347

F-37

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

	S	pecialty	O	Year End utpatient	led	Decembe	r 31, 2012	
		Iospitals		abilitation		Other		
				(In	thousands	s)	
Adjusted EBITDA	\$	381,354	\$	87,024	\$	(62,531)		
Depreciation and amortization		(46,836)		(13,208)		(3,267)		
Stock compensation expense						(5,677)		
							Select Medical	Select
							Holdings	Medical Corporation

				Medical Holdings Corporation		I	Select Medical rporation
Income (loss) from operations	\$ 334,518	\$ 73,816	\$ (71,475)	\$	336,859	\$	336,859
Loss on early retirement of debt					(6,064)		(6,064)
Equity in earnings of unconsolidated							
subsidiaries					7,705		7,705
Interest expense, net					(94,950)		(83,759)
Income before income taxes				\$	243,550	\$	254,741

13. Income per Share

The Company applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings. Effective January 1, 2009 the Financial Accounting Standards Board clarified that share based payment awards that have not yet vested meet the definition of a participating security provided the right to receive the dividend is non-forfeitable and non-contingent. Participating securities are defined as securities that participate in dividends with common stock according to a predetermined formula. These participating securities should be included in the computation of basic earnings per share under the two class method. Based upon the clarification made by FASB, the Company concluded that its non-vested restricted stock awards meet the definition of a participating security and should be included in the Company's computation of basic earnings per share.

Under the two class method:

- (a)

 Net income attributable to Select Medical Holdings Corporation is reduced by any contractual amount of dividends in the current period for each class of stock. There were no contractual dividends for the years ended December 31, 2010, 2011 and 2012.
- (b)

 The remaining income is allocated to common stock and unvested restricted stock to the extent that each security may share in income, as if all of the earnings for the period had been distributed. The total income allocated to each security is determined by adding together the amount allocated for dividends in (a) above and the amount allocated for participation features.
- (c)

 The income allocated to common stock is then divided by the weighted average number of outstanding shares to which the earnings are allocated to determine the income per share for common stock.

F-38

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

In applying the two-class method, the Company determined that undistributed earnings should be allocated equally on a per share basis between the common stock and unvested restricted stock due to the equal participation rights of the common stock and unvested restricted stock (i.e., the voting conversion rights).

The following table sets forth for the periods indicated the calculation of income per share in the Company's Consolidated Statement of Operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively:

	For the Year Ended December 31,							
		2010		2011		2012		
	(In thousands, except per share							
			a	mounts)				
Numerator:								
Net income attributable to Select Medical Holdings Corporation	\$	77,644	\$	107,846	\$	148,230		
Less: Earnings allocated to unvested restricted stockholders		322		1,205		2,514		
Net income available to common stockholders	\$	77,322	\$	106,641	\$	145,716		
Denominator:								
Weighted average shares basic		159,184		150,501		138,767		
Effect of dilutive securities:								
Stock options		258		224		275		
Weighted average shares diluted		159,442		150,725		139,042		
Basic income per common share:	\$	0.49	\$	0.71	\$	1.05		
Diluted income per common share:	\$	0.48	\$	0.71	\$	1.05		

The following amounts are shown here for informational and comparative purposes only since their inclusion would be anti-dilutive:

 $\begin{array}{c|cccc} & For the \ Year \ Ended \\ \hline December \ 31, \\ \hline 2010 & 2011 & 2012 \\ \hline & (In \ thousands) \\ \hline Stock \ options & 2,390 & 2,414 & 1,654 \\ \hline \end{array}$

14. Fair Value

Financial instruments include cash and cash equivalents, notes payable and long-term debt. The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.

The carrying value of Select's senior secured credit facility was \$878.0 million and \$1,226.6 million at December 31, 2011 and December 31, 2012, respectively. The fair value of Select's senior secured credit facility was \$823.3 million and \$1,216.2 million at December 31, 2011 and 2012, respectively. The fair value

F-39

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

of Select's senior secured credit facility was based on quoted market prices for this debt in the syndicated loan market.

The carrying value of Select's 7⁵/8% senior subordinated notes was \$345.0 million and \$70.0 million at December 31, 2011 and December 31, 2012, respectively. The fair value of Select's 7⁵/8% senior subordinated notes was \$326.4 million and \$70.8 million at December 31, 2011 and December 31, 2012, respectively. The fair value of this registered debt was based on quoted market prices.

The carrying value of Holdings' senior floating rate notes was \$167.3 million at both December 31, 2011 and December 31, 2012. The fair value of Holdings' senior floating rate notes was \$143.9 million and \$166.9 million at December 31, 2011 and December 31, 2012, respectively. The fair value of this registered debt was based on quoted market prices.

The Company considers the inputs in the valuation process of its debt instruments to be Level 2 in the fair value hierarchy due to Select's $7^5/8\%$ senior subordinated notes and Holdings senior floating rate notes being thinly traded.

15. Related Party Transactions

The Company rents its corporate office space from related parties affiliated through common ownership or management. The Company made payments for office rent, leasehold improvements and miscellaneous expenses aggregating \$3.9 million during the year ended December 31, 2010 and \$4.0 million during both the years ended December 31, 2011 and 2012 to the affiliated companies.

As of December 31, 2012, future rental commitments under outstanding agreements with the affiliated companies are approximately as follows (in thousands):

2013	\$ 3,481
2014	3,433
2015	3,177
2016	3,300
2017	3,429
Thereafter	19,616
	\$ 36,436

The Company provides contracted services, principally employee leasing services, to related parties affiliated through its equity investments in the BIR and Rehabilitation Institute of Denton, LLC ("Denton") joint ventures. The provision of contracted services to BIR and Denton resulted in net operating revenues amounting to \$92.2 million and \$8.1 million, respectively for the year ended December 31, 2012; \$53.3 million and \$7.3 million, respectively for the year ended December 31, 2011 and \$137 thousand for Denton for the year ended December 31, 2010.

F-40

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

16. Commitments and Contingencies

Leases

The Company leases facilities and equipment from unrelated parties under operating leases. Minimum future lease obligations on long-term non-cancelable operating leases in effect at December 31, 2012 are approximately as follows (in thousands):

2013	\$ 121,272
2014	96,714
2015	72,666
2016	53,946
2017	41,467
Thereafter	288,963
	\$ 675,028

Total rent expense for operating leases, including cancelable leases, for the years ended December 31, 2010, 2011 and 2012 was \$154.8 million, \$163.9 million and \$168.3 million, respectively.

Property rent expense to unrelated parties for the years ended December 31, 2010, 2011 and 2012 was \$118.3 million, \$118.4 million and \$124.1 million, respectively.

Other

A subsidiary of the Company has entered into a naming, promotional and sponsorship agreement with an NFL team for the team's headquarters complex that requires a payment of \$2.9 million in 2013. Each successive annual payment increases by 2.3% through 2025. The naming, promotional and sponsorship agreement is in effect until 2025.

Litigation

The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services ("CMS") or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company's business, financial position, results of operations and liquidity.

To address claims arising out of the operations of the Company's specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of \$2.0 million per medical incident for professional liability claims and \$2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company's other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company's opinion, the outcome of these actions, individually or in the

F-41

Table of Contents

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

On January 8, 2013, a federal magistrate judge unsealed an Amended Complaint in United States of America and the State of Indiana, ex rel. Doe I, Doe II and Doe III v. Select Medical Corporation, Select Specialty Hospital-Evansville, Evansville Physician Investment Corporation, Dr. Richard Sloan and Dr. Jeffrey Selby. The Amended Complaint, which was served on the Company on February 15, 2013, is a civil action filed under seal on September 28, 2012 in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States and Indiana under the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act. The Amended Complaint identifies the plaintiff-relators as Doe I, Doe II and Doe III, and describes them as the CEO and two case managers at the Company's long term acute care hospital in Evansville, Indiana ("SSH-Evansville"). The named defendants include the Company, SSH-Evansville Physician Investment Company, the Company's joint venture partner in SSH-Evansville ("EPIC"), and two physicians who have practiced at SSH-Evansville. On February 6, 2013, the District Court issued an order dismissing EPIC without prejudice after the plaintiff-relators filed, on January 31, 2013, a Notice of Voluntary Dismissal of EPIC, to which the United States and Indiana consented. The Notice of Voluntary Dismissal states, among other things, that the United States filed a notice with the Court on December 28, 2012 that it had not completed its investigation and thus would not intervene in the action at that time. The U.S. Attorney's Office for the Southern District of Indiana has informed the Company's counsel that, despite the lifting of the seal, the United States is continuing its investigation in order to determine whether or not to intervene in the matter at some point.

The Amended Complaint alleges that the defendants manipulated the length of stay of patients at SSH-Evansville in order to maximize reimbursement under the Medicare prospective payment system applicable to long-term acute care hospitals. It also alleges that the defendants manipulated the discharge of patients to other facilities and the timing of readmissions from those facilities in order to enable SSH-Evansville to receive two separate Medicare payments and causing the other facility to submit claims for unnecessary services. The Amended Complaint discusses the federal Stark Law and Anti-Kickback Statute and implies that the behavior of physicians referring to or providing services at SSH-Evansville was based on their financial interests. The Amended Complaint further alleges that Dr. Selby, a pulmonologist formerly on the medical staff of SSH-Evansville, performed unnecessary bronchoscopies at the hospital with the knowledge of the Company, and that Dr. Sloan, the Chief Medical Officer and an attending physician at SSH-Evansville, falsely coded the diagnoses of Medicare patients in order to increase SSH-Evansville's reimbursement. Moreover, the Amended Complaint alleges that the practices at SSH-Evansville involved corporate policies of the Company used to maximize profit at all Select long-term acute care hospitals. The Amended Complaint alleges that, through these acts, the defendants have violated the federal False Claims Act and Indiana False Claims and Whistleblower Protection Act and are liable for unspecified treble damages and penalties.

As previously disclosed, beginning in April 2012, the Company and SSH-Evansville have received various subpoenas and demands for documents relating to SSH-Evansville, including a request for information and subpoenas from the Office of Inspector General of the U.S. Department of Health and

F-42

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Human Services and subpoenas from the Office of Attorney General for the State of Indiana, and the Evansville (Indiana) Police Department has executed a search warrant at SSH-Evansville. The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

17. Supplemental Disclosures of Cash Flow Information

Non-cash investing and financing activities are comprised of the following for the years ended December 31, 2010, 2011 and 2012:

	Select Medical						
	Holdings Corporation						
	For the Year						
	Ended December 31,						
	2010 2011 2			2012			
	(In	ı tho	usands))			
Notes issued with acquisitions ⁽²⁾		\$	1,020	\$	1,844		
Liabilities assumed with acquisitions ⁽²⁾	48,479		701		107		
Contingent consideration related to acquisitions ⁽²⁾					1,500		

	F	cal (or t	elect Corporat he Year ecember		
	2010 2011		2011	2012	
	(Iı	ı th	ousands)		
Dividends declared to Holdings by Select ⁽¹⁾	\$ (12,600)	\$	(5,240)	\$	(5,240)
Notes issued with acquisitions ⁽²⁾			1,020		1,844
Liabilities assumed with acquisitions ⁽²⁾	48,479		701		107
Contingent consideration related to acquisitions ⁽²⁾					1,500

- Recorded in accrued other liabilities on the consolidated balance sheet of Select.
- (2) Refer to Footnote 2 Acquisitions.

18. Subsequent Events

On February 20, 2013, Select entered into an additional credit extension amendment to its senior secured credit facilities providing for a \$300.0 million additional term loan tranche, (the "Series B Tranche B Term Loan") to Select. Select intends to use borrowings under the Series B Tranche B Term Loan to redeem all of its outstanding 7⁵/8% senior subordinated notes due 2015, to redeem all of Holdings' senior floating rate notes due 2015, and to repay a portion of the balance outstanding under its revolving credit facility.

Borrowings under the Series B Tranche B Term Loan will bear interest at a rate equal to Adjusted LIBO plus 3.25%, or Alternate Base Rate plus 2.25%. The Series B Tranche B Term Loan amortizes in equal quarterly installments on the last day of each March, June, September and December in aggregate annual amounts equal to \$3.0 million. The balance of the Series B Tranche B Term Loan will be payable on February 20, 2016.

F-43

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

On February 20, 2013, Select and Holdings each instructed U.S. Bank Trust National Association, as trustee, to deliver an irrevocable notice of redemption to the holders of all of Select's outstanding 75/8% senior subordinated notes due 2015 and all of Holdings' outstanding senior floating rate notes due 2015, respectively, all of which will be redeemed at 100% of the principal amount plus any accrued and unpaid interest to the redemption date on or about March 22, 2013.

Holdings anticipates recognition of a loss on the early retirement of indebtedness of \$1.6 million in the first quarter ending March 31, 2013 for unamortized debt issuance costs, approximately \$0.6 million associated with Select's outstanding 7⁵/8% senior subordinated notes due 2015 and approximately \$1.0 million for Holdings' senior floating rate notes due 2015.

19. Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 75/8% Senior Subordinated Notes

Select's 75/8% senior subordinated notes are fully and unconditionally guaranteed, except for customary limitations, on a senior subordinated basis by all of Select's wholly-owned subsidiaries (the "Subsidiary Guarantors") which is defined as a subsidiary where Select holds all ownership interests. Certain of Select's subsidiaries did not guarantee the 75/8% senior subordinated notes (the "Non-Guarantor Subsidiaries").

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2011 and 2012 and the years ended December 31, 2010, 2011 and 2012.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

The condensed consolidating balance sheets at December 2011 and the condensed consolidating statements of cash flows for the years ended December 31, 2011 and 2010 included in this footnote contain certain immaterial adjustments that were made to the December 31, 2011 condensed consolidating balance sheet and the condensed consolidating statements of cash flows for the years ended December 31, 2011 and 2010 relating to the presentation of intercompany transactions. On the December 31, 2011 condensed consolidating balance sheet, intercompany accounts that were previously reported as both asset and liability balances within the liability section of the balance sheet have been adjusted and presented separately as either an intercompany receivable within the current asset classification or as an intercompany payable within the current liability classification, based upon the account's attributes on each subsidiary's balance sheet. On the condensed consolidating statement of cash flows for the years ended December 31, 2011 and 2010, the changes in intercompany advances that were previously reported as a change in operating assets and liabilities in cash flow provided by (used in) operating activities has been adjusted as a financing activity. These adjustments had no impact on the total equity of the Guarantors, non-Guarantors or Parent Company. They did not alter the net increase or decrease in cash for the Guarantors, non-Guarantors or Parent Company.

On February 20, 2013, Select instructed U.S. Bank Trust National Association, as trustee, to deliver an irrevocable notice of redemption to the holders of all of Select's outstanding $7^5/8\%$ senior subordinated notes due 2015 all of which will be redeemed at 100% of the principal amount plus any accrued and unpaid interest to the redemption date on or about March 22, 2013.

F-44

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation

Condensed Consolidating Balance Sheet December 31, 2012

	Select Medical Corporation (Parent Company Only)	Subsidiary Guarantors	Non-Guarantor Subsidiaries (in thousands)	Eliminations	Consolidated
Assets					
Current Assets:					
Cash and cash equivalents	\$ 35,070	\$ 3,734	\$ 1,340	\$	\$ 40,144
Accounts receivable, net	+,	308,043		(1,645)	359,929
Current deferred tax asset	12,383	1,060		(-,)	17,877
Prepaid income taxes	3,895	1,000	1,151		3,895
Intercompany receivables	3,073	1,021,479	102,694	(1,124,173)	3,075
Other current assets	5,600	19,655		(1,124,173)	31,818
Guier current assets	2,000	17,033	0,505		31,010
Total Current Assets	56,948	1,353,971	168,562	(1,125,818)	453,663
Property and equipment, net	16,344	425,677	59,531		501,552
Investment in affiliates	2,930,022	82,475		(3,012,497)(a)(b)	
Goodwill	2,750,022	1,640,534		(5,512,157)	1,640,534
Other identifiable intangibles		71,745			71,745
Assets held for sale	2,742	71,713			2,742
Non-current deferred tax asset	5,107			(5,107)	2,7 12
Other assets	25,938	63,447	692	(3,107)	90,077
Total Assets	\$ 3,037,101	\$ 3,637,849	\$ 228,785	\$ (4,143,422)	\$ 2,760,313
Liabilities and Equity Current Liabilities:					
Bank overdrafts	\$ 17,836	\$	\$	\$	\$ 17,836
Current portion of long-term debt and					
notes payable	8,916	1,059	1,671		11,646
Accounts payable	4,674	72,213	12,660		89,547
Intercompany payables	1,124,173			(1,124,173)	
Accrued payroll	186	88,096	304		88,586
Accrued vacation	4,249	44,508	6,957		55,714
Accrued interest	17,955	804			18,759
Accrued restructuring		1,726			1,726
Accrued other	58,650	38,150	8,754		105,554
Due to third party payors			2,723	(1,645)	1,078
Total Current Liabilities	1,236,639	246,556	33,069	(1,125,818)	390,446
Long-term debt, net of current portion	872,671	358,104	60,522		1,291,297
Non-current deferred tax liability	072,071	85,287	9,330	(5,107)	89,510
Other non-current liabilities	46,474	20,275		(5,107)	68,502
other non current mannings	70,77	20,273	1,755		00,302
Total Liabilities	2,155,784	710,222	104,674	(1,130,925)	1,839,755
Redeemable non-controlling interests			10,811		10,811
Stockholder's Equity:					
Common stock	0				0
Capital in excess of par	859,839				859,839
Retained earnings	21,478	790,692	21,197	(811,889) ^(b)	21,478
Subsidiary investment		2,136,935	63,673	(2,200,608) ^(a)	

Edgar Filing: CHINA TELECOM CORP LTD - Form 20-F

Total Select Medical Corporation Stockholder's Equity	881,317	2,927,627	84,870	(3,012,497)	881,317
Non-controlling interests			28,430		28,430
Total Equity	881,317	2,927,627	113,300	(3,012,497)	909,747
Total Liabilities and Equity	\$ 3,037,101	\$ 3,637,849 \$	228,785	\$ (4,143,422)	\$ 2,760,313

⁽a) Elimination of investments in consolidated subsidiaries.

(b) Elimination of investments in consolidated subsidiaries' earnings.

F-45

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation

Condensed Consolidating Statement of Operations For the Year Ended December 31, 2012

	Corpo (Pa	Medical oration rent	C.,1	haidiam:	Non 4	Cuamantas			
		npany nly)		arantors		Guarantoı ısidiəries	minations	Co	nsolidated
	0.		Out			ousands)		-	isonautea
Net operating revenues	\$	123	\$ 2	2,549,896	`	398,950	\$	\$	2,948,969
Contract I comment									
Costs and expenses: Cost of services		2,139	2	2,099,734		341,677			2 442 550
General and administrative		67,402		(1,208)		341,077			2,443,550 66,194
Bad debt expense		07,402		33,595		5,460			39,055
Depreciation and amortization		3,267		50,734		9,310			63,311
Depreciation and amortization		3,207		30,734		9,310			05,511
Total costs and expenses		72,808	2	2,182,855		356,447			2,612,110
Total Costs and Expenses		72,000	Ī	,102,000		200,			2,012,110
Income (loss) from operations		(72,685)		367,041		42,503			336,859
Other income and expense:		(72,003)		307,041		42,303			330,639
Intercompany interest and royalty fees		(2,532)		2,494		38			
Intercompany management fees		120,276		(102,096)		(18,180)			
Loss on early retirement of debt		(6,064)		(102,090)		(10,100)			(6,064)
Equity in earnings of unconsolidated		(0,004)							(0,004)
subsidiaries				7,637		68			7,705
Interest expense		(54,167)		(25,348)		(4,244)			(83,759)
interest expense		(34,107)		(23,346)		(4,244)			(03,739)
Income (loss) from operations before									
income taxes		(15,172)		249,728		20,185			254,741
Income tax expense (benefit)		(8,206)		101,795		(15)			93,574
Equity in earnings of subsidiaries		162,470		15,639			$(178,109)^{(a)}$		
Net income		155,504		163,572		20,200	(178,109)		161,167
Less: Net income attributable to									
non-controlling interests						5,663			5,663
Net income attributable to Select									
Medical Corporation	\$	155,504	\$	163,572	\$	14,537	\$ (178,109)	\$	155,504

⁽a) Elimination of equity in earnings of subsidiaries.

F-46

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation Condensed Consolidating Statement of Cash Flows For the Year Ended December 31, 2012

	Select Medical Corporation (Parent Company Only	Subsidiar	y Non-Guaranto rs Subsidiaries (in thousands)		Consolidated
Operating activities			()		
Net income	\$ 155,50	04 \$ 163,5	72 \$ 20,200	0 \$ (178,109)	a) \$ 161,167
Adjustments to reconcile net income to net cash provided by operating	Ψ 100,0	, , , , , , , , , , , , , , , , , , , ,	40,0	o	Ψ 101,107
activities:					
Depreciation and amortization	3,20	57 50,73	34 9,310)	63,311
Provision for bad debts	3,2	33,59			39,055
Equity in earnings of unconsolidated subsidiaires		(7,63			(7,705)
Loss on early retirement of debt	6,00		57) (00	3)	6,064
	0,00		02) 96	۵	
Loss (gain) from disposal or sale of assets	5,6	(6,00	J2) 90	3	(5,906)
Non-cash stock compensation expense					5,677
Amortization of debt discount and issuance costs	7,19				7,190
Deferred income taxes	7,90)9			7,909
Changes in operating assets and liabilities, net of effects from					
acquisition of businesses:			- 0.	.=	
Equity in earnings of subsidiaries	(162,47	/ /	/	178,109 _{(a}	
Accounts receivable		29,72			15,158
Other current assets			41 (2,488	*	(1,607)
Other assets	2,4	18 3,20			5,877
Accounts payable	(2,6)	, , , , ,			(6,117)
Due to third-party payors		(15,2)			(4,448)
Accrued expenses	25,35	50 (3,83	35) 2,231	1	23,746
Net cash provided by operating activities	49,00	00 228,60	06 31,765	5	309,371
Investing activities					
Purchases of property and equipment	(5,1:			5)	(68,185)
Proceeds from sale of assets		16,5			16,511
Investment in businesses, net of distributions		(14,68			(14,689)
Acquisition of businesses, net of cash acquired		(6,04)	43)		(6,043)
Net cash used in investing activities	(5,15	50) (53,38	81) (13,875	5)	(72,406)
Financing activities					
Borrowings on revolving credit facility	495,00	00			495,000
Payments on revolving credit facility	(405,00	00)			(405,000)
Borrowings on 2011 credit facility term loans, net of discount	266,75	50			266,750
Payments on 2011 credit facility term loans	(9,8	75)			(9,875)
Repurchase of 75/8% senior subordinated notes, net of premiums	(278,49	95)			(278,495)
Borrowings of other debt	8,00		278	8	8,281
Principal payments on other debt	(8,04		33) (1,813	3)	(10,295)
Debt issuance costs	(6,52		, (2,010	,	(6,527)
Dividends paid to Holdings	(268,4)				(268,479)
Equity investment by Holdings	1,8				1,817
Proceeds from bank overdrafts	1,22				1,227
Intercompany	183,42		58) (12,363	3)	1,227
Distributions to non-controlling interests	103,42	(171,0,	(3,268	/	(3,268)
Net cash used in financing activities	(20,20	07) (171,49	91) (17,166	5)	(208,864)

Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period	23,643 11,427	3,734	724 616	28,101 12,043
Cash and cash equivalents at end of period	\$ 35,070 \$	3,734 \$	1,340 \$	\$ 40,144

(a) Elimination of equity in earnings of consolidated subsidiaries.

F-47

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation Condensed Consolidating Balance Sheet December 31, 2011

	Co ₁	ct Medical rporation Parent pany Only)	Subsidiary Guarantors	Non-Guarantor Subsidiaries (in thousands)	Eliminations	Co	nsolidated
Assets							
Current Assets:							
Cash and cash equivalents	\$	11,427	\$	\$ 616		\$	12,043
Accounts receivable, net			369,321	52,529	(8,107)		413,743
Current deferred tax asset		11,415	3,221	3,669			18,305
Prepaid income taxes		9,497					9,497
Intercompany receivables			880,537		(978,985)		
Other current assets		6,340	19,407	4,075			29,822
Total Current Assets		38,679	1,272,486	159,337	(987,092)		483,410
Property and equipment, net		14,641	440,736				510,028
Investment in affiliates		2,751,776	83,772		$(2,835,548)^{(a)(b)}$)	
Goodwill			1,631,716				1,631,716
Other identifiable intangibles			72,123				72,123
Assets held for sale		2,742					2,742
Non-current deferred tax asset		2,509			(2,509)		
Other assets		28,386	41,480	853			70,719
Total Assets	\$	2,838,733	\$ 3,542,313	\$ 214,841	\$ (3,825,149)	\$	2,770,738
Liabilities and Equity Current Liabilities:							
Bank overdrafts	\$	16,609	\$	\$	\$	\$	16,609
Current portion of long-term debt and notes	Ψ	10,007	Ψ	Ψ	Ψ	Ψ	10,007
payable		8,853	390	1,605			10,848
Accounts payable		7,353	76,207	,			95,618
Intercompany payables		978,985	, 0,20,	12,000	(978,985)		,,,,,,
Accrued payroll		229	82,518	141	(2,00,000)		82,888
Accrued vacation		3,703	41,305				51,250
Accrued interest		11,843	137				11,980
Accrued restructuring			5,027				5,027
Accrued other		47,829	51,086	7,401			106,316
Due to third party payors			13,633		(8,107)		5,526
Total Current Liabilities		1.075.404	270,303	27.447	(987,092)		386,062
Long-term debt, net of current portion		733,328	425,315	-, -	(,)		1,218,650
Non-current deferred tax liability		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	75,750		(2,509)		82,028
Other non-current liabilities		46,555	17,970				64,905
Total Liabilities		1,855,287	789,338	96,621	(989,601)		1,751,645
Redeemable non-controlling interests		,,07	, , , , , ,	8,988	(~ ~~ ,~~ -)		8,988
Stockholder's Equity:				2,200			- 70 0 0
Common stock		0					0
Capital in excess of par		848,844					848,844
Retained earnings		134,602	627,120	23,154	(650,274)(b)		134,602
Subsidiary investment			2,125,855		(2,185,274) ^(a)		
Total Select Medical Corporation		000 4:5		00	(2.027.746)		000.445
Stockholder's Equity		983,446	2,752,975	82,573	(2,835,548)		983,446

Edgar Filing: CHINA TELECOM CORP LTD - Form 20-F

Non-controlling interests			26,659		26,659
Total Equity	983,446	2,752,975	109,232	(2,835,548)	1,010,105
Total Liabilities and Equity	\$ 2,838,733	\$ 3,542,313	\$ 214,841	\$ (3,825,149)	\$ 2,770,738

⁽a) Elimination of investments in consolidated subsidiaries.

F-48

⁽b) Elimination of investments in consolidated subsidiaries' earnings.

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation Condensed Consolidating Statement of Operations For the Year Ended December 31, 2011

	Select Medical Corporation (Parent Company Only	Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
	Company Omy) Guarantors	(in thousands)	Emimations	Consolidated
Net operating revenues	\$ 12	1 \$ 2,436,177	,	\$	\$ 2,804,507
ret operating revenues	ψ 12	π ψ 2,430,177	Ψ 300,207	Ψ	φ 2,004,307
Costs and expenses:					
Cost of services	1,72	9 1,996,671	310,170		2,308,570
General and administrative	61,99		,		62,354
Bad debt expense	- ,	44,300	7,047		51,347
Depreciation and amortization	4,11	,	,		71,517
•					
Total costs and expenses	67,83	9 2,099,394	326,555		2,493,788
- Company of the Comp	07,00	_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			_,,,,,,,,,
Income (loss) from operations	(67,71	8) 336,783	41,654		310,719
Other income and expense:	(07,71	0) 550,705	11,051		310,717
Intercompany interest and royalty fees	(3,40	(8) 3,382	26		
Intercompany management fees	120,01				
Loss on early retirement of debt	(20,38	, ,	, (- , ,		(20,385)
Equity in earnings of unconsolidated	,				` ' '
subsidiaries		2,870	53		2,923
Interest income	13	2 122	68		322
Interest expense	(41,81	7) (34,612	(4,803)		(81,232)
Income (loss) before income taxes	(13,18	3) 205,575	19,955		212,347
Income tax expense (benefit)	(12,82	1) 92,561	1,244		80,984
Equity in earnings of subsidiaries	126,80	9 13,406		$(140,215)^{(a)}$	
Net income	126,44	7 126,420	18,711	(140,215)	131,363
Less: Net income attributable to					
non-controlling interests			4,916		4,916
Net income attributable to Select					
Medical Corporation	\$ 126,44	7 \$ 126,420	\$ 13,795	\$ (140,215)	\$ 126,447

(a) Elimination of equity in earnings of subsidiaries.

F-49

Table of Contents 160

(a)

Operating activities

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows For the Year Ended December 31, 2011

Select Medical Corporation (ParentSubsidiary Non-Guarantor Company Only) Guarantors Subsidiaries Eliminations Consolidated (in thousands) \$ 126,447 \$ 126,420 \$ 18,711 \$ (140,215)(a) \$ 131,363

Net income	\$ 126,447	\$	126,420	\$ 18,711	\$ (140,215)(a) \$	131,363
Adjustments to reconcile net income to net cash provided by operating						
activities:						
Depreciation and amortization	4,115		58,064	9,338		71,517
Provision for bad debts			44,300	7,047		51,347
Equity in earnings of unconsolidated subsidiaries			(2,870)	(53)		(2,923)
Loss on early retirement of debt	20,385					20,385
Loss (gain) from disposal or sale of assets	13		(5,024)	45		(4,966)
Non-cash stock compensation expense	3,725					3,725
Amortization of debt discount and issuance costs	6,700					6,700
Deferred income taxes	35,305					35,305
Changes in operating assets and liabilities, net of effects from acquisition of						
businesses:						
Equity in earnings of subsidiaries	(126,809))	(13,406)		140,215 _(a)	
Accounts receivable			(98,966)	(12,160)		(111,126)
Other current assets	(1,780))	1,165	(586)		(1,201)
Other assets	(12,069))	9,683	318		(2,068)
Accounts payable	1,326		16,247	3,056		20,629
Due to third-party payors			1,408	(1,181)		227
Accrued expenses	14,823		5,522	794		21,139
Net cash provided by operating activities	72,181		142,543	25,329		240,053
Investing activities						
Purchases of property and equipment	(3,413))	(37,759)	(4,844)		(46,016)
Investment in businesses, net of distributions			(15,699)			(15,699)
Acquisition of businesses, net of cash acquired			(899)			(899)
Proceeds from sale of assets			7,879			7,879
Net cash used in investing activities	(3,413))	(46,478)	(4,844)		(54,735)
Financing activities						
Borrowings on revolving credit facility	735,000					735,000
Payments on revolving credit facility	(720,000))				(720,000)
Borrowings on 2011 credit facility term loans, net of discount	841,500					841,500
Payments on 2011 credit facility term loans	(4,250))				(4,250)
Payments on 2005 credit facility term loans, net of call premium	(484,633))				(484,633)
Repurchase of 75/8% senior subordinated notes, net of premiums	(273,941))				(273,941)
Borrowings of other debt	6,100		955			7,055
Principal payments on other debt	(5,662))	(755)	(1,082)		(7,499)
Debt issuance costs	(18,556))				(18,556)
Repayments of bank overdrafts	(2,183))				(2,183)
Equity investment by Holdings	208					208
Dividends paid to Holdings	(245,729))				(245,729)
Intercompany	114,656		(99,832)	(14,824)		
Distributions to non-controlling interests				(4,612)		(4,612)
Net cash used in financing activities	(57,490))	(99,632)	(20,518)		(177,640)

3,567	649		
3,307	049		4,365
\$	\$ 616 \$	\$	12,043
	\$	\$ \$ 616 \$	\$ 616 \$ \$

(a) Elimination of equity in earnings of consolidated subsidiaries.

F-50

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation

Condensed Consolidating Statement of Operations and Comprehensive Income For the Year Ended December 31, 2010

	Corpora		ntSubsidiary Guarantors			Eliminations	Co	nsolidated
		· · · · · · · · · · · · · · · · · · ·			housands)			
Net operating revenues	\$	107	\$ 2,060,001	`	330,182	\$	\$	2,390,290
Costs and expenses:								
Cost of services		1,473	1,703,096)	277,610			1,982,179
General and administrative		53,035	9,086)				62,121
Bad debt expense			34,267		6,880			41,147
Depreciation and amortization		2,837	57,267		8,602			68,706
Total costs and expenses		57,345	1,803,716)	293,092			2,154,153
Income (loss) from operations		(57,238)	256,285		37,090			236,137
Other income and expense:			,		Í			•
Intercompany interest and royalty fees		(4,057)	4,026	;	31			
Intercompany management fees		101,878	(86,451)	(15,427)			
Equity in losses of unconsolidated subsidiaries			(440))	, , ,			(440)
Other income		632	`					632
Interest expense		(44,921)	(34,965	<u>(</u>)	(4,586)			(84,472)
Income (loss) before income taxes		(3,706)	138,455		17,108			151,857
Income tax expense (benefit)		(7,097)	56,271		2,206			51,380
Equity in earnings of subsidiaries		92,366	10,647			(103,013)	(a)	
Net income		95,757	92,831		14,902	(103,013)		100,477
Less: Net income attributable to non-controlling interests					4,720			4,720
Net income attributable to Select Medical Corporation		95,757	92,831		10,182	(103,013)		95,757
Other comprehensive income:								
Unrealized gain on interest rate swap, net of tax		8,914						8,914
Comprehensive income attributable to Select Medical Corporation	\$	104,671	\$ 92,831	\$	10,182	\$ (103,013)	\$	104,671

(a) Elimination of equity in net income from consolidated subsidiaries.

F-51

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows For the Year Ended December 31, 2010

	Select Medical Corporation (Pare Company Only)	•		Eliminations	Consolidated
Operating activities					
Net income	\$ 95,757	\$ 92,831	\$ 14,902	\$ (103,013)	(a) \$ 100,477
Adjustments to reconcile net income to net cash provided by (used in)					
operating activities:					
Depreciation and amortization	2,837	57,267	8,602		68,706
Provision for bad debts		34,267	6,880		41,147
Equity in losses of unconsolidated subsidiaries	,	440			440
Loss from disposal of assets	4		151		484
Non-cash gain from interest rate swaps	(632				(632)
Non-cash stock compensation expense	2,236				2,236
Amortization of debt discount and issuance costs	6,599				6,599
Deferred income taxes	9,450				9,450
Changes in operating assets and liabilities, net of effects from acquisition of businesses:					
Equity in earnings of subsidiaries	(92,366	(10,647))	103,013 _{(a}	1)
Accounts receivable		(42,549)	(21,780)		(64,329)
Other current assets	826	(1,008)	1,777		1,595
Other assets	(6,492	(1,472)	1,193		(6,771)
Accounts payable	2,798	(9,971)	12		(7,161)
Due to third-party payors		(4,390)	2,488		(1,902)
Accrued expenses	(25,160) 42,387	2,498		19,725
Net cash provided by (used in) operating activities Investing activities	(4,143) 157,484	16,723		170,064
Purchases of property and equipment	(3,078	(33,186)	(15,497)		(51,761)
Proceeds from sale of assets	(5,575	565	(10,157)		565
Acquisition of businesses, net of cash acquired		(165,802))		(165,802)
Net cash used in investing activities	(3,078	(198,423)	(15,497)		(216,998)
Financing activities					
Equity investment by Holdings	241				241
Borrowings on revolving credit facility	227,000				227,000
Payments on revolving credit facility	(202,000				(202,000)
Payments on credit facility term loan	(1,223)			(1,223)
Borrowings of other debt	5,564		783		6,347
Principal payments on other debt	(5,589		(901)		(7,436)
Dividends paid to Holdings	(69,671	,			(69,671)
Proceeds from bank overdrafts	18,792				18,792
Intercompany	(46,684) 43,154	3,530		
Distributions to non-controlling interests			(4,431)		(4,431)
Net cash provided by (used in) financing activities	(73,570) 42,208	(1,019)		(32,381)
Net increase (decrease) in cash and cash equivalents	(80,791	1,269	207		(79,315)
Cash and cash equivalents at beginning of period					

Cash and cash equivalents at end of period \$ 149 \$ 3,567 \$ 649 \$ 4,365

(a) Elimination of equity in earnings of subsidiaries.

F-52

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

20. Selected Quarterly Financial Data (Unaudited)

The table below sets forth selected unaudited financial data for each quarter of the last two years.

	Select Medical Holdings Corporation									
	First Quarter				Third Quarter			Fourth Quarter		
		(in tho	ousands, except per share an					nounts)		
Year ended December 31, 2011										
Net operating revenues	\$	693,186	\$	698,749	\$	694,131	\$	718,441		
Income from operations		87,632		81,026		68,073		73,988		
Net income attributable to Select Medical Holdings Corporation	\$	33,672	\$	11,719	\$	25,596	\$	36,859		
Income per common share:										
Basic	\$	0.22	\$	0.08	\$	0.17	\$	0.25		
Diluted	\$	0.22	\$	0.08	\$	0.17	\$	0.25		

	Select Medical Corporation								
	(First Quarter		Second Quarter	Third Quarter			Fourth Quarter	
				(in thou	ısan	ds)			
Year ended December 31, 2011									
Net operating revenues	\$	693,186	\$	698,749	\$	694,131	\$	718,441	
Income from operations		87,632		81,026		68,073		73,988	
Net income attributable to Select Medical Corporation	\$	38,224	\$	22,272	\$	27,291	\$	38,660	

	Select Medical Holdings Corporation									
	First Quarter		Second Quarter		Third			Fourth		
					(Quarter	Quarter			
	(in thousands, except per share amounts)									
Year ended December 31, 2012										
Net operating revenues	\$	744,021	\$	750,193	\$	713,669	\$	741,086		
Income from operations		91,604		93,513		70,819		80,923		
Net income attributable to Select Medical Holdings Corporation	\$	41,542	\$	43,172	\$	24,110	\$	39,406		
Income per common share:										
Basic	\$	0.29	\$	0.31	\$	0.17	\$	0.28		
Diluted	\$	0.29	\$	0.31	\$	0.17	\$	0.28		

	(First Quarter	ect Medica Second Quarter (in thou	(Third uarter		Fourth Quarter	
Year ended December 31, 2012								
Net operating revenues	\$	744,021	\$ 750,193	\$	713,669	\$	741,086	
Income from operations		91,604	93,513		70,819		80,923	
Net income attributable to Select Medical Corporation	\$	43,279 F-53	\$ 45,018	\$	25,953	\$	41,254	

Table of Contents

The following Financial Statement Schedule along with the report thereon of PricewaterhouseCoopers LLP dated February 26, 2013, should be read in conjunction with the consolidated financial statements. Financial Statement Schedules not included in this filing have been omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.

Select Medical Holdings Corporation Select Medical Corporation

Schedule II Valuation and Qualifying Accounts

Description	Be	lance at ginning f Year	C	arged to ost and xpenses	Acquisitions (A) (In thousands)		Deductions (B)		 lance at l of Year
Allowance for Doubtful									
Accounts									
Year ended December 31, 2012	\$	47,469	\$	39,055	\$		\$	(44,670)	\$ 41,854
Year ended December 31, 2011	\$	44,416	\$	51,347	\$	108	\$	(48,402)	\$ 47,469
Year ended December 31, 2010	\$	43,357	\$	41,147	\$	7,448	\$	(47,536)	\$ 44,416
Income Tax Valuation									
Allowance									
Year ended December 31, 2012	\$	15,733	\$	(2,392)	\$		\$		\$ 13,341
Year ended December 31, 2011	\$	16,622	\$	(889)	\$		\$		\$ 15,733
Year ended December 31, 2010	\$	22,372	\$	(5,750)	\$		\$		\$ 16,622

⁽A) Represents opening balance sheet reserves resulting from purchase accounting entries.

(B) Allowance for doubtful accounts deductions represent write-offs against the reserve for 2010, 2011 and 2012.

F-54